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FAK  Focal adhesion kinase 
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Recent studies have revealed that interactions between tumour cells and the surrounding 
stroma play an important role in facilitating tumour growth and invasion.  Stromal 
fibroblasts produce most of the extracellular matrix (ECM) components found in the 
stroma, including type I collagen.  Previous in vivo studies in our laboratory have shown 
that type I collagen mRNA levels are decreased in stage II and III breast tumour tissue 
compared to adjacent normal tissue.  Since type I collagen forms the main constituent of 
the ECM, the role of tumour cells in regulating the synthesis of type I collagen in 
neighbouring fibroblasts could have important implications for tumour invasion.  The aim 
of this study was therefore to investigate the mechanisms involved in breast tumour-
mediated regulation of type I collagen gene expression in neighbouring fibroblasts.   
 
Results of co-culture experiments showed that MDA-MB-231 breast tumour cells 
negatively regulated type I collagen gene expression when in close contact with either 
CCD-1068SK breast skin or WI38 lung fibroblasts.  Down-regulation of both the COL1A1 
and COL1A2 genes was observed, with specific involvement of the -375/+54 region of the 
COL1A2 promoter.  Since non-tumourigenic MCF12A epithelial cells did not affect type I 
collagen gene expression in co-cultured fibroblasts, the negative regulatory effect on type I 
collagen expression appeared to be tumour-specific. Further ELISA analysis of direct co-
culture medium revealed that well-known negative regulators of type I collagen such as 
TNFα, IFNγ and IL-1, were not secreted during tumour/fibroblast co-cultures. However, 
the expression of IFNα and IFNβ was up-regulated in fibroblast/tumour co-cultures.  Type 
I IFNs activate JAK/STAT signalling and further investigation of this pathway revealed 
that Stat1 mRNA and protein levels were significantly up-regulated in both fibroblasts and 
tumour cells after direct co-culture. Increased Stat1 expression and activation in CCD-
1068SK fibroblasts was shown to occur as a result of a factor secreted during CCD-
1068SK/MDA-MB-231 direct co-cultures, which we suggest is a type I IFN. However, 
inhibition of JAK/Stat signalling did not reverse the negative regulatory effect of tumour 
















Gene expression analysis performed on co-cultured CCD-1068SK fibroblasts showed that 
MMP-1 was overexpressed, while CCN2 gene expression was down-regulated as a result 
of close contact with tumour cells.  Inhibiting CCN2 gene expression in fibroblasts led to a 
significant decrease in type I collagen gene expression levels in fibroblasts, suggesting a 
role for this matricellular protein in tumour-mediated regulation of type I collagen.  
Increased expression of Smad7 observed in co-cultured fibroblasts was shown to play a 
role in tumour-mediated suppression of CCN2 gene expression.  However, inhibition of 
Smad7 gene expression in fibroblasts did not reverse the negative regulatory effect of 
tumour cells on type I collagen gene expression.   
 
The results obtained in this study suggest that tumour cells are able to down-regulate the 
expression of profibrotic genes such as type I collagen and CCN2, while up-regulating 
matrix-degrading MMP gene expression, in fibroblasts when in close contact with these 
cells.  This type of close contact between tumour cells and fibroblasts is only possible in 
the later stages of breast cancer progression, when the basement membrane separating 
these two cell types has been degraded, and the resulting decrease in fibroblast-mediated 
production of the surrounding extracellular matrix could facilitate further tumour invasion 



















Epithelial cell cancers are believed to occur as a result of acquired or inherited genetic 
defects in the DNA of these cells.  Such mutations cause the cells to proliferate at a higher 
rate than normal and in due course uncontrollably, leading to the development of a 
carcinoma.  While some carcinomas remain benign others invade the surrounding stroma 
and may subsequently metastasize to other parts of the body, resulting in the major cause 
of cancer deaths. 
 
Cancer studies have previously focused on how and why epithelial cell mutations occur, 
but recent evidence has shown that the stroma surrounding the epithelial cells plays a 
crucial role in both the promotion and progression of carcinomas.  The stroma consists of 
the extracellular matrix (ECM) and a number of different cell types, including fibroblasts, 
pericytes, immune and inflammatory cells (Weigelt & Bissell 2008). The stroma makes up 
80% of normal human breast tissue which is essential for preserving normal epithelial 
structure and adhesion and serves as a barrier that impedes tumour development (Beacham 
& Cukierman 2005; Parmar & Cunha 2004).  If tumourigenesis occurs, the carcinoma cells 
communicate with the surrounding stromal cells causing abnormal changes in stromal 
homeostasis which may then promote further tumour invasion and metastasis (Bierie & 
Moses 2006).  
 
The focus of this chapter is to discuss previous studies performed on breast cancer and the 
role of the stroma in tumour initiation and development.  More specifically, 
tumour/fibroblast interactions during different stages of tumour progression and the effect 












1.2 Breast cancer  
 
Breast cancer is the most common cancer in women worldwide, with an estimated 1.38 
million women diagnosed with breast cancer in 2008 alone (Ferlay et al. 2008).  In South 
Africa, breast cancer is also the most commonly diagnosed cancer among women, with an 
estimated incidence rate of 41/100 000 women and a mortality rate of 20.7/100 000 women 
(Ferlay et al. 2008).  Increased awareness and diagnosis at earlier stages of the disease 
have led to a decrease in the mortality rate in developed countries, but in developing 
countries breast cancer still remains the most common cause of cancer deaths in women.  
Once tumours have metastasized to secondary sites, the chances of survival are 
significantly decreased (Allinen et al. 2004).  A better understanding of the molecular 
mechanisms involved in tumour invasion and metastasis are therefore essential for the 
development of improved tumour-targeted therapies. 
 
The normal human mammary gland is composed of a branching ductal-lobular system.  
Fifteen to twenty lobes make up each lobule, and these are drained by collecting ducts that 
converge at the nipple.  The lobules, known as terminal duct lobular units, consist of acini 
(alveoli) that function as the secretory units of the mammary gland during lactation 
(Weigelt & 2008).  Two types of glandular epithelial cells make up the mammary ducts 
and acini; the continuous inner layer of luminal epithelium surrounds the hollow lumen 
while the outer myoepithelial cell layer is in direct contact with the basement membrane 
(figure 1.1 A) (Debnath & Brugge 2005; Kalluri & Zeisberg 2006). Myoepithelial cells 
express type IV collagen, laminin, smooth muscle actin, and oxytocin receptor and 
therefore play an important role in the formation of the basement membrane and lactation 
(Gudjonsson et al. 2002).  The laminin-1 produced by these cells is essential for the control 
of luminal cell polarity and differentiation (Gomm et al. 1997; Gudjonsson et al. 2002).  
Myoepithelial cells are also believed to suppress breast cancer cell growth, invasion, and 
angiogenesis by expressing CD44 and proteinase inhibitors (Alpaugh et al. 2000; Barsky 
2003; Xiao et al. 1999).  The epithelial cells of the ducts and glands are separated from the 
surrounding stroma by the basement membrane, which makes up approximately 80% of 
breast tissue and consists mainly of varying amounts of fat, connective tissue, nerves, 












essential for preserving normal epithelial structure and adhesion and serves as a barrier that 
impedes tumour development (Beacham & Cukierman 2005; Parmar & Cunha 2004).  A 
number of different cell types are also found in the stroma; including fibroblasts, immune 




Figure 1.1 (A) In normal female breast tissue, two layers of glandular epithelial cells are separated from the 
surrounding stroma by the basement membrane.  The stroma consists of extracellular matrix (ECM) 
components, as well as blood vessels and fibroblasts. (B) In non-invasive ductal carcinoma in situ (DCIS), 
transformed epithelial cells proliferate to fill the lumen. Fibroblasts are also recruited to the tumour site where 
they are activated and deposit ECM components such as type I collagen. (C) Progression to an invasive 
ductal carcinoma is characterized by basement membrane degradation, which allows the tumour cells to 
migrate into the surrounding stroma. Changes to the stroma include increased angiogenesis and the 
recruitment of immune and inflammatory cells. (D) During advanced stages of breast carcinoma, further 
dedifferentiation of the stroma occurs with the tumour cells forming irregular “nests and cords” as they invade 
the stroma. (Kalluri & Zeisberg, 2006). 
 
Most genetic mutations occur in the luminal epithelial cells of the terminal duct lobular 
unit, while myoepithelial carcinomas are not very common and are mostly benign 
(Sternlicht et al. 1997; Gudjonsson et al. 2006).  The early stages of tumour development, 
characterised by loss of luminal epithelial cell polarity, dedifferentiation and proliferation 
A. Normal breast tissue B. Ductal carcinoma in situ












of the abnormal cells, is known as non-invasive ductal carcinoma in situ (DCIS) (figure 1.1 
B).  The lumen may become filled with the transformed cells, but they remain within the 
duct and are separated from the surrounding stroma by the basement membrane.  Further 
tumour progression is characterised by decreased structural organisation of the acinar 
structure, with displacement of the myoepithelial cells and degradation of the basement 
membrane.  If the carcinoma cells migrate and invade the surrounding stroma, invasive 
ductal carcinoma is diagnosed, which makes up 70% of all breast cancers (figure 1.1 C) 
(Debnath & Brugge 2005; Wozniak & Keely 2005).  Tumour development is often 
accompanied by a loss of myoepithelial cells, increased angiogenesis and a larger number 
of myofibroblasts and immune cells in the surrounding stroma (Gudjonsson et al. 2006; 
Shekhar et al. 2003; Weigelt & Bissell 2008).  Carcinoma cells also communicate with the 
surrounding stromal cells causing abnormal changes to the extracellular matrix, with 
decreased structural differentiation often observed, especially at the invasive front of the 
tumour mass (Bierie & Moses 2006; van Kempen et al. 2005).  
 
Tumours of the mammary gland are quite heterogeneous with regards to morphology, gene 
expression and clinical behaviours.  Tumours can be classified into three different grades 
based on histological assessment (Lacroix et al. 2004); grade I tumours are low grade 
tumour and have quite well differentiated cells, grade III tumours are high-grade and 
display very poor differentiation, and grade II tumours fall between the other two 
categories.  Further division of tumour into 18 subtypes is based on tumour cell growth 
rates and cytological traits (Kreike et al. 2007; Weigelt & Bissell 2008).  However, these 
classification systems are very subjective and misclassification may occur (Weigelt et al. 
2008). 
The introduction of cDNA microarray technologies has allowed for classification of breast 
tumours into five subtypes based on gene expression patterns (Perou et al. 1999; Perou et 
al. 2000; Sorlie et al. 2001). Tumours were divided into two groups based on whether or 
not they expressed oestrogen receptor-α (ER).  Oestrogen positive (ER+) tumours are 
derived from luminal epithelial cells and have been further divided into two subtypes; 












into HER2 positive, normal breast-like and basal-like subtypes, with the latter making up 
about 15 to 20% of breast cancers (Perou et al. 2000; Wienke et al. 2007). 
Gene expression profiling of breast cancers has recently been used to develop diagnostic 
tests to profile clinical samples (Sotiriou & Pusztai 2009).  Researchers from the 
Netherlands Cancer Institute developed a gene prognosis profile based on the expression of 
70 genes (van't Veer et al. 2002;  van de Vijver et al. 2002) which can be used to classify 
tumours into either a ‘good’ or ‘poor’ prognosis group.  This 70 gene signature has 
recently been commercialised as the MammaPrint® (Agendia BV, Amsterdam, The 
Netherlands) and has been approved by the Food and Drug Administration (FDA) for 
clinical use (Sotiriou & Pusztai 2009). This gene signature has proven most useful in 
clinical assessment of intermediate grade tumours (e.g. intermediate expression of ER and 
grade II tumours) which could not be characterised further using conventional clinical and 
pathological assessment (Sotiriou et al. 2006; Nuyten & van de Vijver 2007; Sotiriou & 
Pusztai 2009). When compared with the Adjuvant! Online program 
(www.adjuvantonline.com), which uses conventional pathological features to classify 
tumours, the MammaPrint® gene signature also predicted the outcome more accurately 
(Sotiriou & Pusztai 2009).  A number of other genome-based assays are now being 
developed, including Oncotype DX® (Genomic Health, Redwood City, California), H/I 
(AvariaDX, Carlsbad, California), Theros and MapQuant Dx (Marchionni et al. 2008; 
Sotiriou & Pusztai 2009).  Although these tests have aided in predicting prognosis and 
clinical outcome for patients with ER+ tumours, they still classify all ER- tumours as high-
risk (Sotiriou & Pusztai 2009; Straver et al. 2010). Since the worst prognosis is given for 
patients with ER- basal-like tumours (Kreike et al. 2007), further characterization of this 
group is needed to allow for improved prognosis and treatment. 
1.3 Tumour-stromal interactions 
 
For a number of years cancer has been regarded as a cell-autonomous process resulting 
from the accumulation of DNA mutations in a single somatic cell.  However, more recent 
studies have shown that this “somatic mutation theory” is an oversimplified view of 












involves continuous mutual interactions between tumour cells and their microenvironment 
(Sonnenschein & Soto 2008; Kenny et al. 2007).  Initiation and progression of tumours to 
an invasive and metastatic state is therefore a combination of genetic and epigenetic 
changes as well as abnormal interactions with the surrounding stroma (Vargo-Gogola & 
Rosen 2007). 
 
The stroma is made up of extracellular matrix components such as type I collagen and 
fibronectin as well as a number of different cell types including fibroblasts, endothelial 
cells, immune and inflammatory cells.  During early stages of tumour formation, the 
tumour cells are separated from the surrounding stroma by the basement membrane which 
acts as a barrier to prevent further tumour growth (Beacham & Cukierman 2005).  
However, complex tumour-stromal interactions may result in changes to the stroma that 
facilitate breakdown of the basement membrane, allowing tumour cells to invade the 
surrounding ECM.  Here, the tumour cells interact with both ECM components and 
stromal cells in a way that would not occur under normal, facilitating tumour invasion and 
metastasis (Bissell et al. 2002; Shekhar et al. 2003; Tlsty & Hein 2001; Beacham & 
Cukierman 2005; Parmar & Cunha 2004; Gaggioli 2008; Hu & Polyak 2008).  Stromal 
fibroblasts are responsible for synthesizing and depositing most of the ECM components 
and, therefore, interactions between tumour cells and fibroblasts play an important role in 
determining how tumour cells are able to alter the ECM to facilitate tumour invasion.   
1.3.1 Fibroblasts as key players in tissue remodelling. 
 
Fibroblasts are mesenchymal cells found in the stroma of all epithelial organs in the body. 
They produce most of the components of the ECM, including collagens, 
glycosaminoglycans, reticular and elastic fibres, and glycoproteins.  They also secrete 
ECM-degrading proteases such as matrix metalloproteinases (MMPs), and therefore play 
an important role in maintaining tissue homeostasis.  Fibroblasts also communicate with 
their environment by producing these ECM components and by secreting soluble factors in 













Fibroblasts play an essential role in organ development and in the maintenance of 
epithelial structure.  Type IV collagen and laminin secreted by fibroblasts form important 
components of the basement membrane that separate the epithelial cells from the 
surrounding stroma (Kalluri & Zeisberg 2006). Kuperwasser et al. (2004) showed that 
epithelial cells only formed ductal, lobular and acinar structures that resembled those found 
in human mammary glands when they were co-injected with immortalized human breast 
fibroblasts into the cleared breast pads of NOD/SCID mice.   However, no such structures 
formed when epithelial cells were injected on their own or with mouse fibroblasts.  This 
study also highlights the species-specific role of fibroblasts in mammary gland 
differentiation.  
 
Fibroblasts usually remain dormant and are sparsely distributed in adult tissue (Beacham & 
Cukierman 2005).  Fibroblast activation usually only occurs in adult tissue during tissue 
injury or during disease conditions such as fibrosis, inflammatory diseases and cancer.  
The activated fibroblasts, also known as myofibroblasts, are characterised by high levels of 
α-smooth muscle actin (α-SMA), increased production of ECM components such as type I 
collagne, and an increased ability to contract tissue (Bierie & Moses 2006).  The presence 
of active TGFβ and extra type III domain-A (EDA) fibronectin appear to be important for 
induction of the myofibroblast phenotype (Ronnov-Jessen et al. 1995; Shephard et al. 
2004; Ding et al. 2008) and growth factors such as EGF (epidermal growth factor), PDGF 
(platelet-derived growth factor) and FGF-2 (fibroblast growth factor 2), as well as direct 
cell-cell communication with leukocytes through ICAM1 (intercellular-adhesion molecule 
1) or VCAM1 (vascular-cell adhesion molecule 1) can also result in fibroblast activation 
(Kalluri & Zeisberg 2006).  Little is known about the negative regulation of myofibroblast 
formation, but cytokines such as IFNγ (interferon gamma) and IL1 (interleukin 1) appear 
to be involved (Shephard et al. 2004; Tanaka 2003).   
 
During wound healing myofibroblasts proliferate and migrate to the wounded area by 
binding to matrix components such as fibronectin, vitronectin and fibrin, via their integrin 
receptors (Ovington & Schultz 2004).  Fibroblasts are able to chemotactically detect the 
gradient of growth factors, cytokines and chemokines released at the sight of injury and 












(Ovington & Schultz 2004).  The fibroblasts also secrete proteolytic enzymes such as 
matrix metalloproteases (MMPs) to facilitate their movement through the matrix and to 
assist in matrix remodelling (Eckes et al. 2000; Singer & Clark 1999).  Fibroblasts usually 
only reach the wound site after the initial inflammatory phase (2 to 3 days), where they 
synthesize new connective tissue and promote wound closure by tissue contraction 
(Shephard et al. 2004; Ovington & Schultz 2004).  After the wound has healed the 
myofibroblasts may either return to their resting phenotype or undergo apoptosis (Hinz et 
al. 2007; Eyden et al. 2009).  
 
In disease conditions such as fibrosis and cancer, fibroblasts maintain an activated state 
without returning to the resting phase (Kalluri & Zeisberg 2006).  However, recent 
literature suggests that the carcinoma-associated fibroblasts (CAFs) observed in tumour 
tissue may consist of activated fibroblasts together with other cell types (Ronnov-Jessen & 
Bissell 2008; Franco et al. 2010) such as smooth muscle cells and pericytes from the 
vasculature (Hinz et al. 2007) as well as fibrocytes and bone-marrow-derived 
mesenchymal stem cells (Ishii 2003; Forbes et al. 2004; Chauhan et al. 2003).  Other 
studies suggest that epithelial cells that have undergone epithelial-to-mesenchymal (EMT) 
transition can also develop myofibroblast-like characteristics (Kim et al. 2006; Petersen 
2003; Willis et al. 2005; Selman & Pardo 2006).   
 
A better understanding of the definition of a myofibroblast will also assist researchers in 
determining the origin and functions of CAFs in tumours.  Although myofibroblasts are 
characterised by the expression of α-SMA (alpha smooth muscle actin), this protein is also 
expressed by other cells such as pericytes, some endothelial cells, myoepithelial cells and 
epithelial cells undergoing EMT (Eyden 2009). Therefore, techniques such as 
immunohistochemistry are unable to distinguish these cell types from each other.  Studies 
claiming that EMT-derived cells make up a part of the myofibroblast population have 
either used light microscopy techniques (Willis et al. 2005; Radisky et al. 2007) or have 
been unable to show certain characteristics of fully differentiated myofibroblast (Ng et al. 
1999) such as a rough endoplasmic reticulum and the presence of fibronexuses (Eyden 












myofibroblast-specific features; for example, smooth-muscle cells and myofibroblasts both 
have myofilaments, but only the former has a lamina which can only be detected by means 
of electron microscopy.  Pericytes can also be distinguished by the fact that they are poorly 
differentiated smooth-muscle cells and are usually found near endothelial cells.   
 
Although the exact contribution of each cell type to the CAF population is still under 
debate (Rønnov-Jessen & Bissell 2008; McAnulty 2007), previous studies on CAFs 
suggest that this population is able to facilitate tumour development (Shimoda et al. 2010; 
Kunz-Schughart et al. 2001; Orimo 2005; Tyan et al. 2011).  On the other hand, normal 
fibroblasts are believed to inhibit tumourigenesis, but their role in later stages of tumour 
invasion is still not well understood (Kalluri & Zeisberg 2006). 
1.3.1.1 The role of fibroblasts in tumour initiation. 
 
 
Whether stromal changes precede and facilitate tumourigenesis or rather occur in reaction 
to the tumour is still not clear, and it is possible that either may occur depending on the 
situation (Reilly & Van Dyke 2008).  De Wever and Mareel (2003) suggest that tumour 
cells and the stroma may interact via an efferent or afferent pathway.  In the efferent 
pathway tumourigenic cells may secrete and/or deposit soluble growth factors in the 
surrounding ECM, leading to a reactive stromal response which then facilitates further 
tumour development.  In the afferent pathway reactive stromal cells such as myofibroblasts 
trigger changes in epithel al cells, leading to tumourigenesis.  
 
A further alternative is that benign mutations present in epithelial cells rely on stromal 
changes to facilitate their conversion to a malignant state.  Studies have shown that 
tumours are often unable to overcome the limitations imposed on them by the normal 
microenvironment unless the stroma itself is altered (Beacham & Cukierman 2005; De 
Wever & Mareel 2003; Kuperwasser 2004).  Under normal conditions the stromal 
environment forms a barrier that prevents tumour initiation or progression, and fibroblasts 
in particular play an important role in regulating epithelial cell growth and differentiation 












epithelial MCF10A cells that were co-cultured with normal primary mammary fibroblast in 
reconstituted basement membrane formed structures that resembled the terminal ductal-
lobular units observed in normal breast tissue or early stage DCIS (Shekhar et al. 2001).  
Normal fibroblasts also reduced the proliferation of MCF10A cells and of the more 
progressively transformed cell line, MCF10AT (Sadlonova et al. 2005).  However, normal 
fibroblasts may only be able to regulate tumour cell growth and proliferation up to a 
certain stage in the malignant transformation process, after which the tumour cells appear 
to be resistant to the fibroblast’s cues (Mueller & Fusenig 2002). 
1.3.1.2 The role of fibroblasts in tumour progression 
 
 
Tumour development and progression is characterised by continuous interactions between 
the tumour cells and the surrounding stromal fibroblasts (Elenbaas & Weinberg 2001) and 
these interactions may vary depending on the stage of tumour progression.  One of the 
factors that determine the type of interactions that occur is the distance between tumour 
cells and fibroblasts. 
 
In the early stages, cancer cells are separated from the surrounding stroma by the basement 
membrane, as observed during the DCIS stage of breast cancer.  This ‘reactive stroma’ 
resembles that found at the proliferative phase of wound healing, with increased numbers 
of activated fibroblasts, increased angiogenesis and the deposition of type I collagen and 
fibronectin (Zeisberg & Kalluri 2004; Rønnov-Jessen et al. 1996).  These stromal changes 
imply that the tumour cells are able to communicate with fibroblasts through the basement 
membrane via secreted factors.  Some tumours never progress past the DCIS stage, 
although the role of the tumour environment in either preventing or facilitating progression 
to the invasive stage is not well understood (Franco et al. 2010).  Invasive ductal 
carcinomas are characterised by the degradation of the basement membrane, which allows 
tumour cells to invade the reactive stroma and come into close contact with the activated 
stromal fibroblasts (Zeisberg & Kalluri 2004; Tran-Thanh & Done 2010).  These 
carcinoma-associated fibroblasts (CAFs) represent the most common cell type found in the 












which involves increased deposition of ECM components such as type I collagen, 
fibronectins, proteoglycans and glycosaminoglycans (Rønnov-Jessen et al. 1995; Egeblad 
et al. 2005).  It is still not known whether this desmoplastic reaction is a wound-healing 
response to try and ‘repair’ and contain the tumour or if it actually facilitates tumour 
invasion (Zeisberg & Kalluri 2004).   
 
A number of factors may be involved in cross-talk between CAFs and tumour cells, 
resulting in accelerated tumour growth and development.  Tumour xenografts produced by 
ras-transformed human MCF-7 breast cancer cells co-injected with CAFs into nude mice 
were significantly larger than those produced by tumour cells mixed with normal 
fibroblasts (Orimo et al. 2005), with secretion of stromal cell-derived factor 1 (SDF-1) by 
CAFs shown to play an important role in this increased tumour growth as well as in 
angiogenesis.  CAFs also secrete proteases such as matrix metalloproteases, cathepsins and 
plasminogen activators (Joyce & Pollard 2009) and production of MMP-1, MMP-2 and 
MMP-9 has been associated with invading and metastasizing tumours (Kunz-Schughart et 
al. 2001).  Protease-mediated degradation of the ECM could facilitate tumour invasion by 
breaking adhesions between tumour cells and neighbouring cells or the matrix and 
allowing tumour cells to move freely through the degraded matrix (De Wever et al. 2008; 
Pietras & Ostman 2010).  Growth factors embedded in the matrix are also released as a 
result of degradation, and these may interact with tumour and stromal cell surface receptors 
and facilitate further tumour invasion (Chung et al. 2005; Pietras & Ostman 2010).   
 
The solid malignant tumour formed during the invasive stage usually consists of a necrotic 
centre surrounded by a peripheral region that consists of mixed tumour cells and stromal 
components.  At the edges of this peripheral region lies the invasive front and this is 
separated from the adjacent uninvolved tissue by the peritumoral zone in which oedema 
and inflammation often occur (Ruiter et al. 2002).  Although the role of CAFs in tumours 
has been well investigated, few studies have focussed on interactions that may occur 
between tumour cells and normal fibroblasts during the invasive stages.  In a study looking 
at the peritumoral region of breast tumour tissue, however, a population of fibroblasts was 
observed that did not express α-SMA (Andarawewa et al. 2005). When in close proximity 












associated with tumour invasion and poor patient prognosis (Basset et al. 1990;  Chenard et 
al. 1996).  Fibroblasts at the invasive front also appear to facilitate tumour cell invasion by 
forming tracks in the ECM for the tumour cells to move through, as demonstrated in 
squamous cell carcinomas (Gaggioli et al. 2007).  This track formation occurs as a result of 
increased MMP activity and Rho/ROCK signalling to the fibroblast actomyosin 
cytoskeleton, and may explain how tumour cells that have not undergone EMT are still 
able to invade surrounding tissue and metastasize (Gaggioli 2008). 
 
Although some studies have shown that fibroblasts are activated into myofibroblasts in the 
presence of tumour cells (Rønnov-Jessen et al. 1995; Kojima et al. 2010), not all 
fibroblasts are necessarily converted.  In a study by Kojima et al. (2010), less than 50 % of 
normal fibroblasts mixed with MCF7-ras breast tumour cells and injected into mice were 
shown to express α-SMA, even after 242 days of co-culture. Shekhar et al. (2003) also 
showed that normal skin fibroblast spheroids co-cultured with breast tumour spheroids did 
not display increased levels of α-SMA, even though the tumour cells were seen to migrate 
into the fibroblast spheroids.  Since the exact origins of CAFs are also still in question  
(Rønnov-Jessen & Bissell 2008; Hinz et al. 2007) more studies need to be undertaken to 
examine the specific role of normal fibroblasts in tumours and also to determine how 
invading tumour cells influence normal fibroblasts that they come into contact with at the 
invasive front.   
1.3.1.3 Signalling between tumour cells and fibroblasts 
 
Different regions of a tumour may have variations in ECM characteristics, metabolite 
availability and cellular distribution (Egeblad et al. 2010).  Communication between 
tumour cells and stromal fibroblasts may therefore depend on the proximity of these cells 
to each other and may involve secreted factors and/or cell adhesion molecules (De Wever 
& Mareel 2003).  Secreted factors include cytokines, chemokines and growth factors, 
which move into the surrounding ECM and can affect neighbouring cells over a short or 












receptors such as integrins and cadherins are involved in juxtacrine signalling between 
cells in close contact.     
 
Previous literature suggests that there are a number of secreted factors involved in tumour-
stroma cell signalling, including TGFβ, EGF (epidermal growth factor), HGF (hepatocyte 
growth factor) and stromal derived factor-1 (SDF-1/CXCL12).  TGFβ stimulation can 
trigger increased expression of the chemokine, CXCL12, and its receptor, CXCL14, in 
fibroblasts and this plays a direct role in myofibroblast activation (Kojima et al. 2010).  
Furthermore, SDF-1 secreted by the activated fibroblasts has been shown to increase 
tumours growth rate and angiogenesis (Orimo et al. 2005; Kojima et al. 2010).  On the 
other hand, Tyan et al. (2011) showed that levels of HGF were higher in CAFs than normal 
fibroblasts and that it was this secreted HGF that was responsible for stimulating tumour 
growth.  Interestingly, factors secreted by MDA-MB-468 tumour cells were also able to 
stimulate HGF secretion from normal fibroblasts.  MCF7-ras and MDA-MB-231 breast 
tumour xenografts were also shown to specifically recruit bone-marrow-derived human 
mesenchymal stem cells that were injected into the bloodstream of mice, and these cells 
are believed to also contribute to the myofibroblast population (Karnoub et al. 2007).  The 
breast tumour cells also stimulated the mesenchymal stem cells to secrete CCN5 
(RANTES) which, in turn, acted in a paracrine manner to enhance tumour motility, 
invasion and metastasis.  Therefore, there are a number of complex interactions between 
tumour cells and fibroblasts/CAFs that contribute to tumour growth and invasion.   
 
Although some secreted factors may convey their effect over large distances, others need 
close proximity with neighbouring cells to relay their signals successfully.  Shephard et al. 
(2004) showed that keratinocytes were able to induce a myofibroblast phenotype with 
increased type I collagen gene expression in normal dermal fibroblasts, but that this only 
occurred after cells were directly co-cultured for four days.  Close contact with fibroblasts 
stimulated keratinocytes to secrete IL-1 immediately after co-culture, which inhibited 
TGFβ-stimulated myofibroblast differentiation until day four.  Direct co-culture of dermal 
fibroblasts with activated T-cells was also required for the down-regulation of type I and 












were separated during co-culture (Rezzonico et al. 1998).  Further analysis revealed that 
collagen levels in fibroblasts were negatively regulated by TNFα, IFNγ and IL1 produced 
by T-cells.   The regulation of type I collagen gene expression in these studies could 
therefore be concentration dependent and/or there could be other cell surface receptors 
involved in mediating these effects.   
 
Cell surface adhesion molecules such as integrins and cadherins are also involved in 
communicating signals from the ECM and other cells.  An α and β sub-unit makes up the 
integrin dimer, with up to 24 α/β heterodimer combinations existing to allow specific 
interactions with ECM components (Ivaska & Heino 2011).  Integrins act by binding to 
ECM components via their ectodomains while the smaller cytoplasmic domains bind to the 
cytoskeleton (Arnaout et al. 2007).  This allows interactions and communication to take 
place between the cell and the surrounding matrix.  Binding of integrins to ECM 
components can induce integrin clustering, resulting in a higher local concentrations of 
associated downstream signalling kinases and leading to the activation of these enzymes 
and downstream signalling components (Kim & Ginsberg 2011).  Ligand-induced 
conformational changes in integrins can also results in the separation of the intracellular 
domains of the α and β sub-units, with resulting receptor activation (Kim & Ginsberg 
2011; Du et al. 1991) 
 
Integrins activate similar signalling pathways to those activated when growth factors bind 
to their receptors, and recent studies have shown that cross-signalling between integrins 
and growth factor receptors can occur (Eliceiri 2001; Bosman & Stamenkovic 2003; 
Comoglio et al. 2003). Adhesion molecules can act synergistically with growth factors to 
coordinate biological responses; for example, fibroblasts were unable to migrate in 
response to PDGF or EGF signals when the focal adhesion kinase (FAK) was not available 
(Sieg et al. 2000).  FAK is usually involved in integrin-mediated signalling, but, in this 
case, efficient growth factor-mediated migration only occurred when FAK associated with 
both integrins and growth factor receptors.  Adhesion molecules can also complex with 
growth factor receptors independently of growth factor binding to activate downstream 












the epidermal growth factor receptor (EGFR) on neighbouring epithelial-like 
adenocarcinoma cells at cell-cell contact sites, independently of EGF binding (Yu et al. 
2000).   
 
Integrins may also interact with other cell surface receptors, such as the immunoglobulin-
type receptors ICAMs (intercellular adhesion molecules) and VCAMs (vascular cell 
adhesion molecules), as well as members of the ADAM (a disintegrin and metalloprotease) 
family found on adjacent cells (Bernstein 1998; Oberyszyn et al. 1998; Heino 2000; Danen 
2005).  Other adhesion molecules which are mainly involved in homotypic cell-cell 
interactions include the cadherin family of transmembrane glycoproteins (Alattia et al. 
1999).  E-cadherin is usually involved in maintaining close contact between neighbouring 
epithelial cells, but tumour cells often lose their ability to express E-cadherin while gaining 
N-cadherin expression.  N-cadherin-mediated adhesion of melanoma cells to dermal 
fibroblasts and vascular endothelial cells has previously be n shown to increase melanoma 
cell growth and facilitate tumour migration (Li et al. 2001). 
 
A number of different signalling molecules and mechanisms may therefore be involved in 
tumour/fibroblast cross-talk, with close contact between these cells during tumour invasion 
allowing for interactions to take place that would not occur in normal tissue.  These 
interactions may involve a number of different growth factors, cytokines, cell surface 
receptors and cell adhesion molecules and further research will need to be performed to 
elucidate the exact mechanisms involved and how these influence tumour invasion.  
1.3.2 The role of the stroma in determining tumour prognosis 
As previously discussed, gene expression studies performed on breast tumour tissue have 
facilitated further classification of these tumours into subtypes and therefore improve 
diagnostic capabilities.  These gene expression studies have also been used to characterise 
the stromal component of breast tumours in an attempt to improve our understanding of the 












Since breast tumour development is often regarded as a wound-healing response gone 
wrong, Chang et al. (2004) investigated whether serum activation of fibroblast as observed 
during wound healing could be used to characterise tumours.  Gene expression analysis 
identified a set of 512 genes, termed the fibroblast “core serum-response” (CSR), which 
were then used to classify a group of breast, lung, prostate, hepatocellular and gastric 
carcinomas tissue samples into a “wound activated” and “wound quiescent” subtype.  
Breast cancer patients with the activated CSR signature, which included most basal-like 
tumours, were found to have a poorer metastasis-free survival rate than those without the 
signature (Chang et al. 2005).   
More recently, Finak et al. (2008) used stromal cells isolated from breast tumour tissue for 
gene expression analysis to create a “stroma derived prognostic predictor” (SDPP), with 
differences in immune responses, as well as angiogenic and hypoxic responses detected. 
When this profile was used to classify a set of breast tumour tissue samples, disease 
outcome could be predicted independently of traditionally used clinical prognostic 
methods as well as previously published expression-based predictors which used whole 
tumour tissue samples (including tumour cells and stromal cells) for creating these profiles.    
This predictor set also had increased prognostic power, which was further improved when 
this SDPP was combined with other existing predictors.  In a separate study, Bergamaschi 
et al. (2008) classified primary breast tumours into four groups (ECM1-4) according to a 
set of differentially expressed ECM-related genes.  When these predictors were used to 
classify an independent set of breast carcinoma samples, the ECM1 group proved to be 
useful for predicting specific biological and clinical behaviour. This group was originally 
characterised by the overexpression of genes for integrins and other cell-surface receptors, 
as well as metallopeptidases and some laminins.  Basal-like tumours clustered more in the 
ECM1 group, while Luminal A and B tumours were found in all groups.  However, 
patients with luminal type tumours classified as ECM1 were given a poorer prognosis, 
which may be a result of the high level of vascularization observed in ECM1 tumours.  
Usually patients diagnosed with luminal type breast cancer are placed in a ‘good-
prognosis’ group, but the ECM prognostic set used in this study was able to further 












The results of these gene expression analyses as well as results of other studies looking at 
the relationship between tumour cells and the surrounding stroma provide valuable insights 
that will assist in improving the accuracy of breast cancer diagnosis as well as in 
identifying improved targeted therapeutic agents.  Such therapeutic agents currently under 
development include antibodies or peptides that are able to interfere with interactions 
between the ECM and cell-surface integrins (Chung et al. 2005).  Further analysis of the 
role of the tumour stroma in resistance to chemotherapeutic agents, hormones and radiation 
will also prove vital for the development of future therapeutics (Weigelt & Bissell 2008). 
1.4 Type I Collagen - the major component of the ECM. 
 
Fibroblasts produce most of the ECM components, including type I collagen.  This fibrillar 
collagen is the main constituent of the ECM and plays an important part in giving strength 
and elasticity to connective tissue (Bhogal et al. 2005). Regulating the synthesis and 
degradation of this protein is therefore essential for maintaining tissue homeostasis and a 
number of positive and negative regulators of type I collagen gene expression have been 
identified.   
 
In this section we discuss the literature on type I collagen, including the various factors 
involved in the regulation of type I collagen gene expression.  Specific focus will be placed 
on the role of TGFβ and connective tissue growth factor (CTGF/CCN2) as positive 
regulators and that of interferons (IFNs) as a negative regulator of type I collagen gene 
expression, as well as the varying effects of MAPK signalling pathways on type I collagen 
regulation.  Finally, we will look at how type I collagen is regulated in tumours and which 
factors influence this regulation.  
1.4.1 The structure and function of type I collagen. 
 
Collagens are the most abundantly found protein in vertebrates and this family consists of 
at least twenty eight members.  These can be divided into the following categories:  












interrupted triple helices), MACITs (membrane-associated collagens with interrupted triple 
helices), and MULTIPLEXINs (multiple triple-helix domains and interruptions) 
(Shoulders & Raines 2009).   
 
Collagens are mainly responsible for maintaining tissue integrity and stability, as well as 
regulating cell polarity, migration and survival (van Kempen et al. 2005).  They are 
expressed at high levels in areas of the body needing high tensile strength (e.g. skin, bone, 
tendons, heart, aorta), but at lower levels in most organs and non-structural tissues 
(Stefanovic 2005).  They also play an important role in modulating cellular differentiation 
and morphogenesis during development and wound healing.  Changes in collagen structure 
and metabolism are found in a number of inherited or acquired diseases such as cancer, 
fibrosis, osteogenesis imperfecta, osteoarthritis and atherosclerosis (Trojanowska et al. 
1998; Varga & Jimenez, 1995).  
 
As much as 90% of the collagen found in the body is type I collagen, which is synthesized 
mainly by fibroblasts, osteoblasts and odontoblasts (Verrecchia & Mauviel 2004; Ghosh 
2002).  This fibrillar collagen has a heterotrimeric structure and is composed of two α1(I) 
and one α2(I) polypeptide chains that are produced by the COL1A1 (17q21.31-22.05) and 
COL1A2 (7q21.3-22.1) genes, respectively (Retief et al. 1985).  The α1(I) and α2(I) 
procollagen polypeptides are synthesized in a 2:1 ratio and undergo extensive post-
translational modifications in the endoplasmic reticulum (ER) before being transported to 
the Golgi apparatus and secreted from the cell via secretory vesicles (Verrecchia & 
Mauviel 2004).  Once in the extracellular matrix, the N- and C-propeptides are cleaved by 
specific proteases and cross-linking of the mature collagen molecule occurs, catalysed by 
lysyl oxidase, to form the collagen triple helix known as tropocollagen (Siegel et al. 1978; 
Shoulders & Raines 2009).  The mature tropocollagen monomers then assemble into 
microfibrils and fibrils by covalent cross-linking formed between the telopeptides of one 
collagen molecule and the adjacent helical domains of another collagen molecule 
(Shoulders & Raines 2009) and it is this cross-linking that gives the collagen fibers their 












1.4.2   Transcriptional regulation of type I collagen gene expression. 
 
The regulation of type I collagen synthesis occurs in both a tissue- and cell-specific manner 
and is tightly coordinated.  It can occur at either a transcriptional, post-transcriptional, 
translational or post-translational level (Xu et al. 2006).  Most previous studies have 
focused on the regulation of type I collagen production at a transcriptional level and have 
used transgenic mice generated with reporter genes driven by various segments of the 
mouse α1(I) or α2(I) procollagen promoters.  Results have shown that different cis-acting 
elements modulate procollagen gene expression in different type I collagen-producing cell 
types and tissues.  Studies in rats and humans produced similar results, suggesting 
conservation of cis-acting elements in different species (Rossert et al. 1995).  There are, 
however, variations in transcriptional regulation of the mouse and human procollagen 
promoters (Ihn et al. 1996; Leaner et al. 2005).  Because of the species and cell-type 
specific variations often observed in type I collagen regulation, this review will focus 
mainly on the regulation of type I collagen in normal human fibroblasts. 
 
Transcriptional regulation of the COL1A1 and COL1A2 genes appear to be modulated by 
the binding of similar transcription factors, although the regulatory promoter regions have 
distinctly different structural arrangements (Boast et al. 1990).  The exact controlling 
regions also appear to vary depending on cell type and tissue, and conflicting results have 
been obtained (Boast et al. 1990; Bornstein & Mckay 1988; Slack et al. 1991).  Results 
from a number of transcriptional regulation studies indicate that maximal COL1A1 
promoter expression in human fibroblasts only requires the -174 bp region of the proximal 
promoter, with a negative regulatory element found between -804 bp and -5.3 kb (Jimenez 
et al. 1994; Artlett et al. 1998; Boast et al. 1990; Bornstein & Mckay 1988; Hitraya & 
Jimenez 1996).  Binding of three transcription factors (Sp1, Sp3 and CBF (CCAAT 
binding factor)) to four sites on the -174 to -84 bp promoter region is all that is required for 
basal COL1A1 gene expression (Chen et al. 1998) (Figure 2.1 A). CBF was shown to only 
bind to the inverted CCAAT box located at -100 to -96 bp, but not to the one at -125 to -
121 bp (Saitta et al. 2000).  Sp1 binds to both the -120 to -115 region (distal) and the -86 to 
-81 bp region (proximal), while Sp3 associates with a TCCTCC motif at -158 to -153 bp 












form protein-protein contacts with the TATA-associated factors (TAFs) and therefore 




FIGURE 1.2 Transcription factors involved in regulating basal COL1A1 and COL1A2 promoter activity.  
(A) COL1A1 promoter activity is positively regulated by Sp1, Sp3 and CBF (CCAAT binding factor).  Sp1 
associates with the -120 to -115 bp as well as the -86 to -81 bp region of the promoter, while Sp3 associates 
with the -158 to -153 region. The inverted CCAAT box at -100 to -96 bp is bound by CBF.  RFX suppresses 
COL1A1 promoter activity by associating with the -11 to +10 bp region (Adapted from Saitta et al., 2000).  (B) 
Most of the transcription factors involved in regulatingCOL1A2 promoter activity bind to the -380 to +54 bp 
region of the promoter.  Association of Sp1 with the GCC-rich region at -300bp and Sp1 or Sp3 with the TCC-
rich region at -125 bp leads to increased COL1A2 promoter activity, while binding of Sp1 or Sp3 to the -160 bp 
TCC-rich region negatively regulates promoter activity. Binding of the CBF/NFY (CCAAT binding 
factor/nuclear factor Y) trimer to the inverted CCAAT box in the -80 bp region also positively regulates 
promoter activity.  Ets-1 (positive regulator) and Fli-1 (negative regulator) compete for binding to the -285 to -
282 bp region. C/EBPβ (CCAAT/Enhancer binding protein β) also acts as a positive regulator of basal 
COL1A2 promoter activity, while AP-1 and RFX5 are negative regulators.. 
 
Sp1 family members play an important role in both basal and TGFβ induced expression of 
the COL1A1 and COL1A2 genes (Ihn et al. 1996; Artlett et al. 1998; Pogulis & Freytag 
1993; Verrecchia et al. 2001b; Tamaki et al. 1995).  The -380 to +54 region of the 
COL1A2 promoter, which constitutes the minimal proximal promoter, contains three 
sequences which are essential for Sp1 binding and basal COL1A2 promoter activity (Boast 
et al. 1990; Inagaki et al. 1994) (figure 1.2 B).   The site at -300 bp is bound only by Sp1, 
while the two TCC-rich boxes at -160 (distal) and -125 bp (proximal) can associate with 
Sp1 and Sp3.  The -300 bp Sp1 site and the proximal TCC-rich box are involved in 
positive regulation of COL1A2 promoter activity while binding to the distal TCC-rich box 
results in negative regulation of both the downstream TCC-rich box and the upstream 
GCC-rich elements (-300bp region). However, this association does not affect the activity 
TCCTCC ATTGG GGCCGG ATTGG GGGCGG
AP-1
-158 -153 -125 -115 -100 -96 -86 -81
C/EBPβ
GCC



























of the inverted CCAAT motif at -80 bp, which associates with a CBF/NFY (CAAT 
binding factor/nuclear factor Y) trimer (Ihn et al. 1996; Ramirez et al. 2006).   Other 
functionally distinct DNA elements in the -300 bp region bind AP1, Ets1, and C/EBPβ 
(CCAAT/enhancer binding protein beta) proteins (Ramirez et al. 2006).   The Ets1 
transcription factor binds to the -285 to -282 bp region of the COL1A2 promoter to 
positively regulate transcription (Czuwara-Ladykowska et al. 2002).  However, the 
negative regulator Fli-1 competes with Ets-1 for binding to both the COL1A1 and 
COL1A2 promoters in normal dermal fibroblasts to regulate the expression of both genes 
(Czuwara-Ladykowska et al. 2002; Kubo et al. 2003).  C/EBP-β interacts with the -330 to   
-303 bp region of the COL1A2 promoter, although the role of this protein in regulating 
COL1A2 transcription depends on the conditions under which it is expressed.  
Overexpression of C/EBPβ in foreskin fibroblasts was shown to induce COL1A2 promoter 
expression (Ghosh 2002); on the other hand, C/EBPβ is a negative regulator of the TGFβ 
response and a positive regulator of TNFα repression of COL1A2 gene expression 
(Greenwel et al. 2000).  Binding of AP-1 to a site between -265 and -241 bp also appears 
to play a role in COL1A2 promoter regulation (Chung et al. 1996), and association of 
RFX5 with the COL1A2 (+ 7 bp) and COL1A1 (-11/+10 bp) promoter negatively regulates 
the transcription of both genes (Sengupta et al. 2002; Sengupta et al. 2005).   
1.4.3 Cytokines, growth factors and signalling pathways involved in type 
I collagen gene regulation 
 
Extracellular signalling molecules such as cytokines and growth factors play an important 
role in regulating type I collagen production via a number of signal transduction pathways 
(Verrecchia & Mauviel 2004).  TGFβ is a well-studied cytokine involved in type I collagen 
up-regulation (Dijke & Hill 2004; Verrecchia & Mauviel 2004; Massague & Wotton 
2000), but other factors such as insulin-like growth factor (IGF1), endothelin 1 (ET1), IL4, 
and IL13 also stimulate type I collagen production (Ramirez et al. 2006; Serpier et al. 
1998; Buttner et al. 2004). Well-studied negative regulators of type I collagen gene 
expression include TNFα (Inagaki et al. 1995; Kouba et al. 1999; Mori et al. 1996), IFNγ 












1994), and these all function by antagonizing TGFβ signalling (Verrecchia & Mauviel 
2002; Higashi et al. 1998).   
1.4.3.1 TGF-mediated regulation of type I collagen gene expression. 
 
TGF regulates a number of different cellular processes in both embryonic development 
and in the adult organism.  These include cell survival, differentiation, migration, adhesion, 
and synthesis of ECM components (Inagaki & Okazaki 2007).  This growth factor is the 
most potent stimulator of type I collagen gene expression and plays an important role in 
ECM synthesis and remodeling.  Overexpression of TGF has also been associated with a 
number of fibrotic diseases (Leask & Abraham 2004).   
 
TGF is secreted as a latent protein complex and associates with ECM components such as 
type IV collagen, fibronectin and fibrillin.  TGF is activated during tissue remodeling by 
factors such as MMPs, αv6 integrin and thrombospondins.  It then binds to the TGF type 
II receptor (TGFBRII) on the cell surface, resulting in the activation of the Smad signalling 
pathway.  TGFBRII phosphorylates TGFBRI (TGFβ type I receptor) which, in turn, 
phosphorylates two serine residues in the C-terminal motif of Smad2 and Smad3.  These 
are known as the receptor-activated Smads (R-Smads) and form hetero-oligomers with 
Smad4 (Co-Smad) before translocating to the nucleus.  Here the Smad complex regulates 
the transcription of a number of genes either by directly binding to the CAGAC consensus 
sequence or through interaction with transcription coactivators such as p300 and CBP 
(Ramirez et al. 2006).   
 
The -330 to -255 region of the COL1A2 promoter is known as the TGF-responsive 
element (TRE) consisting of Box 3A and Box B (figure 1.3).  In response to TGF, Box 
3A-bound Sp1 interacts with Box B-bound Smad3 and p300/CBP coactivators, leading to 
stimulation of COL1A2 gene transcription (Inagaki & Okazaki 2007; Zhang et al. 2000).  
Box 5A, upstream and overlapping Box 3A, binds C/EBP, which suppresses TGFβ-
stimulated COL1A2 promoter activity (Inagaki & Okazaki 2007). The COL1A1 promoter 












binding sites (Gaidarova et al. 2002; Jimenez et al. 1994)).  The Smad signalling pathway 
also appears to be involved in mediating the COL1A1 promoter response to TGFβ 
response, since overexpression of Smad3 increases COL1A1 promoter activity (Verrecchia 
et al. 2001a).  However, further studies need to be performed to determine how 
transcription factors associate with the COL1A1 promoter during TGFβ stimulation. 
 
 
FIGURE 1.3 The TGFβ-responsive element (TGFβ-RE) is involved in COL1A2 promoter activation by 
TGFβ.  TGFβ stimulation results in the activation of Smad2 and Smad3, which form a complex with Smad4 
before translocating into the nucleus.  The Smad complex then associates with p300/CBP and binds to the 
COL1A2 promoter in the -263 to -258 bp region (box B).  Further association of the Smad complex with Sp1, 
bound to the -300 bp region (box 3A), is required for complete COL1A2 promoter activity.  C/EBPβ negatively 
regulates TGFβ stimulated COL1A2 promoter activity by associating with the -330 to -303 bp region (box 
5A).  (Adapted from Inagaki & Okazaki, 2007). 
 
Binding of TGF to its receptor complex also stimulates production of Smad7, which then 
acts as a negative regulator of the TGF response by either interfering with Smad-receptor 
or Smad-Smad interactions (Itoh & ten Dijke 2007; Massague et al. 2005).  Smad7 can 
compete with R-Smads for binding to TGFβRI and thereby prevent their phosphorylation 
(Hayashi et al. 1997; Nakao et al. 1997).  Shi et al. (2004) reported that Smad7 can also 
induce dephosphorylation and deactivation of TGFRI itself by stabilizing and recruiting 
the protein phosphatase PP1/GADD34 complex to the receptors.  Smad7 can also recruit 
the ubiquitin ligase Smurf1 to the activated TGF receptors, leading to eventual 
degradation of the receptor (Heldin et al. 2009; Ramirez et al. 2006).   In human skin 
fibroblasts, overexpression of Smad7 may lead to a decrease in basal COL1A2 promoter 
activity as well as TGFβ-stimulated COL1A1 and COL1A2 promoter activity (Chen et al. 






















TGFβ is believed to be one of the important players in the tumour environment.  In normal 
and premalignant tissue TGFβ is responsible for inhibiting epithelial cell growth 
(differentiation, apoptosis, cytostasis) and also influences the stroma by suppressing 
inflammation and stroma-derived mitogens (Heldin et al. 2009; Massague 2008).  It is also 
involved in fibroblasts activation to myofibroblasts during conditions such as wound 
healing (Shephard et al. 2004).  However, TGFβ’s role in cancer is still controversial. 
Initially it is believed to act as a tumour suppressor, inhibiting cell growth and inducing 
apoptosis.  However, at later stages TGFβ secretion by tumour cells may trigger 
surrounding cells to secrete cytokines that result in tumour cell resistance to growth arrest 
stimuli and EMT induction (Bierie & Moses 2006). TGFβ then acts as a tumour promoter 
that may be used by the tumour cells to initiate immune evasion, promoting angiogenesis 
and facilitate tumour invasion and metastasis (Heldin et al. 2009; Massague 2008). 
 
The importance of TGFβ signalling in tumour-fibroblast interactions was highlighted in a 
recent mouse study (Bhowmick et al. 2004b), involving transplantation of fibroblasts with 
a targeted deletion of TGFBRII into mice together with breast tumour cells.  The resulting 
tumours were found to be more aggressive, with an increased number of metastases 
compared to those transplanted with normal fibroblasts.  Increased production of TGFα 
and hepatocyte growth factor (HGF) by these TGFβ-unresponsive fibroblasts was shown to 
play a role in this accelerated tumour cell growth observed.  These results suggest that 
TGFβ would usually act by limiting the production of these mitogenic factors by 
fibroblasts, and that unresponsiveness of fibroblasts to TGFβ signalling facilitates tumour 
development.   
1.4.3.1.1  CCN2 as a mediator of TGFβ’s effect on type I collagen gene 
expression. 
 
Connective tissue growth factor (CTGF/CCN2) is a member of the CCN family and these 
extracellular matrix-associated (matricellular) proteins are involved in mediating cellular 
responses to environmental factors and stimuli by their interactions with cell surface 












mediator of the biological effects induced by other molecules rather than stimulating 
responses directly (Blom et al. 2002); for example, CCN2 has been shown to enhance 
TGFβ-stimulated responses which includes increasing type I collagen gene expression 
(Leask et al. 2003; Quan et al. 2009; Shi-wen et al. 2006).  Although originally called 
CTGF, this protein is in fact not a growth factor and will hereafter be referred to as CCN2.   
 
The development of a CCN2-null mouse model has revealed the essential role of CCN2 in 
regulating the production of cartilage ECM during development (Ivkovic 2003).  CCN2 
knockout mice die soon after birth, mainly as a result of respiratory failure caused by 
skeletal defects, and fibroblasts from these mice had a reduced ability to migrate, form 
actin stress fibres, as well as attach to and contract the surrounding matrix (Blom et al. 
2002; Shi-wen et al. 2008).  These fibroblasts also express lower levels of certain pro-
angiogenic cytokines and have a decreased ability to produce type I collagen and α-SMA 
when stimulated with TGFβ.  CCN2 is constitutively expressed at low levels in adult 
tissues and biological fluids (Oliver et al. 2010), but expression is increased during 
inflammation and wound healing as well as in most fibrotic disorders (Khoo et al. 2006; 
Leask et al. 2009; Shi-wen et al. 2000).  In fact, constitutive CCN2 expression is a marker 
of pathological fibrosis (Chen et al. 2001;  Holmes et al. 2001) and most CCN2 studies 
have focussed on their role in fibrotic disorders with less information available on their 
function in normal adult tissue (Mason 2009; Oliver et al. 2010). 
 
CCN family member genes are highly conserved among species.  The CCN2 gene itself 
has five exons which are predicted to code for a signal peptide and four domains (see 
figure 1.4) (Blom et al. 2002).  The first exon is translated into a 37 amino acid secretory 
signal peptide that is involved in the export of CCN2 from the ER to the Golgi.  Exon II 
encodes for the first domain which is very similar to insulin-like growth factor binding 
protein (IGFBP) and is able to bind IGF with low affinity, while the second domain, 
encoded by exon 3, is very similar to the Von Willebrand factor type C repeat and is 
thought to play a role in oligomerisation.  The third domain is a thrombospondin type I 
domain (TSP1) which contains a cell attachment motif, and exon 5 encodes the C-terminal 












which is involved in cell surface receptor binding.  Since all four domains are highly 
similar to other known proteins, it has been suggested that the CCN2 gene evolved as a 





FIGURE 1.4 CCN2 protein domain structure. The CCN2 protein consists of an N-terminal secretory signal 
peptide (SP) and 4 domains.  IGFBP, Insulin growth factor binding protein; VWC, Von Willebrand factor type C 
repeat; TSP-1, Thrombospondin type 1 domain; CT, C-terminal domain.  
 
CCN2 can either be secreted through the Golgi apparatus into the stroma or remain 
attached to the cell surface and ECM (Blom et al. 2002; Chen et al. 2001).  CCN2 is 
expressed as a 38-kDa protein, but cleaved forms of the CCN2 protein have also been 
observed in different cell types, tissues and body fluids (Wahab et al. 2001).  The flexible 
hinge region joining the N-terminal domain (containing the IGFBP and VWC motifs) to 
the C-terminal domain (containing the TSP-1 and CT motifs) can undergo protease 
digestion resulting in products of 16-20 kDa that still maintain their biological activity and 
are capable of acting independently of each other (Grotendorst & Duncan 2005).  The N-
terminal domain, for example, interacts with IGF-2 to mediate differentiation and collagen 
synthesis while the C-terminal domain facilitates cell proliferation in partnership with EGF 
(Grotendorst & Duncan 2005).  CCN2 can also be cleaved into monomers (10-12 kDa), 
consisting of only one motif, and homodimers (~70-80 kDa) as well as phosphorylated 
forms of CCN2 (~44 kDa) have also been observed (Ball et al. 2003; Khoo et al. 2006; 
Holbourn et al. 2008; Tikellis et al. 2004; Wahab et al. 2001).  Much of the variation in 
CCN2 forms appears to be cell type specific (Blom et al. 2002). 
 
Although a unique CCN2 receptor has not been found, this protein appears to mediate 
much of its effects through cell adhesion receptors such as integrins and heparin sulphate 
proteoglycans (HSPG) (Chen & Lau 2009; Leask & Abraham 2004).  Association of 















CCN2 with these cell surface proteins leads to the activation of intracellular signalling 
molecules such as FAK (focal adhesion kinase), MAPK p42/44, PI3K and Rac which can 
in turn promote cell survival, proliferation, adhesion, and extracellular matrix production 
(Grotendorst et al. 2004; Mason 2009).  CCN2 may also form complexes with other 
growth factors, such as IGF, and binds either to the corresponding growth factor receptor 
or to an as yet unknown receptor (Grotendorst et al. 2004).  Secreted CCN2 may also be 
internalized again and undergo endosomal degradation, mediated by binding of the C-
terminal CT motif of CCN2 to the low density lipoprotein receptor related protein 
(LRP)/α2-macroglobulin receptor (α2-MR) (Chen et al. 2001; Segarini et al. 2001). 
 
Basal expression of CCN2 varies according to cell type, but it is constitutively expressed at 
low levels in normal human skin in vivo and in primary human skin fibroblasts (Quan et al. 
2009). CCN2 expression is regulated mainly at the transcriptional level (Grotendorst et al. 
1996; Leask et al. 2003) and one of the most potent induc rs of CCN2 gene expression in 
fibroblasts, but not in epithelial cells, is TGFβ (Hishikawa et al. 1999; Leask et al. 2003).  
CCN2 also acts as a co-mediator of TGF-β’s ability to promote type I collagen synthesis, 
with ccn2-/- embryonic fibroblasts being unable to induce type I collagen synthesis in 
response to TGFβ (Shi-wen et al. 2006).  An important relationship therefore exists 
between TGFβ, CCN2 and type I collagen, and in aged human skin (≥ 80 years) the 
expression of all three of these proteins is co-ordinately reduced when compared to levels 
in younger skin samples (21-30 years) (Quan et al. 2009).   
 
Regulation of CCN2 gene expression by TGFβ involves the association of a Smad3/Smad4 
complex with a Smad binding element (SBE) on the CCN2 promoter, with no involvement 
of either Smad2 or p300 (Holmes et al. 2001).  The CCN2 promoter also has a TGFβ 
response element (TGFβRE) which appears to be important for the regulation of basal 
CCN2 gene expression in fibroblasts, and is therefore also called the basal control element 
(BCE-1) (Holmes et al. 2001).  Other signalling pathways that are involved in basal and 
TGFβ-mediated CCN2 up-regulation include the ras/MEK/ERK and protein kinase C 
(PKC) pathways (Blom et al. 2002; Leask et al. 2003).  CCN2 gene expression is also 












IL-1, prostaglandin E2, lefty and cAMP (cyclic adenosine monophosphate) act as negative 
regulators (Lin et al. 1998; Khoo et al. 2006; Mason et al. 2002; Nowinski et al. 2002).  
 
Although CCN2 is known to enhance TGFβ-mediated up-regulation of type I collagen 
gene expression, the exact mechanism involved in this regulation is not well understood 
(Quan et al. 2009; Shi-wen et al. 2006).  However, changes in CCN2 gene expression have 
previously been linked to changes in type I collagen gene expression (Ponticos et al. 2009; 
Shi-wen et al. 2006; Uchio et al. 2004), with overexpression of CCN2 in dermal fibroblasts 
resulting in increased COL1A2 gene expression, with specific involvement of the -376/+54 
region of the promoter (Shi-wen et al. 2000).  In lung epithelial cells, CCN2 increased 
TGFβ binding to its receptor complex, with a resulting increase in Smad2 phosphorylation 
and Smad-dependent gene transcription (Abreu et al. 2002).  However, Smad-dependent 
signalling was not found to be directly involved in CCN2-mediated regulation of type I 
collagen in normal skin fibroblasts (Quan et al. 2009).  Here, knockdown of CCN2 caused 
a significant down-regulation in COL1A2 promoter activity, but neither abrogation nor 
overexpression of CCN2 affected Smad2 or Smad3 phosphorylation.   
 
CCN2 is thought to play a role in cancer cell migration, invasion and angiogenesis (Chu et 
al. 2008; Shi-wen et al. 2008).  However, the exact role of this protein in cancer is still not 
well understood, and both positive and negative correlations have been drawn between 
CCN2 levels and tumour progression (Chu et al. 2008; Cicha & Goppelt-Struebe 2009). 
This may indicate that the action of CCN2 in cancer is context-dependent (Oliver et al. 
2010).  Increased expression of CCN2 has been detected in a number of cancers, including 
esophageal, melanoma and pancreatic cancer (Koliopanos et al. 2002; Kubo et al. 1998; 
Wenger et al. 1999). One study on breast tumour samples found that ~55% of samples had 
higher than normal CCN2 mRNA levels (Xie et al. 2001).  However, in a separate study, 
significantly lower than normal CCN2 mRNA and protein expression was observed in 
breast tumour samples and this was correlated with poor prognosis, increased risk of 
metastasis and higher mortality rate (Jiang et al. 2004).    CCN2 also formed part of a 
“bone metastasis gene signature” that cooperatively facilitated metastasis of MDA-MB-












distinguish between CCN2 expression in tumour cells themselves versus expression in 
surrounding stromal cells such as fibroblasts.  Since regulation of this gene is cell-type 
specific and CCN2’s associations with ECM proteins may vary, the function of CCN2 
could also differ according to cell type. 
1.4.3.2 Interferon-mediated regulation of type I collagen gene expression. 
 
Interferons (IFNs) are proinflammatory cytokines that play an important role in innate and 
acquired immune responses (Leask & Abraham 2004).  The interferon family consists of 
type I, II and III IFNs.  Type I IFNs include IFNα and IFNβ, and are usually produced as a 
first line of defense against infections, where they function by limiting the spread of 
pathogens in the first few days of infection and by stimulating the adaptive immune 
response (Zhou et al. 2007).  IFNγ, the only type II IFN, is usually produced by T-cells and 
NK cells as part of the adaptive immune response, while the recently discovered type III 
IFNs (IFNλ1, IFNλ2 and IFNλ3) function similarly to type I IFNs but act through a 
different cell surface receptor (Ghosh et al. 2001; Zhou et al. 2007). Both type I and type II 
IFNs have been shown to down-regulate type I collagen gene expression via the JAK/Stat 
signalling pathway, but more studies have focused on IFNγ’s role as an antifibrotic 
cytokine (Buttner et al. 2004; Duncan & Berman 1985; Inagaki et al. 2003;  Sengupta et al. 
2002; Sengupta et al. 2005).    
 
Although both type I and type II interferons activate the JAK/Stat signalling pathway, they 
generally use different mechanisms (figure 1.5).  Association of type I IFNs with the IFN-
α/β receptor (IFNαR1 & IFNαR2) causes JAK1 and TYK2 to bind to the receptor complex 
and induce tyrosine phosphorylation of Stat1α/β and Stat2.  The Stat1/2 dimer associates 
with IRF-9 (IFN regulatory factor nine) to form the ISGF3 complex which is translocated 
into the nucleus (Ihle & Kerr 1995; Schindler et al. 2007).  Here, the ISGF3 complex binds 
to interferon-stimulated response elements (ISREs) (AGTTTN3TTTCC) on specific gene 
promoters resulting in the transcription of the relevant genes.  When IFNγ binds to its 
receptor (IFNγR1 and IFNγR2), JAK1 and JAK2 are activated and, in turn, induce tyrosine 












the nucleus where they activate genes containing a γ-activation sequence (GAS) 
(TTTCCNGGAAA) in their promoters.  Type I IFN induction can also cause Stat1 
homodimer formation, but usually to a lesser extent than that found in the ISGF3 complex 
(Sadzak et al. 2008). 
 
 
FIGURE 1.5 The antagonistic effects of interferons (IFNs) on TGFβ-stimulated COL1A2 transcription.  
Binding of TGFβ to its receptors stimulates Smad2 and Smad3 phosphorylation, and these Smads form a 
complex with Smad4 before translocating to the nucleus.  Here, the complex interacts with p300 and 
stimulates COL1A2 transcription by binding to the TGFβ response element (TbRE) of the promoter. Binding of 
IFNγ to its receptors activates the JAK/Stat signalling pathway, resulting in Stat1 phosphorylation and 
dimerization and/or activation of the Y Box binding protein (YB-1).  Both these factors antagonize TGFβ-
stimulated COL1A2 promoter activity by preventing interaction of Smad3 with p300. YB-1 also negatively 
regulates COL1A2 promoter activity by binding to the interferon gamma response element (IgRE) on the 
COL1A2 promoter.  Binding of the RFX5/CIITA complex to the +7 region of the COL1A2 promoter also inhibits 
transcription.  IFNα and IFNβ can also negatively regulate COL1A2 promoter activity by activating JAK/Stat 
signalling.  IFNα-dependent regulation involves activated Stat1, which prevents p300/Smad3 association with 














































COL1A2 promoter regulation by IFNγ has been well studied, and has mostly focussed on 
the role of Stat1 in antagonizing TGFβ-mediated stimulation of type I collagen gene 
expression.   IFNγ-stimulation of fibroblasts does not affect Smad3 or Smad4 expression 
or localisation (Gosh et al. 2001), however activated Stat1 is able to compete with Smad3 
for binding to p300/CBP, which is essential for COL1A2 promoter activation by TGFβ 
(Ghosh et al. 2001).  IFNγ has also been shown to up-regulate Smad7 gene expression 
during skin wound healing (Ishida et al. 2004) and also in epithelial and hepatic stellate 
cells (Ulloa et al. 1999; Weng et al. 2007), although Ghosh et al. (2001) did not observe 
any changes in Smad7 gene expression in fibroblasts stimulated with IFNγ.  These 
discrepancies in results may be a result of variations in cell lineage-specific interactions.  
IFNγ-mediated repression of COL1A1 gene expression in skin fibroblasts appears to 
involve the -129 to -107bp region of the COL1A1 promoter as well as the transcription 
factor IRF-1 (interferon regulated factor 1), although the exact mechanism of action is not 
known (Yuan et al. 1999).   
   
IFNγ may also inhibit type I collagen gene expression in a Stat1-independent manner. The 
transcription factor YB-1 is also activated by IFNγ and negatively regulates COL1A2 
promoter activity by preventing p300/Smad3 interactions, or by binding directly to the 
interferon gamma response element (IgRE) on the COL1A2 promoter (Higashi et al. 
2003a; Higashi et al. 2003b).  IFNγ stimulation has also been shown to increase binding of 
RFX5, in association with CIITA, to the transcription start site (+7) of the COL1A2 
promoter (Fang et al. 2009; Sengupta et al. 2002; Sengupta et al. 2005; Xu et al. 2003).  
COL1A1 promoter activity can also be negatively regulated by binding of the 
RFX5/CIITA complex to the -11/+10 promoter region in response to IFNγ (Sengupta et al. 
2005). 
 
Although IFNγ down-regulates both COL1A1 and COL1A2 gene expression, much less is 
known about the role of type I IFNs in regulating type I collagen gene expression.  IFNα 
has been shown to negatively regulate COL1A2 promoter activity by associating with 












negatively regulate type I collagen synthesis (Duncan & Berman 1985), however further 
studies need to be performed to establish the mechanisms involved.   
1.4.3.3 Regulation of type I collagen by MAPK signalling pathways.  
 
MAP kinases are a group of serine-threonine specific protein kinases involved in 
conveying various extracellular signals from the cell surface to the nucleus.  MAPK 
signalling pathways play an essential role in controlling a number of cellular responses, 
including cell proliferation, differentiation and death (Bardwell 2006).  The three major 
MAPK subfamilies are the extracellular signal-regulated kinases (ERK1 and ERK2), the 
stress-activated protein (SAP) kinases (c-Jun N-terminal kinases – JNK1, JNK2 and JNK3) 
and the p38 MAP kinases (α, β, δ, γ) (Javelaud & Mauviel 2005) (figure 1.6).  MAPKs are 
phosphorylated by MAPK kinases (MAPKKs) which, in turn, are activated by MAPK 
kinase kinases (MAPKKKs).  Membrane-associated kinases, such as growth factor or 
cytokine receptors, activate these signalling pathways and downstream targets include a 
number of different nuclear kinases and transcription factors.  Both positive and negative 
regulation of type I collagen by MAPKs have previously been observed, and some studies 
have shown conflicting results which suggest that regulation occurs in a cell-type specific 
manner (Leask & Abraham 2004; Javelaud & Mauviel 2005).  
1.4.3.3.1 The MEK/ERK signalling pathway 
 
The MEK/ERK signalling pathway can be activated in response to growth factors, 
mitogens and G-coupled protein receptors (GPCRs).  ERK1 and ERK2 are phosphorylated 
by MEK1 and MEK2 (MAPKK’s) which are, in turn, activated by Raf-1 (a MAPKKK).  
The membrane-bound onco-protein Ras is one of the proteins that can activate Raf-1 after 














FIGURE 1.6 MAP kinase signalling pathways potentially involved in tumour-mediated type I collagen 
down-regulation.  The MAPK pathways include the MEK/ERK, SAPK/JNK and p38 MAPK signalling 
pathways.  These signalling pathways convey extracellular signals to the nucleus by means of a signalling 
cascade involving activation of a MAPK by a MAPKK which is, in turn, is activated by a MAPKKK in response 
to cell surface receptor signals.  (Adapted from www.cellsignal.com). 
 
The MEK1-ERK1/2 signalling pathway plays an important role the regulation of type I 
collagen steady-state mRNA levels in dermal fibroblasts.  Phosphorylated ERK1/2 has 
been observed in quiescent dermal fibroblasts and inhibition of MEK/ERK activation 
results in a modest increase in both COL1A1 and COL1A2 mRNA levels with increased 
stabilization of COL1A1 mRNA levels (Sato et al. 2004).  Addition of EGF (Mimura et al. 
2006), C2-ceramide (Reunanen et al. 2000) and lysophosphatidic acid (LPA) (Sato et al. 
2004) to dermal fibroblasts also negatively regulates type I collagen gene expression in a 
MEK/ERK-dependent manner.   EGF stimulation resulted in decreased type I collagen 
mRNA stability with no effect on COL1A2 promoter activity, while synthetic C2-ceramide 
inhibited COL1A2 promoter activity as well as type I collagen mRNA levels and stability.  
Addition of the extracellular phospholipid LPA to fibroblast inhibited TGFβ-mediated up-
regulation of type I collagen gene expression in an ERK-dependent manner, and also 
decreased type I collagen mRNA stability.   
 
These results suggest that the MEK/ERK signalling pathway is involved in negative 







































that ERK2, and not ERK1, is involved in increasing type I collagen synthesis after TGFβ 
stimulation of NIH/3T3 fibroblasts.  Addition of IL-4 or IL-13 to dermal fibroblasts also 
increases type I collagen promoter activity in an ERK-dependent manner (Bhogal & Bona 
2008).  The effect of MEK/ERK signalling on type I collagen gene expression may 
therefore be dependent on interactions with other signalling pathways and/or may involve 
differential activation of either ERK1 or ERK2. 
1.4.3.3.2 The JNK signalling pathway 
 
JNK signalling is often activated in response to extracellular stress signals and plays a role 
in both the innate and adaptive immune response (Huang et al. 2009).  The regulation of 
this pathway is very complex and may be influenced by a number of upstream kinases such 
as TGFβ-activated kinase 1 (TAK1), MEK1 and MLK3 (Johnson & Lapadat 2002; Huang 
et al. 2009).  Activated JNK is translocated to the nucleus where it phosphorylates a 
number of transcription factors, including JunB, p53, and Stat3.  JNK is also the only 
MAPK known to phosphorylate c-Jun, which forms the main component of the AP-1 
complex (Javelaud & Mauviel 2005).   
 
The role of the JNK signalling pathway in type I collagen regulation appears to be context 
dependent.  TGFβ stimulation can up-regulate the expression of c-Jun and JunB in a Smad-
dependent manner and both c-Jun and JunB then form part of a negative autoregulatory 
feedback loop by binding to Smad3 and thereby preventing the association of Smad3 with 
the Smad binding elements (SBE) in TGFβ-responsive promoters such as the COL1A2 
promoter (Verrecchia & Mauviel 2004; Verrecchia et al. 2001a).  However, TGFβ 
activation of the JNK signalling pathway is also involved in the induction of a 
myofibroblast phenotype with a resulting increase in type I collagen gene expression, as 
demonstrated in studies performed on embryonic mice fibroblasts (Liu et al. 2007). 
Myofibroblast activation involved upstream focal adhesion kinase (FAK) and increased 
ECM contraction, which suggests that activation of the FAK/JNK pathway by TGFβ could 
induce a matrix-remodelling phenotype with cross-talk between TGFβ signalling and 













To complicate matters even further, the pro-inflammatory cytokines TNFα and IL-1β also 
activate the JNK signalling pathway in order to antagonize TGFβ-induced type I collagen 
gene expression via a mechanism involving the sequestration of p300 by cJun or JunB 
(Dennler et al. 2000; Verrecchia et al. 2000; Verrecchia et al. 2003).  Decreased levels of 
p300 are therefore available for association with the Smad complex on the COL1A2 
promoter, resulting in decreased COL1A2 gene transcription.  The regulation of type I 
collagen gene expression by the JNK signalling pathway is therefore quite complex and 
appears to vary depending on signals obtained from a number of different cell surface 
receptors. 
1.4.3.3.3 The p38 MAPK signalling pathway 
 
The p38 MAP kinase pathway is activated in response to physical stress signals (e.g. 
osmotic shock, heat, and UV light) and appears to play an important role in regulating 
inflammation.  The proinflammatory cytokines such as TNFα and IL1 can trigger p38 
MAPK signalling activation, however anti-inflammatory TGFβ can also activate this 
pathway (Huang et al. 2009; Katsoulidis et al. 2005; Zhang et al. 2007a).  Once activated, 
p38 can phosphorylate a number of downstream kinases and transcriptions factors such as 
ATF-2 (activating transcription factor 2), Stat1 and COX2 (cyclooxygenase 2) (van Boxel-
Dezaire et al. 2006; Zhang et al. 2007b).     
 
A number of studies have shown that type I collagen gene expression is up-regulated in 
response to p38 MAPK activation (Inagaki & Okazaki 2007). In dermal fibroblasts 
stimulated with TGFβ, activation of p38 MAPK signalling enhanced the association of 
Smad3 with p300/CBP coactivators and therefore increased the expression of type I 
collagen (Abecassis et al. 2004; Sato et al. 2002).   Upstream TAK1 appeared to be 
involved in activating p38 in response to TGFβ, since blocking TAK1 expression 
prevented TGFβ-stimulated type I collagen up-regulation (Hanafusa et al. 1999; Ono et al. 












complex with Smad4 in response to TGF-β stimulus (Hanafusa et al. 1999).  However, the 
role of this interaction in type I collagen regulation is not yet known.  
 
Although p38 up-regulates type I collagen gene expression in response to TGFβ 
stimulation, the role of p38 in IFN-mediated regulation of type I collagen has not 
previously been examined.  The p38 signalling pathway is activated in response to both 
IFNα and IFNγ via a mechanism involving Stat1 up-regulation and serine phosphorylation 
(Goh et al. 1999; Uddin et al. 1999).  However, further work will need to be performed to 
determine whether IFN-stimulated p38 activation has any effect on type I collagen 
regulation. 
1.4.4 Type I collagen gene regulation in tumour devel pment. 
 
Studies that have analyzed type I collagen levels in tumour tissue have shown variations in 
results.  In many types of solid tumours (including breast, lung, prostate and colon) a 
desmoplastic response has been observed, involving activation of fibroblasts in the area 
and leading to an increased deposition of type I collagen and increased expression of α-
SMA (Tlsty & Hein 2001).  However, other studies have shown that type I collagen levels 
are decreased in later stages of tumourigenesis (Fenhalls et al. 1999; van Kempen et al. 
2005).  Variations in factors such as the stage of tumour development and the region of the 
tumour tissue that was examined may contribute to the discrepancies in results. 
 
Previous findings suggest that levels of type I collagen present in tumour tissue may differ 
depending on the stage of tumour progression.  In a study performed in our laboratory 
(Fenhalls et al. 1999) an up-regulation of type I collagen gene expression was observed in 
stage I breast tumours, while type II and III tumour tissue showed lower levels of type I 
collagen gene expression.  In a study on melanoma tissue, type I collagen gene expression 
was also shown to be lower in the deeply invasive vertical growth phase of melanomas in 
the reticular dermis when compared to levels observed in the earlier stages in the papillary 
dermis (van Kempen et al. 2005).  Increased MMP expression was also detected in both 












type I collagen protein observed in the tumour tissue could be a result of both degradation 
by collagenases in the ECM and decreased type I collagen gene expression by fibroblasts 
in later stage tumours.  
 
Different regions of the tumour may also show variations in type I collagen levels.  While 
the tumour mass itself may have higher levels of type I collagen in the ECM (Bhowmick et 
al. 2004b), later stage invasive tumours need to overcome the barriers of the surrounding 
ECM by degrading type I collagen at the invasive front and in the peripheral tumour 
regions in order to invade the surrounding tissue (Rowe & Weiss 2009).  Recent studies 
have shown that fibroblasts and tumour cells at the invasive front can form migration 
tracks to facilitate further tumour cell migration (Gaggioli et al. 2007; Wolf et al. 2007).  
These microtracks are formed in an MMP and adhesion-force-dependent manner, with 
MT-MMP1 (membrane-type matrix metalloproteinase 1) playing an important role in 
matrix degradation at the leading invasive edge (Rowe & Weiss 2009).  The microtracks 
facilitate further collective invasion of groups of tumour cells which widen the tracks 
further to form macrotracks (Wolf et al. 2007).  This collective invasion allows tumour 
cells which have retained their cell-cell junctions to also invade the ECM (Ilina & Friedl 
2009).   
 
The presence of certain serum constituents such as urokinase-type plasminogen activator 
(u-PA) could also play a role in facilitating MMP secretion by tumour cells.  Morgan & 
Hill (2005) found that three different breast cancer cell lines (MDA-MB-231, ZR-75-1 and 
MCF-7) grown on a type I collagen matrix were capable of degrading the surrounding 
collagen by secreting MMPs (MMP-1, -3, -9, -13, -14), but only in the presence of  u-PA.    
Interestingly, the urokinase-type plasminogen activator receptor-associated protein 
(Endo180) was also shown to be involved in the uptake and degradation of type I collagen 
by tumour cells (Wienke et al. 2007).  Under normal conditions this protein is only 
expressed by fibroblasts, where it functions as a collagen receptor involved in the binding 
and uptake of extracellular collagens, which are then targeted to intracellular organelles for 
degradation.  It therefore facilitates ECM remodeling and also functions as a promigratory 












cells and in epithelial tumour cell lines that have a high invasive ability.  The expression of 
this protein by tumour cells was linked to increased tumour growth and reduced tumour 
collagen content, and was also an independent predictor for shorter disease-free patient 
survival.  Interestingly, mice with a targeted deletion in the Endo180 gene that were 
crossed with tumour-prone mice had a decreased tumour burden, thought to be a result of 
the inability of surrounding stromal fibroblast to clear collagens from the invasive front 
(Madsen et al. 2007; Curino et al. 2005; Wienke et al. 2007).  The balance between type I 
collagen synthesis and degradation is therefore essential in determining the ability of 
tumour cells to invade the surrounding ECM.   
1.4.5 Study hypothesis 
 
This study is based on the hypothesis that tumour cells grown in close proximity to normal 
fibroblasts have a negative regulatory effect on type I collagen gene expression. 
1.4.6 Significance 
 
Current knowledge of the role of tumour cells in regulating the expression of ECM 
production in neighbouring fibroblasts is limited.  Since type I collagen forms the main 
component of the ECM, a better understanding of the mechanisms involved in tumour-
mediated regulation of type I collagen gene expression in fibroblasts could result in a better 
understanding of the process of tumour invasion and lead to the development of novel drug 
targets to inhibit tumour invasion and metastasis. 
1.4.7 Aims and objectives 
 
The goal of this study was to investigate the effect of breast tumour cells on type I collagen 
gene expression in neighbouring fibroblasts.  An in vitro co-culture system was used to 
investigate the role of cytokines, adhesion molecules and fibroblast signalling pathways in 













1)  To investigate the effect of breast tumour cells on type I collagen gene expression 
and production in fibroblasts. 
Direct and indirect co-culture models will be used to determine how tumour cells 
regulate type I collagen gene expression in fibroblasts.  Fibroblasts will also be 
transfected with COL1A2 promoter deletion constructs to determine whether 
tumour cells regulate COL1A2 promoter activity.   
 
2) To identify signalling pathways involved in tumour-mediated down-regulation of 
type I collagen gene expression. 
Fibroblast/tumour co-culture medium will be screened for the presence of 
cytokines and/or growth factors that could be involved in negatively regulating type 
I collagen gene expression.  Specific fibroblast signalling pathways that could be 
involved in tumour-mediated regulation of type I collagen gene expression will also 
be further investigated.  
 
3) To characterize the effect of tumour cell/fibroblast co-culture on cell adhesion and 
ECM components. 
An Extracellular Matrix and Adhesion Molecule microarray will be used to 
determine the effect of tumour cells on ECM and adhesion molecule gene 
expression in co-cultured fibroblasts.  The role of differentially expressed genes in 
























BREAST TUMOUR CELL-MEDIATED MODULATION OF TYPE I 




In normal mammary tissue, epithelial cells form ducts that are separated from the 
surrounding stroma by a basement membrane.  The stroma is made up of fibrillar 
extracellular matrix (ECM), capillaries and cells such as fibroblasts a d immune cells 
(Kalluri & Zeisberg 2006).   The ECM is essential for maintaining tissue structure and 
homeostasis and loss of this normal tissue architecture has often been associated with 
cancers (Kenny et al. 2007; Nelson & Bissell 2006).   
 
During the invasive stage of tumour progression, the basement membrane is degraded and 
tumour cells move into the surrounding stroma, where they come into close contact with 
stromal cells such as fibroblasts (Kalluri & Zeisberg 2006).  This close contact allows for 
heterotypic interactions to occur between tumour cells and fibroblasts, which would not be 
possible under normal conditions.  Since fibroblasts produce the type I collagen that forms 
the main component of the ECM, these fibroblast-tumour interactions could lead to 
changes in type I collagen production by fibroblasts with resultant changes in the tumour 
ECM.  
 
Previous studies on breast cancer tissue have shown that type I collagen mRNA levels are 
increased in fibroblasts adjacent to stage I tumours compared to levels in normal breast 
tissue, but decreased in stage II and stage III tumours.  Further in vitro studies showed that 
type I collagen mRNA and protein levels were negatively regulated by direct co-culture of 
either primary breast tumour cells or WI38 lung fibroblasts with four different breast 














The aim of this chapter was to further investigate the role of breast tumour cells in 
modulating type I collagen gene expression in normal fibroblasts.  Direct and indirect co-
culture systems were used to determine the effect of MDA-MB-231 breast tumour cells on 
type I collagen gene expression in normal WI38 lung fibroblasts and CCD-1068SK breast 
skin fibroblasts.  The MDA-MB-231 breast tumour cell line was chosen, since these cells 
had previously been shown to significantly repress type I collagen gene expression in 
normal fibroblasts during direct co-culture experiments (Fenhalls et al. 1999).  This tumour 
cell line was originally derived from a patient with invasive ductal carcinoma (grade III, 
poorly differentiated) and has been characterised as a basal type breast cancer that is 
oestrogen and progesterone negative (Lacroix et al. 2004).  It therefore represents a highly 
invasive and relatively aggressive type of breast cancer.  Fibroblasts were also co-cultured 
with MCF12A non-tumourigenic epithelial cells to enable comparison of the effect of non-
tumourigenic epithelial versus tumour cells on type I collagen gene expression.  The effect 
of tumour cells on COL1A2 promoter activity was also inv stigated in WI38 fibroblasts by 
using COL1A2 promoter deletion constructs.  The results of these experiments enabled us 
to determine the region of the COL1A2 promoter that was involved in tumour-mediated 



























2.2.1 The effect of breast tumour cells on type I collagen gene expression after 
indirect co-cultures with normal fibroblasts. 
 
Tumour cells are able to communicate with fibroblasts in a paracrine manner by secreting 
soluble factors such as cytokines and growth factors.  MDA-MB-231 breast tumour cells 
may therefore modulate type I collagen gene expression in neighbouring fibroblasts via 
such secreted factors.  To investigate this possibility, an indirect co-culture system was 
used to separate the fibroblasts from the tumour cells during co-culture. 
 
CCD-1068SK breast skin fibroblasts were indirectly co-cultured with an equal number of 
MDA-MB-231 tumour cells for 48 hours (section 6.3).  A transwell insert with a 0.2 μm 
pore size was used to allow secreted factors to pass through, but prevent direct contact 
between fibroblasts and tumour cells.  RNA was extracted from CCD-1068SK fibroblasts 
after indirect co-culture and used for quantitative real-time PCR analysis (section 6.6 to 
6.8).  Results showed that neither COL1A1 nor COL1A2 mRNA levels were changed in 
CCD-1068SK fibroblasts indirectly co-cultured with MCF12A epithelial cells, when 
compared to levels observed in co-cultures with CCD-1068SK fibroblasts (figure 2.1 A). 
Indirect co-culture with MDA-MB-231 tumour cells also did not affect COL1A2 mRNA 
levels, while COL1A1 mRNA levels were significantly up-regulated.  Protein was also 
extracted from co-cultured cells and used to determine endogenous α1(I) and α2(I) 
procollagen levels by means of immunoblotting with a type I collagen antibody that 
recognises both procollagen chains (section 6.9 - 6.11).  Results showed that procollagen 
levels in CCD-1068SK fibroblasts were not affected by indirect co-culture with either 


















FIGURE 2.1 Type I collagen mRNA and protein levels in normal fibroblasts after indirect co-culture 
with MDA-MB-231 breast tumour cells.  MDA-MB-231 tumour cells were indirectly co-cultured with an equal 
number of CCD-1068SK or WI38 fibroblasts for 48 hours.  (A) Real-time PCR results show relative COL1A1 
and COL1A2 mRNA levels in CCD-1068SK fibroblasts after indirect co-culture with MDA-MB-231 tumour 
cells.  Indirect co-cultures of CCD-1068SK fibroblasts with an equal number of MCF12A cells or CCD-1068SK 
fibroblasts were used as controls. The graph shows the mean ± SD from a representative experiment. 
(*p≤0.05, n=3). (B) Immunoblotting results show endogenous α1(I) and α2(I) procollagen levels in CCD-
1068SK fibroblasts after indirect co-culture with tumour cells. β-tubulin was used as a loading control. (C) 
Real-time PCR analysis of COL1A1 and COL1A2 mRNA levels in WI38 fibroblasts indirectly co-cultured with 
tumour cells. (D) Immunoblotting analysis of endogenous α1(I) and α2(I) procollagen levels in WI38 fibroblasts 
after indirect co-culture.  Abbreviations: CCD, CCD-1068SK; MDA, MDA-MB-231.  Brackets enclose the cell 
line with which CCD-1068SK or WI38 fibroblasts were indirectly co-cultured. 
 
WI38 lung fibroblasts were also indirectly co-cultured with MDA-MB-231 tumour cells in 
a similar manner to CCD-1068SK fibroblasts.  Real-time PCR results showed that 
COL1A1 and COL1A2 mRNA levels in WI38 fibroblasts were not changed after indirect 
co-culture with MCF12A or MDA-MB-231 cells (figure 2.1 C).  Levels of α1(I) and α2(I) 
procollagen were also not affected by indirect co-culture of WI38 fibroblasts with either 
MCF21A or MDA-MB-231 cells (figure 2.1 D).   
 
Regulation of type I collagen gene expression in both CCD-1068SK and WI38 fibroblasts 
was therefore not significantly influenced by factors secreted from either MCF12A 
epithelial cells or MDA-MB-231 tumour cells when cell types were separated from each 


















































































































indirectly co-cultured with MDA-MB-231 tumour cells, COL1A2 mRNA and type I 
procollagen levels remained unchanged.    
 
2.2.2 The effect of breast tumour cells on type I collagen gene expression in direct 
co-cultures with fibroblasts. 
 
To determine the effect of breast tumour cells on type I collagen gene expression when in 
close contact with fibroblasts, a direct co-culture system was employed.  This involved 
mixing MDA-MB-231 tumour cells with an equal number of normal fibroblasts for 48 
hours (section 6.2).   
 
After direct co-culture of CCD-1068SK fibroblasts with MDA-MB-231 or MCF12A cells, 
RNA and protein was extracted from mixed cells and used for further analysis. Since 
MDA-MB-231 and MCF12A cells do not express type I collagen, results obtained are only 
a reflection of type I collagen production by fibroblasts.  Real-time PCR analysis of RNA 
isolated from CCD-1068SK/MDA-MB-231 co-cultures showed that both COL1A1 and 
COL1A2 mRNA levels were significantly down-regulated (p ≤ 0.01) when compared to 
levels in CCD-1068SK monocultures.  No change in COL1A1 or COL1A2 mRNA levels 
was observed in the control CCD-1068SK/MCF12A co-cultures (figure 2.2 A).  Levels of 
endogenous α1(I) and α2(I) procollagen were also lower in CCD-1068SK fibroblasts 
directly co-cultured with MDA-MB-231 cells, but remained unchanged in co-cultures with 
MCF12A cells (figure 2.2 B).   
 
A radioactive-based assay was used to independently determine the level of secreted α1(I) 
and α2(I) procollagen protein synthesised by CCD-1068SK fibroblasts during co-cultures.  
Briefly, [3H]-proline was added to CCD-1068SK/MDA-MB-231 co-culture medium 
during incubation, which allowed for its incorporation into α1(I) and α2(I) procollagen.  
Type I collagen cross-linking was prevented by adding β-aminopropionitrile to the 
medium.  After 20 hours incubation the medium was removed from cells and the samples, 
containing secreted procollagen, were processed as described in Materials and Methods 
(section 6.12). The results showed that lower levels of α1(I) and α2(I) procollagen were 












tumour cells, when compared to levels in CCD-1068SK monocultures and CCD-
1068SK/MCF12A co-cultures (figure 2.2 C).  The results of the [3H]-proline assay also 
confirmed that the α1(I) and α2(I) procollagen polypeptides were being synthesized in the 
correct 2:1 ratio.  This ratio was not observed in immunoblotting assays due to differences 
in specificity of the type I collagen antibody for α2(I) and α1(I) procollagen. 
 
 
FIGURE 2.2 Type I collagen mRNA and protein levels in normal fibroblasts after direct co-culture with 
MDA-MB-231 breast tumour cells.  MDA-MB-231 tumour cells were directly co-cultured with an equal 
number of fibroblasts for 48 hours.  Fibroblast monocultures and co-cultures with MCF12A cells were used as 
controls. (A) Real-time PCR analysis of COL1A1 and COL1A2 mRNA levels in CCD-1068SK/MDA-MB-231 
co-cultures. The graph shows the mean ± SD from a representative experiment (** p0.01, n=3).                   
(B) Immunoblotting results show endogenous α1(I) and α2(I) procollagen protein levels in CCD-1068SK 
fibroblasts after direct co-cultures.  (C) De novo synthesis of type I collagen measured by [3H]-proline 
incorporation into CCD-1068SK/MDA-MB-231 co-culture medium. (D) Real-time PCR analysis of COL1A1 and 
COL1A2 mRNA levels in WI38/MDA-MB-231 co-cultures. The graphs shows the mean ± SD. (* p0.05, n=3). 
(E) Immunoblotting results show endogenous α1(I) and α2(I) procollagen protein levels in WI38/MDA-MB-231 




















































































































































Direct co-culture of MDA-MB-231 tumour cells with WI38 lung fibroblasts also resulted 
in a decrease in both COL1A1 and COL1A2 mRNA levels in fibroblast, relative to WI38 
monocultures and co-cultures with MCF12A cells (figure 2.2 D).  Close contact with 
MDA-MB-231 tumour cells also decreased endogenous α1(I) and α2(I) procollagen levels 
(figure 2.2 E) and de novo synthesis of type I procollagen (figure 2.2 F).  MCF12A co-
culture did not significantly influence type I procollagen levels in WI38 fibroblasts.   
 
These results show that MDA-MB-231 tumour cells require close contact with the normal 
CCD-1068SK and WI38 fibroblasts in order to down-regulate type I collagen gene 
expression. This regulation occurs at the mRNA level with a resulting decrease in 
endogenous α1(I) and α2(I) procollagen levels as well as the amount of secreted 
procollagen polypeptides.  No change in type I collagen gene expression was observed in 
direct co-cultures with MCF12A cells, and therefore the negative regulatory effect on type 
I collagen synthesis is specifically as a result of the presence of tumour cell.   
 
2.2.3 Separation of normal breast skin fibroblasts after direct co-culture with breast 
tumour cells. 
 
Thus far, analysis of type I collagen gene expression involved the extraction of total RNA 
and protein from the combined CCD-1068SK/MDA-MB-231 cell populations after direct 
co-culture.  Although type I collagen was only produced by fibroblasts, the housekeeping 
genes and proteins used to normalize the results were produced by both cell types.  To 
more accurately determine type I collagen mRNA and procollagen levels in fibroblasts 
after co-culture, CCD-1068SK fibroblasts were separated from MDA-MB-231 tumour 
cells again after direct co-culture.    
 
CCD-1068SK fibroblasts were labelled with PKH67 green fluorescent dye before direct 
co-culture with MDA-MB-231 cells and, after 48 hours co-culture, the two cell types were 
separated by means of fluorescence-activated cell sorting (FACS) (section 6.5).  According 
to post-sort analysis, the separated populations of CCD-1068SK fibroblast and MDA-MB-
231 cells were 97 % and 99.5 % pure, respectively (figure 2.3 A & B).  Although the 












low, with an average of 20% of the original population being collected.  This low number 
could be due to factors such as cell clumping, low fluorescent intensity or high flow rate.  
However, further attempts to optimize these parameters did not result in any major increase 




FIGURE 2.3 Type I collagen mRNA and protein levels in CCD-1068SK fibroblasts after direct co-culture 
with tumour cells and separation of cell types by means of FACS.  CCD-1068SK fibroblasts were labeled 
with PKH67 green fluorescent dye and directly co-cultured with an equal number of MDA-MB-231 tumour cells 
for 48 hours.  FACS was used to separate the fibroblasts and tumour cell populations after co-culture. (A) 
Post-sort analysis of CCD-1068SK fibroblast population purity. (B) Post-sort analysis of MDA-MB-231 cell 
population purity.  (C) Real-time PCR results show COL1A1 and COL1A2 mRNA levels in CCD-1068SK 
fibroblasts after co-culture with MDA-MB-231 cells. The graph shows the mean ± SD from a representative 
experiment (* p≤0.05, n=3).  (D) Immunoblotting results show endogenous type I procollagen levels in CCD-
1068SK fibroblasts after direct co-culture with MDA-MB-231 tumour cells. Type I procollagen bands were 
quantified by densitometry analysis and averaged against β-tubulin values to determine relative type I 
procollagen levels. 
 
Real-time PCR analysis of COL1A1 and COL1A2 mRNA levels in separated CCD-
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a significant down-regulation in type I collagen mRNA levels as well as a decrease in 
procollagen levels (figure 2.3 C & D), and therefore confirm our previous findings.    
2.2.4 Temporal regulation of type I collagen gene expression in normal breast skin 
fibroblasts after direct co-culture with breast tumour cells. 
 
Thus far, type I collagen mRNA and protein levels appear to be down-regulated in CCD-
1068SK and WI38 fibroblasts after 48 hours direct co-culture with MDA-MB-231 cells.  
We therefore wanted to further investigate at what point this negative regulation started 
and for how long this effect lasted.  To determine these parameters, CCD-1068SK 
fibroblasts were directly co-cultured with MDA-MB-231 cells as previously described, 
with RNA and protein being extracted from cells at varying time points ranging between 4 
hours and 6 days.   
 
Analysis of COL1A1 and COL1A2 mRNA levels showed that MDA-MB-231 tumour-
mediated down-regulation of type I collagen gene expression in fibroblasts occurred as 
early as four hours after changing medium on co-cultured cells, with a more substantial 
decrease observed after 24 hours (figure 2.4 A). Type I procollagen levels were also only 
noticeably decreased after 24 hours (figure 2.4 B). This discrepancy between mRNA and 
protein levels at four and eight hours could be a result of delayed protein processing. Type 
I procollagen polypeptides undergo extensive post-translational modification in the ER and 
Golgi before being secreted from the cell. Therefore, endogenous type I procollagen 
processed before co-culture could still have been present in the fibroblasts four and eight 
hours after addition of tumour cells.  Both type I collagen mRNA and protein levels were 
however still significantly decreased for up to 6 days after CCD-1068SK/MDA-MB-231 
co-culture.   
 
These results suggest that MDA-MB-231 tumour-mediated down-regulation of type I 
collagen mRNA levels in CCD-1068SK fibroblasts occurs at an early time point, with a 
delayed response at the protein level, possibly due to extensive procollagen processing.  
Since the negative modulatory effect of tumour cells on both type I collagen mRNA and 
protein levels was observed up to 6 days later, this effect is most likely not a result of 













FIGURE 2.4 Temporal analysis of type I collagen mRNA and protein levels in fibroblast/tumour direct 
co-cultures. CCD-1068SK fibroblasts were directly co-cultured with an equal number of MDA-MB-231 tumour 
cells and allowed to settle overnight. Medium was then changed and RNA and protein was isolated from cells 
at different time points (4h, 8h, 24h, 4 days and 6 days) for further analysis. Fibroblast monocultures and co-
cultures with MCF12A epithelial cells were used as controls. (A) Real-time PCR results show COL1A1 and 
COL1A2 mRNA levels in CCD-1068SK/MDA-MB-231 co-cultures. The graph shows the mean ± SD from a 
representative experiment (*p≤0.05, n=3). (B) Immunoblotting results show endogenous α1 and α2(I) 
procollagen levels in CCD-1068SK fibroblasts after direct co-culture with MDA-MB-231 tumour cells. 
2.2.5 COL1A2 promoter activity in normal WI38 lung fibroblasts directly co-
cultured with breast tumour cells. 
 
Since tumour cells negatively regulate type I procollagen mRNA levels in neighbouring 
WI38 and CCD-1068SK fibroblasts, regulation may be occurring at the transcriptional 
level as a result of decreased COL1A1 and COL1A2 promoter activity.  We therefore 
investigated whether MDA-MB-231 tumour cells negatively regulate COL1A2 promoter 
activity in fibroblasts during direct co-cultures and, if so, which region(s) of the promoter 
are involved.     
 
Since both WI38 and CCD-1068SK fibroblasts responded to tumour cell co-culture in a 
similar manner and, since the transfection efficiency for CCD-1068SK fibroblasts was 
very poor, COL1A2 promoter studies were performed in WI38 lung fibroblasts. Three 
COL1A2 promoter deletion constructs were used for COL1A2 promoter assays, each 
 








































































































































































containing a luciferase gene driven by either the -700/+54, -375/+54, or -107/+54 region of 
the COL1A2 promoter.  WI38 lung fibroblasts were co-transfected with promoter 
constructs and a CMV-βgal plasmid, which was used as an internal control. Transfected 
WI38 fibroblasts were then co-cultured with an equal number of MDA-MB-231 or 
MCF12A cells for 48 hours.  Reporter assays were then performed as described in 
Materials and Methods (section 6.13).   
 
The three COL1A2 promoter deletion constructs had varying basal promoter activity when 
expressed in WI38 fibroblasts (figure 2.5).  The -375/+54 and -700/+54 promoter 
constructs had similar basal activity, while the activity of the -107/+54 was lower.  
COL1A2 promoter activity was significantly down-regulated in all three constructs upon 
co-culture of WI38 fibroblasts with MDA-MB-231 tumour cells.  
  
 
FIGURE 2.5 COL1A2 promoter activity in WI38 lung fibroblasts directly co-cultured with tumour cells.  
WI38 fibroblasts were co-transfected with one of three minimal COL1A2 promoter deletion constructs and 
pCMV-βgal.  These cells were then co-cultured with MDA-MB-231 tumour cells for 48 hours.  WI38 
monocultures and co-cultures with MCF12A cells were used as controls. Results of luciferase assays show 
promoter activity for the -721/+54, -375/+54, and -107/+54 COL1A2 promoter region.  Luciferase values were 
normalized against β-galactosidase values. The graph shows the mean ± SD from a representative 
experiment (*p≤0.05, n=3) 
 
These results suggest that MDA-MB-231 tumour cells negatively regulate COL1A2 
promoter activity, with specific involvement of the -375/+54 region of the COL1A2 
promoter.  Although the activity of the -107/+54 region was also decreased after tumour 
cell co-culture, the low basal activity of this region of the promoter makes it difficult to 
discern its true role in tumour-mediated down-regulation of type I collagen gene 












0 0.5 1 1.5

















The results in this chapter suggest that close contact between MDA-MB-231 breast tumour 
cells and normal breast skin or lung fibroblasts results in a significant down-regulation of 
type I collagen gene expression as well as protein secretion from fibroblasts into the 
medium.  Tumour-mediated suppression of COL1A2 gene transcription was shown to 
occur at the promoter level, with specific involvement of the -375/+54 region of the 
COL1A2 promoter.  Since no change in type I collagen gene expression was observed in 
normal fibroblasts co-cultured with non-tumourigenic epithelial cells, negative regulation 
of type I collagen appears to be tumour-specific and would therefore not occur under 
normal conditions.   
 
The fact that MDA-MB-231 tumour cells were only able to down-regulate type I collagen 
gene expression when in close contact with normal fibroblasts suggests that this regulation 
may well occur during the invasive stages of breast cancer, when tumour cells are in close 
contact with surrounding fibroblasts as a result of basement membrane degradation.  These 
results support those reported using breast tumour tissue (Fenhalls et al. 1999) and 
melanoma tissue (van Kempen et al. 2005), showing that levels of type I collagen gene 
expression were only decreased in later stages of tumour progression.   
 
Although previous work by Fenhalls et al. (1999) also showed that direct co-culture of 
normal breast skin and lung fibroblasts with MDA-MB-231 breast tumour cells resulted in 
a decrease in type I collagen gene expression, our study has expanded on these results by 
using more sensitive techniques such as real-time PCR to analyse COL1A1 and COL1A2 
mRNA levels and immunoblotting analysis to analyse endogenous type I procollagen 
levels.  Our study was also the first to show that the presence of tumour cells during 
analysis of type I collagen gene expression was not skewing the results.  This was done by 
using FACS to separate the fibroblasts from the tumour cells before further analysis of 
type I collagen mRNA and protein levels in fibroblasts only. Addition of tumour-
conditioned medium to fibroblasts by Fenhalls et al. (2009) did not result in any change in 
type I collagen gene expression, and we observed similar results in our indirect co-culture 












fibroblasts into the medium do not stimulate tumour cells to produce a factor which would, 
in turn, negatively regulate type I collagen gene expression.   
 
MDA-MB-231 breast tumour cells negatively regulated type I collagen gene expression in 
both normal breast skin and lung fibroblasts in a similar manner, which could be a result of 
inherent similarities between the breast and lung tissue environments. The “seed and soil” 
hypothesis, originally proposed by Stephen Paget (Paget 1889, reprinted as Paget, 1989), 
states that tumour cells (“seeds”) that have moved from the primary tumour into the 
vasculature will only metastasize to organs with a compatible tissue environment (“soil”).  
This model has become widely accepted as a way of explaining why certain tumours 
metastasize to specific organs with higher frequency (Lu & Kang 2007) and could 
therefore explain why breast tumour cells often metastasize to the lung.  It also suggests 
that MDA-MB-231 breast tumour cells may regulate type I collagen gene expression in a 
similar manner in primary breast tissue and secondary lung metastatic sites. 
 
A number of previous studies performed on invasive breast tumour tissue have observed 
the presence of activated fibroblasts in and around the invasive tumour mass (Kunz-
Schughart & Knuechel 2002a; Rønnov-Jessen et al. 1996).  These so called carcinoma 
associated fibroblasts (CAFs) have an abnormal myofibroblast-like phenotype and are 
characterised by increased production of α-SMA and ECM components such as type I 
collagen (Kunz-Schughart & Knuechel 2002a; Kunz-schughart et al. 2003; De Wever et al. 
2008).  Since our results showed that type I collagen gene expression was reduced in 
fibroblasts in close contact with tumour cells, it is unlikely that myofibroblast activation 
occurred in these co-cultured fibroblasts.  Although some studies have shown that normal 
fibroblast are activated when co-cultured with breast tumour cells (Kojima et al. 2010; 
Rønnov-Jessen et al. 1995), Kunz-Schughart et al. (2001) showed that breast tumour 
spheroids co-cultured with normal skin fibroblast spheroids did not induce α-SMA 
expression in the fibroblasts, even though the tumour cells were seen to migrate into the 
fibroblast spheroids.  These results suggest that myofibroblast differentiation may occur 
independently of tumour invasion and migration.  The exact origin of CAFs is also still 












derived stem cells could form part of the CAF population found in tumour tissue (Rønnov-
Jessen & Bissell 2008; Hinz et al. 2007).     
 
Further characterisation of tumour-mediated type I collagen gene expression in our study 
revealed that negative regulation of type I collagen mRNA levels in normal fibroblasts 
occurred as early as four hours after co-culture, and that both α1(I) and α2(I) procollagen 
mRNA and protein levels were still repressed up to six days after co-culture.  In a previous 
study by Shephard et al (2004), fibroblasts directly co-cultured with keratinocytes were 
shown to produce high levels of the cytokine interleukin-1 (IL-1) during the first four days 
of co-culture, which prevented fibroblasts from being able to respond to TGFβ secreted by 
keratinocytes until day four.  IL-1 levels then dropped, allowing TGFβ to stimulate the 
differentiation of fibroblasts into myofibroblasts.  However, the results of our study 
suggest that the type I collagen-regulating factor produced by MDA-MB-231 tumour cells 
is capable of maintaining its effect for an extended period of time.    
MDA-MB-231 tumour cells appear to negatively regulate COL1A1 and COL1A2 mRNA 
levels, α1(I) and α2(I) procollagen levels, as well as the secretion of both procollagen 
polypeptides from fibroblasts into the medium.  Most type I collagen regulation is thought 
to occur at a transcriptional level and our results show that MDA-MB-231 tumour cells 
repress COL1A2 promoter activity, with specific involvement of the -375/+54 region. 
Since this region of the COL1A2 promoter contains a number of different binding sites for 
various transcription factors that may be involved in tumour-mediated negative regulation 
of COL1A2 promoter activity, further investigation of upstream signalling pathways could 





















SIGNALLING PATHWAYS INVOLVED IN TUMOUR CELL-





Results described in chapter two of this study indicate that type I collagen gene regulation 
by tumour cells requires close contact between normal fibroblasts and tumours cells.  
MDA-MB-231 tumour cells could therefore communicate with the fibroblasts either 
through cell adhesion molecules and/or through secreted factors that can only mediate their 
effect on cells in close proximity.   
 
The effect of secreted cytokines on COL1A1 and COL1A2 gene expression has been well 
studied.  However, very little is known about the role of tumour-secreted factors in 
regulating type I collagen gene expression in neighbouring fibroblasts.  Previous studies 
investigating keratinocyte or T-cell interactions with fibroblasts during co-culture showed 
that regulation of type I collagen gene expression by secreted factors such as IL-1, TNFα, 
IFNγ and TGFβ only occurred when these cells were directly co-cultured with fibroblasts 
(Rezzonico et al. 1998; Shephard et al. 2004), suggesting that the regulation of type I 
collagen gene expression by these secreted factors could be concentration dependent or 
require the presence of other cell surface receptors (e.g. integrins).   
 
The expression of both the COL1A1 and COL1A2 genes are regulated by a number of 
different growth factors and cytokines that bind to fibroblast cell surface receptors and 
activate specific signalling pathways. TGFβ is a well studied positive regulator of type I 
collagen gene expression, and exerts its effect via the Smad signalling pathway (Chen et al. 
1999; Verrecchia & Mauviel 2004; Verrecchia et al. 2001a).  Negative regulators of type I 
collagen gene expression include cytokines such as TNFα (Inagaki et al. 1995; Kouba et al. 
1999; Mori et al. 1996), IFNγ (Higashi et al. 2003; Xu et al. 2004), IL-1 (Mauviel et al. 












growth factors secreted either by MDA-MB-231 tumour cells themselves, or as a result of 
tumour/fibroblast co-culture, were responsible for negatively regulating type I collagen 
gene expression.  To this end, medium obtained from CCD-1068SK/MDA-MB-231 co-
cultures and monocultures was analysed by means of an ELISA to determine the levels of 
12 different cytokines and growth factors secreted by these cells.  
 
The role of CCD-1068SK breast skin fibroblast signalling pathways in MDA-MB-231 
tumour-mediated regulation of type I collagen gene expression was also further 
investigated.  The JAK/Stat signalling pathway has previously been shown to negatively 
regulate type I collagen mainly through the action of activated Stat1, which competes with 
Smad3 for binding to p300/CBP and thereby prevents association with and activation of 
the COL1A2 promoter (Ghosh et al. 2001; Inagaki et al. 2003).  The role of type I 
interferons and the JAK/Stat signalling pathway in tumour-mediated type I collagen 
regulation was therefore further investigated.   
 
Other signalling pathways that could play a role in tumour-mediated regulation of type I 
collagen gene expression include members of the MAPK family.  MAPKs are involved in 
mediating cellular responses to a large number of external stimuli (Dhanasekaran & 
Johnson 2007). They therefore play an important role in maintaining cellular homeostasis 
and are often deregulated in cancers (Dhanasekaran & Johnson 2007; Dhillon et al. 2007).  
The JNK, ERK and p38 MAPK signalling pathways have previously been shown to 
regulate type I collagen gene expression, although their effect appear to be context 
dependent (Leask & Abraham 2004; Javelaud & Mauviel 2005).  Therefore, the role of 
these MAPK signalling pathways in MDA-MB-231 tumour-mediated regulation of type I 
collagen gene expression in CCD-1068SK fibroblasts was further investigated by using 
inhibitors against JNK, MEK1/2 and p38 MAPK. 
 

















3.2.1 Analysing factors secreted during fibroblast/tumour co-culture. 
 
A number of cytokines and growth factors are known to be involved in negatively 
regulating type I collagen gene expression.  We therfore used the Multi-Analyte Profiler 
ELISarray kit (SA Biosciences) to quantify the levels of 12 cytokines, chemokines and 
growth factors in MDA-MB-231/CCD-1068SK co-culture medium.  These included the 
well-known regulators of type I collagen: IFNγ, TNFα, IL-1 and TGFβ as well as IL4, IL6, 
IL10, IL12 and IL17, MCP1 (monocyte chemoattractant protein 1), MIP1α and MIP1β 
(macrophage inflammatory protein 1α and 1β).   
 
CCD-1068SK fibroblasts were directly co-cultured with an equal number of MDA-MB-
231 tumour cells for 48 hours in serum-free medium and the ELISarray kit was used to 
profile the levels of the secreted factors in the medium, as described in Materials and 
Methods (section 6.14).  Of the 12 cytokines analysed, only TGFβ, IL6 and MCP1 were 
detected at levels above background in both CCD-1068SK fibroblasts and MDA-MB-231 
tumour cells (figure 3.1).  The level of TGFβ produced by MDA-MB-231 cells was two-
fold higher than levels observed in CCD-1068SK medium, while levels in the CCD-
1068SK/MDA-MB-231 co-culture medium were slightly lower than would be expected if 
the TGFβ values obtained for the fibroblast and tumour monocultures were averaged.  
These results suggest that levels of secreted TGFβ are decreased as a result of co-culturing 
CCD-1068SK fibroblasts with MDA-MB-231 tumour cells.  Results also indicate that, 
although IL6 and MCP1 were secreted by both fibroblasts and tumour cells, levels 
observed in CCD-1068SK/MDA-MB-231 co-cultures did not appear to change as a result 
of direct co-culture.  Levels of the remaining factors screened for were all below detectable 














FIGURE 3.1 Cytokine and growth factor production in fibroblast/tumour direct co-cultures. CCD-
1068SK fibroblasts were directly co-cultured with MDA-MB-231 tumour cells for 48 hours in serum-free 
medium.  The Multi-Analyte Profiler ELISarray kit (SA Biosciences) was used to quantify levels of 12 different 
cytokines in the medium of CCD-1068SK/MDA-MB-231 co-cultures, relative to levels obtained in the medium 
of monocultures of each cell type.  These cytokines include IL1b, IL4, IL6, IL10, IL12, IL17a, IFNγ, TNFα, 
TGFβ, MCP1, MIP1a and MIP1b.  Values were normalized to levels observed in the medium of CCD-1068SK 
monocultures.  The graph represents the results of a single experiment with one samples for each assay.   
Tumour growth factor beta (TGFβ), interleukin 6 (IL6) and monocyte chemoattractant protein 1 (MCP1) were 
detected in the medium of all three cultures, while levels of the other 9 cytokines were all below background. 
 
These results suggest that none of the negative regulatory factors screened for, including 
IFNγ, TNFα, IL-1 or IL-10, are secreted by fibroblasts or tumour cells during co-culture or 
monoculture conditions.  These factors are therefore unlikely to be involved in MDA-MB-
231 tumour-mediated repression of type I collagen gene expression. 
 
3.2.2 IFNα and IFNβ gene expression in co-cultured cells. 
 
Results of the ELISarray on CCD-1068SK/MDA-MB-231 co-culture medium showed that 
IFNγ could not be detected in either cell type in monoculture or during direct co-culture.  
However, this array did not include type I IFNs (IFNα and IFNβ).  Since previous studies 
have shown that both IFNα and IFNβ may negatively regulate type I collagen gene 
expression (Duncan & Berman 1985; Inagaki et al. 2003), we examined the effect of direct 































Since type I IFN production is mainly controlled at the level of gene transcription (Honda 
et al. 2006), real-time PCR analysis was used to determine IFNα and IFNβ gene expression 
in CCD-1068SK fibroblasts and MDA-MB-231 cells after co-culture and FACS 
separation.  The results showed that IFNα and IFNβ were expressed by both CCD-1068SK 
fibroblasts and MDA-MB-231 cells in monocultures.  Co-culture with MDA-MB-231 
tumour cells resulted in a significant increase in mRNA levels of both IFNα and IFNβ in 
CCD-1068SK fibroblasts, with IFNβ levels increased more than 40-fold (figure 3.2 A & 
B).   Interestingly, although IFNα mRNA levels remained unchanged in MDA-MB-231 
cells after co-culture, IFNβ mRNA levels were significantly up-regulated relative to levels 




FIGURE 3.2 Type I IFN mRNA levels in directly co-cultured fibroblasts and tumour cells.  CCD-
1068SK/MDA-MB-231 co-cultures were incubated for 48 hours before separating cell using FACS. Real-time 
PCR analysis was performed on isolated RNA.  (A) Relative interferon alpha (IFNα) mRNA levels in CCD-
1068SK fibroblasts after co-culture. (B) Relative IFNα mRNA levels in MDA-MB-231 tumour cells after co-
culture. (C) Interferon beta (IFNβ) mRNA levels in co-cultured CCD-1068SK fibroblasts compared to those 
obtained in monocultures. (D) IFNβ mRNA levels in co-cultured MDA-MB-231 cells compared to those 
obtained in monocultures. (*p≤0.05, n=3).  The graphs shows the mean ± SD from representative 
experiments. Abbreviations: CCD, CCD-1068SK; MDA, MDA-MB-231; CCD(MDA), CCD-1068SK fibroblasts 
co-cultured with MDA-MB-231 tumour cells and separated by FACS; MDA(CCD), MDA-MB-231 tumour cells 
co-cultured with CCD-1068SK fibroblasts and separated by FACS. 
 
These results suggest that direct co-culture of CCD-1068SK fibroblasts with MDA-MB-














































































































1068SK fibroblasts, and an increase in IFNβ gene expression in MDA-MB-231 tumour 
cells.  Therefore, signalling via type I IFNs could be involved in mediating the negative 
regulatory effect of MDA-MB-231 tumour cells on type I collagen gene expression. 
 
3.2.3 Stat1 gene expression in co-cultured cells. 
 
Since the type I IFNs were up-regulated in CCD-1068SK fibroblasts and MDA-MB-231 
tumour cells during direct co-culture, close contact between these two cell types could be 
inducing an interferon response.  Type I and type II IFNs exert most of their effects via the 
JAK/Stat signalling pathway, which has previously been shown to negatively regulate type 
I collagen gene expression in fibroblasts in response to IFN stimulation (Ghosh et al. 2001; 
Higashi et al. 2003; Inagaki et al. 2003).  Since Stat1 is one of the main mediators of this 
IFN response, the role of Stat1 in mediating the negative regulatory effect of MDA-MB-
231 tumour cells on type I collagen gene expression in CCD-1068SK fibroblasts was 
further investigated. 
 
To determine the effect of co-culture on Stat1 gene expression in fibroblasts and tumour 
cells, these cells were separated by means of FACS after 48 hours direct co-culture.  Real-
time PCR results showed that Stat1 mRNA levels were significantly increased in both 
CCD-1068SK fibroblasts and MDA-MB-231 cells after co-culture (figure 3.3 A & B).  
Immunoblotting analysis of total Stat1 protein was performed using an anti-Stat1 p84/p91 
antibody that detected both the Stat1α (91 kDa) isoform as well as its splice variant Stat1β 
(84 kDa), which lacks 38 residues at the carboxyl-terminus (Schindler & Darnell 1995).  
Although only Stat1α was detected in CCD-1068SK fibroblast monocultures, direct co-
culture with MDA-MB-231 cells led to an increase in the levels of both the Stat1α and 
Stat1β isoforms (figure 3.3 C).  Both these isoforms were also produced by MDA-MB-231 
cells in monoculture, with increased levels of both Stat1α and Stat1β in co-cultures with 
fibroblasts. Phosphorylation of Stat1 protein at the tyrosine-701 site was also increased in 
both CCD-1068SK and MDA-MB-231 cells after co-culture, although this increase 
appeared to be greater in the fibroblasts.  Levels of Stat1α phosphorylation were also much 















FIGURE 3.3 Stat1 mRNA and protein levels in fibroblast/tumour co-cultures.  CCD-1068SK/MDA-MB-
231 direct co-cultures were incubated for 48h before being separated again by means of FACS for further 
analysis. (A) Real-time PCR results show Stat1 mRNA levels in CCD-1068SK fibroblasts after co-culture with 
MDA-MB-231 tumour cells compared to those obtained in CCD-1068SK monocultures.  (B) Stat1 mRNA 
levels in MDA-MB-231 tumour cells after co-culture with CCD-1068SK fibroblasts, compared to those obtained 
in MDA-MB-231 monocultures (*p≤0.05, n=3). The graphs shows the mean ± SD from a representative 
experiment.  (C) Immunoblotting analysis of total Stat1 (αStat1 & βStat1) and Tyr-701 phosphorylated Stat1 
(p-αStat1 & p-βStat1) in CCD-1068SK fibroblasts and MDA-MB-231 cells after direct co-culture.  
Abbreviations: CCD, CCD-1068SK; MDA, MDA-MB-231; CD(MDA), CCD-1068SK fibroblasts co-cultured 
with MDA-MB-231 tumour cells and separated by FACS; MDA(CCD), MDA-MB-231 tumour cells co-cultured 
with CCD-1068SK fibroblasts and separated by FACS. 
 
These results show that direct co-culture of CCD-1068SK fibroblasts with MDA-MB-231 
tumour cells leads to a significant increase in Stat1 gene expression as well as increased 
phosphorylation of Stat1 protein in both cell types.  Since Stat1 is known to negatively 
regulate type I collagen gene expression, it is possible that MDA-MB-231 tumour cells 
suppress type I collagen gene expression by activating the JAK/Stat signalling pathway in 
neighbouring fibroblasts (figure 1.5). 
 
3.2.4 The effect of inhibiting JAK activation on type I collagen gene expression in 
co-cultured cells. 
 
Activation of Stat1 occurs via tyrosine phosphorylation mediated by upstream Janus 
Kinases (JAKs).  The four known members of the JAK family are JAK1, JAK2, JAK3 and 
TYK2, which bind in specific combinations to different cell surface receptors to form 







































































effect of tumour cells on type I collagen gene expression in fibroblasts, an inhibitor was 
used to prevent the activation of all members of the JAK family (JAK1, JAK2, JAK3 and 




FIGURE 3.4 The effect of inhibiting JAK activation in fibroblast/tumour co-cultures on type I collagen 
mRNA levels. JAK inhibitor I was added to CCD-1068SK monocultures, as well as CCD-1068SK/MCF12A 
and CCD-1068SK/MDA-MB-231 co-cultures and incubated for 24 hours. (A) Immunoblotting results show the 
effect of the JAK inhibitor on Stat1 phosphorylation and total Stat1 protein levels. (B) Real-time PCR results 
show relative COL1A1 and COL1A2 mRNA levels in co-cultures incubated with JAK inhibitor I. The graphs 
show the mean ± SD from representative experiments (*p≤0.05, n=3).  
 
CCD-1068SK/MDA-MB-231 co-cultures were incubated with 10 μM JAK inhibitor I for 
24 hours (section 6.15).  Immunoblotting analysis confirmed that levels of total and 
phosphorylated Stat1 were only increased in CCD-1068SK/MDA-MB-231 co-cultures, 
with no change in Stat1 protein levels observed in fibroblast co-cultures with MCF12A 
cells (figure 3.4 A). Results also showed that Stat1 phosphorylation was inhibited after 
addition of the JAK inhibitor to CCD-1068SK/MDA-MB-231 co-cultures.  Having 
established that the JAK inhibitor blocked Stat1 phosphorylation in CCD-1068SK/MDA-

















































































































COL1A2 mRNA expression. Real-time PCR analysis revealed that inhibition of JAK 
signalling in directly co-cultured cells had no effect on COL1A1 or COL1A2 mRNA 
levels (figure 3.4 B).   
 
These results show that, although direct co-culture of CCD-1068SK fibroblast with MDA-
MB-231 tumour cells led to an increase in Stat1 gene expression and protein activation, 
inhibition of the upstream activators of Stat1 did not reverse the negative regulatory effect 
of MDA-MB-231 tumour cells on type I collagen gene expression. 
 
3.2.5 The effect of silencing Stat1 in fibroblasts on type I collagen gene expression in 
co-cultures. 
 
While no change in type I collagen gene expression was observed upon addition of the 
JAK inhibitor to co-cultured cells, up-regulation of Stat1 gene expression and activation 
could still occur via a different signalling pathway.  Also, since the JAK inhibitor blocked 
Stat1 phosphorylation in both CCD-1068SK fibroblasts and MDA-MB-231 cells during 
co-cultures, we could not determine the effect of blocking JAK/Stat signalling in each 
individual cell type on type I collagen gene regulation.  Further experiments therefore 
involved the selective silencing of Stat1 gene expression in CCD-1068SK fibroblasts 
before direct co-culture with MDA-MB-231 tumour cells.   
 
CCD-1068SK fibroblasts were transfected with Stat1 siRNA (section 6.16) and then 
directly co-cultured with non-transfected MDA-MB-231 cells.  Quantification of Stat1 
mRNA and protein levels in transfected CCD-1068SK fibroblasts confirmed that Stat1 
siRNA efficiently silenced Stat1 gene expression, with mRNA levels reduced by more than 
90 % (figure 3.5 A & B).  Results also showed that type I procollagen levels were not 
affected by Stat1 silencing in fibroblasts (figure 3.5 B).  Analysis of type I collagen mRNA 
levels in Stat1-inhibited CCD-1068SK fibroblasts after MDA-MB-231 co-culture showed 
that neither COL1A1 nor COL1A2 mRNA levels were changed, when compared to levels 















FIGURE 3.5 The effect of silencing Stat1 expression in fibroblasts on type I collagen mRNA levels in 
co-cultures with tumour cells.  CCD-1068SK fibroblasts were transfected with Stat1 siRNA and directly co-
cultured with MDA-MB-231 cells for 48 hours. (A) Real-time PCR results show Stat1 mRNA levels in CCD-
1068SK fibroblasts after transfection with Stat1 siRNA. (B) Immunoblotting results show total Stat1 protein 
levels in CCD-1068SK fibroblasts transfected with Stat1 siRNA. (C) COL1A1 and COL1A2 mRNA levels in 
CCD-1068SK fibroblasts transfected with Stat1 siRNA and directly co-cultured with MDA-MB-231 tumour 
cells. The graphs show the mean ± SD from representative experiments (*p≤0.05, n=3).  
 
These results show that inhibiting Stat1 gene expression in CCD-1068SK fibroblasts does 
not revert the negative regulatory effect of MDA-MB-231 on type I collagen gene 
expression, which suggests that the increased Stat1 gene expression observed in co-
cultured CCD-1068SK fibroblasts may not be involved in the tumour-mediated regulation 
of type I collagen gene expression.  
 
3.2.6 The effect of silencing Stat1 gene expression in tumour cells on type I collagen 
gene expression in co-cultured fibroblasts. 
 
Since Stat1 expression was also up-regulated in MDA-MB-231 cells after direct co-culture 
with CCD-1068SK fibroblasts, we examined the effect of inhibiting Stat1 gene expression 









































































MDA-MB-231 tumour cells were transfected with Stat1 siRNA and directly co-cultured 
with CCD-1068SK fibroblasts.  Stat1 mRNA and protein levels were successfully silenced 
in MDA-MB-231 cells, as confirmed by real-time PCR and immunoblotting, respectively 
(figure 3.6 A & B).  However, neither COL1A1 nor COL1A2 mRNA levels were altered 
in CCD-1068SK fibroblasts co-cultured with Stat1-inhibited MDA-MB-231 cells, when 
compared to non-transfected co-cultures (figure 3.6 C).   
 
These results show that Stat1 inhibition in tumour cells does not revert the negative 
regulatory effect of these cells on type I collagen gene expression, and suggests that the 
increased gene expression and activation of Stat1 observed in co-cultured MDA-MB-231 
tumour cells does not play a role in negatively regulating type I collagen gene expression 
in neighbouring CCD-1068SK fibroblasts. 
 
 
FIGURE 3.6 The effect of silencing Stat1 expression in tumour cells on type I collagen mRNA levels in 
co-cultured fibroblasts. MDA-MB-231 tumour cells were transfected with Stat1 siRNA and co-cultured with 
CCD-1068SK fibroblasts for 48 hours. (A) Real-time PCR results show Stat1 mRNA levels in MDA-MB-231 
cells transfected with Stat1 siRNA. (B) Immunoblotting results show Stat1 protein levels in MDA-MB-231 cells 
transfected with Stat1 siRNA. (C) COL1A1 and COL1A2 mRNA levels in CCD-1068SK fibroblasts directly co-
cultured with Stat1 siRNA-transfected MDA-MB-231 cells. The graphs show the mean ± SD from 






































































3.2.7 Stat1 gene expression in indirect fibroblast/tumour co-cultures. 
 
Results thus far show that direct co-culturing of CCD-1068SK fibroblasts with MDA-MB-
231 tumour cells leads to the up-regulation and possible secretion of type I IFNs into the 
medium.  Binding of these IFNs to IFNα/β receptors on both fibroblasts and tumour cells 
could, in turn, result in the activation of the JAK/Stat signalling pathway with increased 
Stat1 phosphorylation, as observed in both cell types.  We were interested in determining 
the exact nature of the IFN response observed during tumour/fibroblast co-culture, and 
therefore investigated whether Stat1 was being activated in response to factors secreted 
during CCD-1068SK/MDA-MB-231 direct co-cultures or as a result of factors secreted by 
MDA-MB-231 cells only.  
 
The indirect co-culturing system was used to determine whether Stat1 and type I collagen 
gene expression in CCD-1068SK fibroblasts were influenced by secreted factors produced 
by either MDA-MB-231 cell monocultures or directly co-cultured CCD-1068SK/MDA-
MB-231 cells (section 6.3) (figure 3.7 A).  This system was previously employed to 
determine whether MDA-MB-231 tumour cells influenced type I collagen gene expression 
in CCD-1068SK fibroblasts when separated by a transwell insert (section 2.2.1).  No 
change in type I collagen mRNA or protein levels were observed (figure 2.1), and further 
analysis showed that Stat1 mRNA levels in CCD-1068SK fibroblasts were also not 
changed as a result of factors secreted by MDA-MB-231 cells only (figure 3.7 B).  
However, in CCD-1068SK fibroblasts indirectly co-cultured with mixed CCD-
1068SK/MDA-MB-231 cells, Stat1 mRNA levels were increased more than 7-fold.  Total 
Stat1 and phosphorylated Stat1 protein levels in CCD-1068SK fibroblasts were also only 
increased in indirect co-cultures with mixed fibroblast/tumour cells (figure 3.7 C). 
However, real-time PCR analysis of COL1A1 and COL1A2 mRNA levels in CCD-
1068SK fibroblasts showed that, even when Stat1 activation occurred, type I collagen gene 
expression remained unchanged after indirect co-culture with mixed CCD-1068SK/MDA-
MB-231 cells (figure 3.7 D).  
 
In summary these results show that Stat1 mRNA and protein levels, as well as protein 












fibroblasts were in close contact with MDA-MB-231 tumour cells.  However, type I 
collagen gene expression remained unchanged in CCD-1068SK fibroblasts even when 
Stat1 activation occurred.  These results therefore suggest that the JAK/Stat signalling 
pathway is not involved in MDA-MB-231 tumour-mediated down-regulation of type I 




Figure 3.7 The effect of secreted factors produced during co-cultures on Stat1 gene expression in 
CCD-1068SK fibroblasts.  CCD-1068SK fibroblasts were indirectly co-cultured with CCD-1068SK fibroblasts, 
MDA-MB-231 tumour cells or mixed CCD-1068SK/MDA-MB-231 cells for 48 hours. (A) Diagram representing 
the transwell co-culture experiment in which CCD-1068SK fibroblasts were separated from an equal number 
of CCD-1068SK fibroblasts, MDA-MB-231 cells or a mixture of both during co-culture. (B) Stat1 mRNA levels 
in CCD-1068SK fibroblasts after indirect co-culture with mixed CCD-1068SK/MDA-MB-231 cells. The cells 
shown in brackets were cultured in the transwell insert. (C) Immunoblotting results show total and 
phosphorylated Stat1, as well as α1(I) and α2(I) procollagen levels in CCD-1068SK fibroblasts after indirect 
co-culture.  (D) Real-time PCR results show COL1A1 and COL1A2 mRNA levels in CCD-1068SK fibroblasts 
after indirect co-culture. The graphs show the mean ± SD from representative experiments (*p≤0.05, n=3). 
Abbreviations: CCD, CCD-1068SK; MDA, MDA-MB-231.  Brackets enclose the cell line with which CCD-
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3.2.8 MAPK signalling in fibroblast/tumour co-cultures. 
 
MAP kinases are a group of intracellular signalling molecules that play an important role 
in controlling cellular responses such as cell growth, differentiation and apoptosis 
(Bardwell 2006).  Deregulation of these signalling pathways is therefore often associated 
with tumour formation and progression.  Tumour cells may also deregulate MAPK 
signalling pathways in neighbouring fibroblasts by means of paracrine signalling and, 
since these signalling pathways have previously been shown to influence type I collagen 
gene expression, the role of the JNK, MEK/ERK and p38 MAPK signalling pathways in 
mediating the negative regulatory effect of tumour cells on type I collagen gene expression 
in CCD-1068SK fibroblasts was further investigated.  
 
3.2.8.1 JNK signalling in co-cultures. 
 
JNK MAPKs are activated when cells are exposed to specific cytokines, growth factors, 
and environmental stresses such as UV irradiation and heat shock (Davis 2000).  The pro-
inflammatory cytokine TNFα is known to antagonise TGFβ-mediated COL1A2 promoter 
activity by activating JNK signalling with downstream phosphorylation of cJun (and in 
some cases JunB) which, in turn, binds to Smad3 and inhibits TGFβ/Smad-mediated 
stimulation of COL1A2 promoter activity (Verrecchia et al., 2003).  Although no TNFα 
was secreted during CCD-1068SK/MDA-MB-231 co-cultures, negative regulation of type 
I collagen gene expression by the JNK pathway could be mediated via other mechanisms 
(figure 3.1). 
 
The role of JNK signalling in MDA-MB-231 tumour-mediated type I collagen gene 
regulation in CCD-1068SK fibroblasts was examined by using SP600125, an inhibitor that 
prevents JNK (JNK-1, -2 and -3) phosphorylation by competing with JNK for ATP.  CCD-
1068SK/MDA-MB-231 co-cultures were incubated with SP600125 for 24 hours before 
isolating RNA and protein from co-cultured cells for further analysis (section 6.16).  
Immunoblotting results showed that the level of Serine-63/73 phosphorylated cJun was 
very high in CCD-1068SK/MDA-MB-231 co-cultures compared to the level in CCD-
1068SK monocultures or CCD-1068SK/MCF12A co-cultures (figure 3.8 A).  Total cJun 












significant reduction in levels of phosphorylated cJun, but did not influence total cJun 
expression.  However, type I collagen protein and mRNA levels were not affected by the 
addition of SP600125 to co-cultured cells (figure 3.8 A & B).  These results suggest that 
the JNK signalling pathway is not involved in MDA-MB-231 tumour-mediated down-




FIGURE 3.8 The effect of JNK pathway inhibition on type I collagen mRNA and protein levels in 
fibroblast/tumour co-cultures.  The JNK inhibitor, SP600125, was incubated with CCD-1068SK/MDA-MB-
231 co-cultures for 24 hours before isolating mRNA and protein from cells for further analysis.  CCD-1068KS 
monocultures and co-cultures with MCF12A cells were used as controls. (A) Immunoblotting result shows the 
effect of SP600125 on type I procollagen, as well as phosphorylated (Ser63/73) and total cJun levels.  (B) 
Real-time PCR results show COL1A1 and COL1A2 mRNA levels in CCD-1068SK fibroblasts co-cultured with 
tumour cells, in the presence of 30 µM SP600125. The graphs show the mean ± SD from a representative 
experiment (*p≤0.05, n=3). 
 
3.2.8.2 MEK/ERK signalling in co-cultures. 
 
The MEK/ERK signalling pathway is involved in type I collagen down-regulation in 
fibroblasts as a result of EGF (Mimura et al. 2006), lysophosphatidic acid (Sato et al. 
2004) or C2-ceramide stimulation (Reunanen et al. 2000).  Work in our laboratory has also 
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expression in fibroblasts cultured on a fibroblast-derived matrix (Dzobo et al. 2011).  
However, the exact mechanism whereby ERK regulates type I collagen gene expression is 




FIGURE 3.9 The effect of MEK/ERK pathway inhibition on fibroblasts/tumour co-culture. CCD-1068SK 
fibroblast were co-cultured with MDA-MB-231 tumour cells for 24 hours in the presence of the MEK inhibitor, 
U0126, before isolating RNA and protein for further analysis.  CCD-1068SK monocultures and co-cultures 
with MCF12A cells were used as controls.  (A) Immunoblotting result showing the effect of U0126 on type I 
procollagen as well as phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK2 levels. (B) Real-time PCR 
results show the effect of U0126 on COL1A1 and COL1A2 mRNA levels. The graphs show the mean ± SD 
from a representative experiment (*p≤0.05, n=3). 
 
To determine the role of the MEK/ERK signalling pathway in MDA-MB-231-tumour 
mediated type I collagen gene regulation, CCD-1068SK/MDA-MB-231 co-cultured cells 
were incubated with U0126, which specifically inhibits MEK1 and MEK2 activation 
(section 6.16).  Immunoblotting analysis was performed using a phospho-ERK 1/2 
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significantly affected by direct co-culturing of CCD-1068SK fibroblasts with MDA-MB-
231 tumour cells or MCF12A epithelial cells (figure 3.9 A).  Addition of U0126 was also 
shown to effectively inhibited ERK1/2 phosphorylation in all cell cultures, with no 
significant effect on total ERK2 levels observed.  Endogenous type I procollagen and 
mRNA levels in co-cultured fibroblasts were not affected by the addition of U0126 to co-
cultured cells (figure 3.9 A & B).   Therefore, the MEK/ERK signalling pathway does not 
appear to be involved in tumour-mediated regulation of type I collagen gene expression. 
 
3.2.8.3 p38 MAPK signalling in co-cultures. 
 
The p38 MAPK pathway is often activated in response to physical stress and also plays an 
important role in cell proliferation, differentiation, apoptosis and inflammation (Zhang et 
al. 2007a).  Previous studies have shown that p38 is involved in the activation of type I 
collagen gene expression in response to TGFβ stimulation (Abecassis et al. 2004; Hanafusa 
et al. 1999;  Inagaki & Okazaki 2007; Sato et al. 2002).  However, type I IFNs are also 
known to activate p38 signalling (Katsoulidis et al. 2005) and since IFNα and IFNβ gene 
expression was up-regulated in CCD-1068SK/MDA-MB-231 co-cultures, we investigated 
the possible role of p38 in negatively regulating type I collagen gene expression in a 
tumour cell-dependent manner. 
 
CCD-1068SK/MDA-MB-231 co-cultures were incubated with SB203580, which is a 
pyridinyl imidazole inhibitor that prevents p38 phosphorylation by competing for the ATP-
binding site on p38 (specifically p38α and p38β) (section 6.16).  Immunoblotting analysis 
performed on isolated protein showed that phosphorylated p38 (Thr180/Tyr182) as well as 
total p38 protein levels were the same in CCD-1068SK fibroblasts monocultures and in co-
cultures with either MCF12A or MDA-MB-231 tumour cells (figure 3.10 A).  Addition of 
SB203680 to cells resulted in almost complete inhibition of p38 activation, but did not 
affect total p38 levels.  Type I collagen protein levels were, however, not significantly 
influenced by the addition of SB203580 to CCD-1068SK/MDA-MB-231 co-cultures.  
Analysis of type I collagen mRNA levels showed that SB203580 addition to 
fibroblast/tumour co-cultures caused a 2-fold increase in levels of both COL1A1 and 












However, mRNA levels of COL1A1 and COL1A2 in SB203580-inhibited co-cultured 
fibroblasts were still significantly down-regulated in comparison to levels in control CCD-
1068SK fibroblasts.  
 
These results suggest that p38 may play a part in tumour-mediated negative regulation of 
type I collagen levels in neighbouring fibroblasts, but that other signalling pathways and/or 




FIGURE 3.10 The effect of p38 MAPK pathway inhibition on type I collagen mRNA and protein levels in 
fibroblast/tumour co-cultures.  CCD-1068SK fibroblasts were co-cultured with MDA-MB-231 tumour cells 
for 24 hours in the presence of SB203580 (+).  CCD-1068SK monocultures and co-cultures with MCF12A 
cells were used as controls (-).  (A) Immunoblotting results show the effect of SB203580 on type I procollagen 
levels as well as phosphorylated p38 MAPK (Thr180/Tyr182) and total p38 MAPK levels. (B) Real-time PCR 
results show the effect of SB203580 on COL1A1 and COL1A2 mRNA levels in CCD-1068SK/MDA-MB-231 
co-cultures. The graphs show the mean ± SD from representative experiments and significance was 
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3.3  DISCUSSION 
 
In this study we show that close contact between CCD-1068SK fibroblasts and MDA-MB-
231 tumour cells results in increased type I IFN and Stat1 gene expression as well as Stat1 
protein activation in both fibroblasts and tumour cells.  The increased expression and 
activation of Stat1 observed in fibroblasts was shown to only occur as a result of factors 
secreted during direct fibroblast/tumour co-culture, which suggests that type I IFNs could 
be involved in mediating this response.  However, inhibition studies and indirect co-culture 
experiments showed that the increased Stat1 activity observed in tumour/fibroblast co-
cultures did not affect type I collagen gene expression, which suggests that the JAK/Stat 
signalling pathway is not involved in mediating the negative regulatory effect of tumour 
cells on type I collagen gene expression. 
 
Based on the results obtained, we propose a model for the inflammatory response 
occurring during fibroblast/tumour co-cultures (figure 3.11).  Firstly, a tumour-produced 
factor causes increased IFNα and IFNβ gene expression in fibroblasts that are in close 
contact with tumour cells.  These type I IFNs are then secreted into the medium and, since 
these cytokines can signal in both an autocrine and paracrine fashion (Stetson and 
Medzhitov 2006), they bind to type I IFN receptors on both the fibroblasts and tumour cell 
surfaces and activate the JAK/Stat signalling pathway.  As a result, Stat1 gene expression 
and activity is increased, which leads to a further increase in type I IFN gene expression in 
both cell types, particularly of IFNβ.  Previous microarray studies performed using MDA-
MB-231/fibroblast co-cultured cells have shown that a set of interferon response genes, 
including Stat1, is up-regulated during direct co-culture (Buess et al. 2007).  
Immunohistochemical studies also showed that Stat1 was strongly induced in a subset of 
breast tumour cells, specifically at the tumour-stroma border, and this increased Stat1 
expression was inversely correlated with poor patient outcome.  Our findings support those 














FIGURE 3.11 A proposed model showing the interferon response occurring when fibroblasts are 
directly co-cultured with tumour cells.  When MDA-MB-231 tumour cells are directly co-cultured with CCD-
1068SK fibroblasts, the tumour cells produce an unknown factor that results in an increase in IFNα and IFNβ 
expression in neighbouring fibroblasts (1).  These interferons are secreted by the fibroblasts into the medium 
(2) where they bind to type I IFN receptors on both the fibroblast and tumour cell surfaces.  This binding 
activates the JAK/Stat signalling pathway in both cell types (3), with a resulting increase in Stat1 gene 
expression and protein phosphorylation. JAK/Stat signalling activation causes a further increase in IFNβ 
expression in tumour cells and in both IFNα and IFNβ gene expression in fibroblasts (4). 
 
Increased production of type I IFNs and activation of the interferon response usually 
occurs as part of the innate immune response to intracellular pathogens.  This response is 
triggered by the recognition of pathogen-associated molecular patterns (PAMPs) by pattern 
recognition receptors (PRR) such as toll-like receptors (TLRs) and NOD-like receptors 
(NLRs) on the cell surface (Honda et al. 2006; Takaoka & Yanai 2006).  PRRs can also be 
activated in sterile conditions in response to damage-associated molecular patterns 
(DAMPs) generated by injured or damaged cells (Matzinger 1994; Matzinger 2007).  Since 
DAMP production by tumour cells has also been linked to increased inflammation in the 
tumour environment (Srikrishna & Freeze 2009) it is possible that DAMPs produced by 
MDA-MB-231 tumour cells may be detected by PRRs on the fibroblast cell surface, 
initiating an inflammatory response.  However, further studies would need to be performed 
to determine the exact nature of this tumour-produced factor. 
 
The increase in type I IFN production by fibroblasts in close contact with tumour cells 
























are regarded as sentinel cells in chronic inflammation because they aid in the migration of 
leukocytes to the wound site (Smith et al. 1997).  Type I IFNs are usually regarded as a 
tumour suppressor and have been used for the treatment of tumours (Takaoka & Yanai 
2006), however recruitment of immune cells to the tumour site does not always result in 
tumour eradication and the results may be context dependent. Chronic activation of certain 
types of innate immune cells at the tumour site, such as tumour-associated macrophages 
(TAMs), could result in a proinflammatory tumour environment and facilitate further 
tumour invasion and metastasis (de Visser et al. 2006).  This type of inflammation has 
previously been observed in breast tumours in which no pre-existing inflammation was 
found (Mantovani et al. 2008). 
 
The increased interferon gene expression observed in CCD-1068SK/MDA-MB-231 co-
cultures was accompanied by an increase in Stat1 phosphorylation in both cell types.  
Since increased Stat1 activation did not lead to any changes in type I collagen gene 
expression in fibroblasts exposed to secreted factors from tumour/fibroblast co-cultures, 
the JAK/Stat signalling pathway does not appear to be involved in tumour-mediated type I 
collagen regulation.  These results also confirm that negative regulation of type I collagen 
gene expression is not a result of a secondary response induced by factors secreted during 
fibroblasts/tumour direct co-cultures, but that this negative regulatory effect occurs as a 
direct result of close contact between tumour cells and fibroblasts.   
 
Analysis of cytokines secreted in fibroblast/tumour direct co-culture medium showed that 
previously characterised negative regulators of type I collagen gene expression such as 
TNFα, IFNγ and IL1 are also not involved in tumour-mediated type I collagen suppression 
in fibroblasts.  Further examination of MAPK signalling pathways in fibroblast/tumour co-
cultures revealed that JNK and MEK signalling did not play a role in tumour-mediated 
type I collagen regulation, but that the p38 MAPK signalling pathway may be partially 
involved.  Since the inhibitors used in these experiments were added to co-cultured cells, 
they would inhibit the specific MAPK in both fibroblasts and tumour cells.  Therefore, 
further investigation of the role of p38 MAPK signalling would require selective inhibition 













Our investigations have revealed that a number of cytokines known to be negative 
regulators of type I collagen gene expression are not involved in MDA-MB-231 tumour-
mediated regulation in neighbouring fibroblasts.  Since close contact between fibroblasts 
and tumour cells is required for negative regulation of type I collagen synthesis, it is 
possible that cell-surface receptors and cell matrix proteins may be involved in regulation.  
Further investigation of these factors may lead to a better understanding of type I collagen 





































THE EFFECT OF BREAST TUMOUR CELLS ON THE EXPRESSION 





Invading tumour cells could communicate with surrounding fibroblasts in a number of 
different ways, with the proximity to these cells playing a role in the types of signalling 
that could take place.  Apart from paracrine signalling to neighbouring fibroblasts via 
secreted factors, tumour cells in closer proximity to fibroblasts could also communicate via 
cell adhesion molecules, which could lead to changes in the expression of extracellular 
matrix genes such as type I collagen.  
 
Adhesion molecules such as integrins and cadherins are known mediators of cell-matrix 
and cell-cell signalling.  Integrins may bind to E M proteins and in so doing assist in cell 
adhesion and in communicating signals from the surrounding ECM to the cell.  Integrins 
α1β1, α2β1, α10β1 and α11β1 are the most well-known receptors for collagens and can be 
differentiated from other integrin subunits by the extra subdomain (Iα) in their α-subunit, 
which binds to collagen in the ECM (Heino 2000).  Integrins are also able to associate with 
other cell adhesion molecules on adjacent cells, including immunoglobulin-type receptors 
ICAMs (intercellular adhesion molecules) and VCAMs (vascular cell adhesion molecules), 
as well as members of the ADAM (a disintegrin and metalloprotease) family (Bernstein 
1998; Danen 2005; Heino 2000; Oberyszyn et al. 1998).  Another group of cell surface 
receptors are the cadherins, which are mainly involved in cell-cell adhesion. N-cadherin 
has specifically been detected in a number of tumours and has been shown to be involved 
in melanoma cells adhesion to dermal fibroblasts and vascular endothelial cells (Li et al. 
2001).  Although changes in the gene expression of cell adhesion proteins have been 
associated with tumour initiation, growth and metastasis (Danen 2005), the role of these 
proteins in tumour cell communication with neighbouring fibroblasts and how this could 













Another group of proteins that play a role in modulating cell-ECM interactions and ECM 
synthesis are the extracellular-matrix associated or “matricellular” proteins (Bornstein & 
Sage 2002), which include TSP-1 (thrombospondin-1), SPARC (secreted protein, acidic 
and rich in cysteine), tenascin-C, osteopontin and members of the CCN family.  
Matricellular proteins are secreted into the ECM and, although they do not play a direct 
role in maintaining structural integrity (Bornstein 2009), they are involved in regulating the 
cell’s response to other environmental factors and can interact with cell surface receptors, 
ECM components, growth factors, cytokines and proteases (Bornstein & Sage 2002; Chen 
& Lau 2009).  Connective tissue growth factor (CTGF/CCN2) is a matricellular protein 
that is involved in matrix remodelling and is often implicated in fibrosis (Shi-wen et al. 
2000).  CCN2 can signal through integrins and heparin-sulfate proteoglycans (HSPG) 
(Leask et al. 2009), although the exact signalling mechanisms may vary according to cell 
type and conditions in the cellular environment (Shi-wen et al. 2008).  CCN2 gene 
expression can be induced by TGF-β, and CCN2 also acts as a co-mediator of TGFβ-
stimulated type I collagen gene expression (Igarashi et al. 1993; Leask et al. 2003; Shi-wen 
et al. 2000).   
 
TGFβ binding to its receptors activates the Smad signalling pathway which positively 
regulates both CCN2 and type I collagen gene expression in fibroblasts (Hishikawa et al. 
2007; Leask et al. 2003; Ramirez et al. 2006).  The Smad3/4 complex binds to the CCN2 
promoter, while the Smad2/3/4 complex associates with p300 to positively regulate 
COL1A2 promoter activity (figure 4.1) (Holmes et al. 2001; Inagaki & Okazaki 2007; 
Zhang et al. 2000).  COL1A1 is also known to be a Smad3/4 gene target and a Smad 
binding element has been identified in the COL1A1 promoter (Verrecchia et al. 2001a; 
Lakos et al. 2004).   An intact Smad signalling pathway is also reported to be essential for 
CCN2-mediated regulation of type I collagen gene expression in skin fibroblasts (Quan et 
al. 2009).  Smad7 is a well-known negative regulator of the Smad signalling pathway that 
is able to interfere with R-Smad/TGFβ receptor interactions and Smad-Smad interactions, 
as well as induce TGFβRI degradation (Hayashi et al., 1997; Heldin et al. 2009; Leask & 












previously been found to decrease COL1A1, COL1A2 and CCN2 gene expression (van 
Beek et al. 2006; Chen et al. 1999; Holmes et al. 2001; Quan et al. 2009).   
 
 
Figure 4.1. TGFβ-mediated regulation of CCN2 and COL1A2 gene expression.  Binding of TGFβ to the 
TGFβ-receptor complex results in the phosphorylation of Smad2 and Smad3, which form a complex with 
Smad4 and translocate to the nucleus.   The Smad2/3/4 complex associates with p300 and binds to the TbRE 
(TGFβ response element) of the COL1A2 promoter, resulting in increased transcription of COL1A2.  CCN2 
promoter activity is also increased when the Smad3/4 complex binds to the CCN2 promoter.  Smad7 acts as a 
negative feedback inhibitor of the Smad signalling pathway.       
 
The aim of this chapter was to investigate the possible role of adhesion molecules and 
ECM components in MDA-MB-231 tumour-mediated suppression of type I collagen gene 
expression in CCD-1068SK fibroblasts. Since there is not much information available on 
how fibroblast/tumour co-culture affects ECM or adhesion molecules, a microarray was 
used to specifically examine the expression of ECM and cellular adhesion molecule genes 
in CCD-1068SK fibroblast after direct co-culture with MDA-MB-231 cells.  Further 
studies involved determining the role of CCN2 and Smad7 in mediating the negative 
regulatory effect of MDA-MB-231 tumour cells on type I collagen gene expression in 































4.2.1 ECM and adhesion molecule gene expression in fibroblasts after tumour cell 
co-culture. 
 
Our earlier results show that MDA-MB-231 tumour cells require close contact with normal 
fibroblasts to exert a negative regulatory effect on type I collagen gene expression.  It is 
therefore possible that cell surface molecules, such as adhesion proteins, could be involved 
in triggering the tumour-induced inhibitory effect on type I collagen synthesis.  The effect 
of direct co-culture with MDA-MB-231 tumour cells on cell adhesion molecule and ECM 
molecule gene expression in CCD-1068SK fibroblasts was therefore further investigated. 
 
CCD-1068SK fibroblasts were directly co-cultured with MDA-MB-231 tumour cells and 
separated by FACS.  RNA was isolated from CCD-1068SK fibroblasts and used to profile 
the expression of 113 genes (table 4.1) that form part of the Oligo GEArray® Human 
Extracellular Matrix and Adhesion Molecules microarray (SABiosciences), as described in 
Materials and Methods (section 6.17).  The expression images obtained were uploaded 
onto the web-based GEArray Expression Analysis Suite for data analysis (figure 4.2).   
 
 
FIGURE 4.2 A representative chemiluminescent image of an OligoGE nylon membrane array.  Sample 
oligonucleotide probes were hybridised to OligoGE membrane arrays and detected with CDP-Star.  Each 






















Table 4.1. Genes included on the Extracellular Matrix and Adhesion Molecules Oligo GEarray.     
Abbreviations: HAS, hyaluronan synthase; ICAM, intercellular adhesion molecule; NCAM, neural cell adhesion 
molecule; PECAM, platelet endothelial cell adhesion; VECAM, vascular endothelial cell adhesion molecule; 
SELE, E-selectin; SELL, L-selectin; SELP, P-selectin; ITGA, integrin α; ITGB, integrin β; MMP, matrix 
metalloproteinase; SGCE, episilon-sarcoglycan; SPG7, paraplegin; COL, collagen; CTNN, catenin; ADAMTS, 
A disintegrin and metalloproteinase with thrombospondin motifs; SPP, stromal processing peptidase; THBS, 
thrombospondin; CNTN, contactin; VCAN, versican; FN, fibronectin; KAL1, anosmin-1; LAMA, laminin α; 
LAMB, laminin β; CLEC, Tetranectin; VTN, vitronectin; TIMP, tissue inhibitors of metalloproteinases; ECM, 
extracellular matrix protein. 
 




Transmembrane Molecules CD44, CDH1, SGCE 
HAS1,  
ICAM1, NCAM1, PECAM1, VCAM1, 
SELE, SELL, SELP 
ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, 
ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, ITGB5,  
MMP14, MMP15, MMP16, SPG7 
Cell-Cell Adhesion CD44, CDH1,  




Cell-Matrix Adhesion ADAMTS13,  
CD44, SGCE 
ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGA7, ITGA8, ITGAL, ITGAM, 
ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, 
SPP1, 
THBS3. 
Other Adhesion Molecules CNTN1, VCAN, CLEC3B  
CCN2, THBS1, THBS2, TNC 
CTNNA1, CTNNB1, CTNND2,  
Collagens & ECM 
Structural Constituents COL11A1, COL12A1, COL14A1, COL15A1, COL16A1, COL1A1, COL4A2, COL5A1, COL6A1, COL6A2, COL7A1, COL8A1, 
FN1,  
KAL1. 
ECM Proteases ADAMTS1, ADAMTS13, ADAMTS8, 
MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP2, 
MMP3, MMP7, MMP8, MMP9,  
SPG7, 
TIMP1 
ECM Protease Inhibitors COL7A1, 
KAL1,  
THBS1, 
TIMP1, TIMP2, TIMP3 
Basement Membrane 
Constituents COL4A2, COL7A1, LAMA1, LAMA2, LAMA3, LAMB1, LAMB3, LAMC1,  
SPARC. 
Other ECM Molecules VCAN, CLEC3B 
CCN2, THBS2, THBS3, TNC 
ECM1, VTN 













Expression analysis revealed that very few of the genes on the array were differentially 
regulated.  MMP-1 gene expression was however shown to be up-regulated in co-cultured 
CCD-1068SK fibroblasts, while the expression of a number of collagen genes was down-
regulated in response to tumour co-culture (table 4.2).  Although COL1A2 was not 
included on the array, the down-regulation of COL1A1 observed in co-cultured CCD-
1068SK fibroblasts confirmed our earlier results.  Microarray results also showed that 
CCN2 was substantially decreased in fibroblasts co-cultured with tumour cells.  The 
microarray findings were independently confirmed by means of real-time PCR analysis.  
MMP-1 gene expression was significantly up-regulated in co-cultured fibroblasts (figure 
4.3 A), while CCN2 mRNA levels were decreased more than 5-fold in fibroblasts in close 
contact with tumour cells (figure 4.3 B).   
 
Table 4.2 Differential gene expression in CCD-1068SK fibroblasts after direct co-culture with MDA-MB-

















                                                            
These results suggest that tumour cells affect fibroblast genes involved in ECM 
remodelling. Since the CCN2 protein has previously been shown to play a role in type I 
collagen gene expression, CCN2 may be involved in mediating the negative regulatory 















Figure 4.3 MMP1, COL1A1 and CCN2 mRNA levels in fibroblasts after direct co-culture with tumour 
cells.  CCD-1068SK fibroblasts were directly co-cultured with MDA-MB-231 tumour cells for 48 hours, 
followed by separation of cell types again by FACS.  Real-time PCR analysis was carried out to determine 
relative MMP-1 (A), COL1A1 and CCN2 (B) mRNA levels in co-cultured CCD-1068SK fibroblasts. The graphs 
show the mean ± SD from representative experiments (* p≤0.05, ** p≤0.01; n=3). Abbreviations: CCD, CCD-
1068SK; CCD(MDA), CCD-1068SK fibroblasts after co-culture and FACS separation from MDA-MB-231 cells.   
 
4.2.2 The effect of CCN2 on type I collagen gene expression. 
 
CCN2 is a matricellular protein that has been reported to be a co-mediator of TGF-β’s 
ability to promote ECM synthesis, including that of type I collagen (Blom et al. 2002).  
CCN2 is overexpressed in a number of fibrotic disorders such as scleroderma and has been 
well studied in these diseases (Abraham 2008; Khoo et al. 2006; Leask et al. 2009; 
Ponticos et al. 2009; Uchio et al. 2004).  Previous studies suggest that, in fibroblasts, TGFβ 
stimulates CCN2 gene expression, which facilitates in increasing type I collagen gene 
expression in response to TGFβ (Khoo et al. 2006; Ponticos et al. 2009; Quan et al. 2009).  
Since our microarray and RT-PCR results showed that both type I collagen and CCN2 
mRNA levels were significantly decreased in CCD-1068SK fibroblasts directly co-
cultured with MDA-MB-231 tumour cells, we investigated a possible role for CCN2 in 
tumour-mediated type I collagen regulation.   
 
4.2.2.1 CCN2 gene expression in tumour/fibroblast co-cultures. 
 
CCN2 is a 36-38 kDa protein, depending on its degree of glycosylation, which is either 
secreted through the Golgi apparatus into the stroma or remains attached to the cell surface 
and ECM (Blom et al. 2002).  CCN2 has been observed as homodimers (~70-80 kDa) or as 
cleavage products (16-20 kDa or 10-12 kDa), which are still biologically active (Ball et al. 

































































Wahab et al. 2001) and much of the variation found in CCN2 appears to be cell type 
specific (Blom et al. 2002).  We therefore wanted to determine how tumour/fibroblast co-
culture was affecting CCN2 production in both cell types, as well as secretion of CCN2 
into the medium. 
 
To determine CCN2 protein levels in CCD-1068SK fibroblasts and MDA-MB-231 tumour 
cells after direct co-culture, immunoblotting analysis was performed on total endogenous 
protein isolated from both cell types after FACS separation.  A human anti-CCN2 antibody 
against the region mapping within amino acids 150-200 was used for the analysis.  This 
region contains the hinge joining the N- and C-terminal domains as well as amino acids 
from both domains.  Results of immunoblotting identified the 36-38 kDa CCN2 protein as 
present in both CCD-1068SK fibroblasts and MDA-MB-231 tumour cells, with the double 
band representing differences in CCN2 glycosylation (figure 4.4 A & B).  Direct co-culture 
of CCD-1068SK fibroblasts with tumour cells resulted in a decrease in CCN2 levels when 
compared to levels in control fibroblasts (figure 4.4 A).  However, CCN2 levels in co-
cultured MDA-MB-231 tumour cells were similar to those observed in tumour 




FIGURE 4.4 CCN2 protein levels in fibroblast/tumour direct co-cultures. CCD-1068SK fibroblasts were 
directly co-cultured with MDA-MB-231 tumour cells for 48 hours and then separated by FACS.  Equivalent 
amounts of total cell lysate were used for immunoblotting analysis with the CCN2 antibody as described in 
Materials and Methods (section 6.11).  CCN2 was expressed as a 36-38 kDa protein in CCD-1068SK 
fibroblasts (A) and MDA-MB-231 tumour cells (B). CCN2 protein was isolated from CCD-1068SK/MDA-MB-
231 co-culture and monoculture cell medium and equal protein was used for immunoblotting analysis (C).  
CCN2 was detected at both 36-38 kDa and at ~72 kDa.  Abbreviations: CCD, CCD-1068SK; MDA, MDA-MB-
231; CCD(MDA), CCD-1068SK fibroblasts after co-culture and FACS separation from MDA-MB-231 cells; 









































Since CCN2 is a matricellular protein that is thought to perform most of its functions in the 
ECM, immunoblotting analysis was performed to determine the levels of CCN2 present in 
the medium of CCD-1068SK/MDA-MB-231 co-cultures and monocultures of each cell 
type after 48 hours incubation.  Results showed that CCN2 found in control CCD-1068SK 
medium occurred mainly as a ~72 kDa fragments, presumed to be CCN2 dimers, with no 
36-38 kDa form detected (figure 4.4 C).  In control MDA-MB-231 cell medium, the 72 
kDa band was present to a lesser degree, compared to the monomeric form of CCN2.  
CCD-1068SK/MDA-MB-231 co-culture cell medium showed all forms observed in both 
cell type monocultures.     
 
These results suggest that CCN2 is expressed as a 36-38 kDa protein in both fibroblast and 
tumour cell monocultures, but that endogenous CCN2 levels are lower in CCD-1068SK 
fibroblasts co-cultured with MDA-MB-231 tumour cells, as observed at an mRNA level.  
Since decreased CCN2 levels may cause decreased type I collagen levels under co-culture 
conditions, we next investigated the effect of inhibiting fibroblast CCN2 expression on 
type I collagen gene expression. 
 
4.2.2.2 The effect of CCN2 inhibition on type I collagen gene expression. 
 
To determine whether decreased CCN2 gene expression influences type I collagen gene 
expression in CCD-1068SK fibroblasts, these cells were transfected with CCN2 siRNA 
and incubated for 48 hours before harvesting protein.   
 
Immunoblotting results showed that CCN2 protein levels were decreased by up to 90% in 
CCD-1068SK fibroblasts transfected with 40 nm CCN2 siRNA (figure 4.5 A & B).  The 
effect of silencing CCN2 on type I collagen gene expression only became apparent at 40 
nm CCN2 siRNA and above, which resulted in a two-fold decrease in type I collagen 
protein levels (figure 4.5 A & C).  CCN2 mRNA levels were also significantly decreased 
in fibroblasts transfected with 40 nm CCN2 siRNA (figure 4.5 D).  As observed at a 
protein level, CCN2 inhibition resulted in a 2-fold decrease in COL1A1 mRNA levels, 
although COL1A2 mRNA levels were only slightly lower than those observed in control 













Since silencing CCN2 expression in CCD-1068SK fibroblasts resulted in a decrease in 
type I collagen mRNA and protein levels, it is possible that MDA-MB-231 tumour-
mediated negative regulation of CCN2 gene expression in fibroblasts could, in turn, result 





FIGURE 4.5 Silencing CCN2 expression in CCD-1068SK  fibroblasts.  CCD-1068SK fibroblasts were 
transfected with varying concentrations of CCN2 siRNA and incubated for 48 hours.  (A) Immunoblotting 
analysis of endogenous CCN2 and type I procollagen protein levels in CCD-1068SK fibroblasts transfected 
with CCN2 siRNA. (B) Quantitation of relative CCN2 levels. (C) Quantitation of relative type I procollagen 
levels.  (D) Real-time PCR analysis of CCN2, COL1A1 and COL1A2 mRNA levels in CCD-1068SK fibroblasts 
transfected with CCN2 siRNA. The graph shows the mean ± SD from a representative experiment (*p≤0.05,   
** p≤0.01; n=3).   
 
4.2.2.3 The effect of Smad7 on CCN2 and type I collagen gene expression. 
 
The Smad signalling pathway plays an important role in the positive regulation of both 
CCN2 and type I collagen gene transcription, with TGFβ being the most well-known 
activator of this signalling pathway.  The important relationship between TGFβ signalling 
and CCN2 and type I collagen gene expression was also highlighted by a recent study 





































































































in aged human skin samples (≥ 80 years) (Quan et al. 2009). Smad7 is known to act as a 
negative regulator of the Smad signalling pathway, and an increase in Smad7 gene 
expression may therefore result in suppression of both CCN2 and type I collagen gene 
expression.  As we observed a decrease in both CCN2 and type I collagen gene expression 
in co-cultured fibroblasts, the potential role of Smad7 in tumour-mediated regulation of 
these genes was further investigated. 
 
4.2.2.3.1 The effect of tumour cells on Smad7 gene expression in co-cultured 
fibroblasts. 
 
To determine if tumour cells caused any change in Smad7 mRNA and/or protein levels in 
co-cultured fibroblasts, MDA-MB-231/CCD-1068SK co-cultures were incubated for 48 
hours and separated by means of FACS.   
 
Real-time PCR analysis revealed that tumour cell co-culture caused a significant increase 
in Smad7 mRNA levels in CCD-1068SK fibroblasts (figure 4.7 A).  Smad7 protein levels 
were also increased in co-cultured fibroblasts, albeit not to the degree observed at an 
mRNA level (figure 4.7 B & C).  
 
These results show that direct co-culture with MDA-MB-231 tumour cells results in an 
increase in both the mRNA and protein levels of Smad7 in CCD-1068SK fibroblasts.  We 
speculate that Smad7 may therefore play a role in tumour-mediated negative regulation of 

















FIGURE 4.7 Smad7 mRNA and protein levels in fibroblasts after direct co-culture with tumour cells.  
Fluorescently labeled CCD-1068SK fibroblasts were directly co-cultures with MDA-MB-231 tumour cells for 48 
hours, followed by FACS separation.  RNA and protein was extracted from separated CCD-1068SK 
fibroblasts for further analysis. (A) Relative Smad7 mRNA levels in co-cultured CCD-1068SK fibroblasts were 
quantified by means of real-time PCR. The graph shows the mean ± SD from a representative experiment 
(*p≤0.05, n=3).  (* p≤0.05). (B) Immunoblotting results show Smad7 levels in co-cultured CCD-1068SK 
fibroblasts. Relative Smad7 levels were also quantified by means of densitometry.  Abbreviations: CCD, CCD-
1068SK; MDA, MDA-MB-231; CCD(MDA), CCD-1068SK fibroblasts directly co-cultured with MDA-MB-231 
cells and separated again by means of FACS. 
 
4.2.2.3.2 Type I collagen and CCN2 gene expression in Smad7 inhibited fibroblasts. 
 
Since Smad7 gene expression wa  up-regulated in fibroblasts after co-culture with tumour 
cells, we wanted to determine whether preventing Smad7 gene expression would reverse 
the negative regulatory effect of the tumour cells on CCN2 and type I collagen gene 
expression in CCD-1068SK fibroblasts. 
 
Smad7 gene expression was silenced in CCD-1068SK fibroblasts by transfecting cells with 
Smad7 siRNA, with real-time PCR and immunoblotting results confirming that both 
Smad7 mRNA and protein levels were decreased as a result (figure 4.8 A & B).  Smad7 
inhibition led a significant increase in CCN2 mRNA levels and levels of the 72 kDa CCN2 
dimer band were substantially increased in Smad7 inhibited cells (figure 4.8 C & D).  
However, levels of 36-38 kDa CCN2 remained largely unchanged compared to levels in 































































although no change in COL1A2 mRNA levels was observed (figure 4.8 E).  On the other 
hand, both α1(I) and α2(I) procollagen levels was increased in Smad7-inhibited fibroblasts 
(figure 4.8 F). 
 
To determine the involvement of Smad7 in mediating the effects of tumour cells on CCN2 
and type I collagen gene expression in co-cultured fibroblasts, Smad7-inhibited CCD-
1068SK fibroblasts were co-cultured with MDA-MB-231 cells.  As expected, Smad7 
mRNA levels were significantly decreased in Smad7-inhibited co-cultures when compared 
to control co-cultures (figure 4.9 A).   Interestingly, real-time PCR analysis revealed that 
Smad7 inhibition resulted in a significant increase in CCN2 mRNA levels in 
fibroblast/tumour co-cultures compared to control samples (figure 4.9 B), suggesting that 
Smad7 was able to revert tumour-mediated repression of CCN2 gene expression.  
However, neither COL1A1 nor COL1A2 mRNA levels were affected by Smad7 inhibition 
(figure 4.9 C) and immunoblotting analysis similarly show d that type I procollagen levels 
remained unchanged when Smad7 expression was decreased (figure 4.9 D & E).   
 
Results of these experiments suggest that Smad7 is involved in negatively regulating basal 
CCN2 and type I collagen gene expression in CCD-1068SK fibroblasts, although the effect 
on type I collagen protein levels was more prominent than that observed at an mRNA 
level.  Smad7 also appears to play a role in mediating the negative regulatory effects of 
tumour cells on CCN2 gene expression in co-cultured CCD-1068SK fibroblasts.  However, 
our results do not provide conclusive evidence that Smad7 is involved in tumour-mediated 
















FIGURE 4.8 The effect of Smad7 inhibition on CCN2 and type I collagen gene expression in fibroblasts.  
CCD-1068SK fibroblasts were transfected with 80 nm Smad7 siRNA and incubated for 48 hours (section 
6.16).  RNA and protein was isolated from fibroblasts for further analysis. (A) Quantitative real-time PCR 
analysis was performed using RNA isolated from Smad7 siRNA-transfected CCD-1068SK fibroblasts and 
compared to levels in fibroblasts transfected with control siRNA. (B) Immunoblotting analysis of Smad7 protein 
in CCD-1068SK fibroblasts transfected with Smad7 siRNA. (C) Relative CCN2 mRNA levels in Smad7-
inhibited CCD-1068SK fibroblasts. (D) CCN2 protein levels in Smad7-inhibited fibroblasts.  The CCN2 
antibody detected a band at 36-38kDa and 72 kDa, with a minor band detected just below 72 kDa.    (E) 
Relative COL1A1 and COL1A2 mRNA levels in Smad7-inhibited CCD-1068SK fibroblasts.  (F) The effect of 
silencing fibroblast Smad7 expression on α1(I) and α2(I) procollagen levels. The graphs show the mean ± SD 































































































































































FIGURE 4.9 The effect of tumour cells on CCN2 and type I collagen gene expression in Smad7 
inhibited fibroblasts during direct co-cultures.  CCD-1068SK fibroblasts were transfected with 80 nm 
Smad7 siRNA and directly co-cultured with MDA-MB-231 tumour cells for 48 hours. As a control, fibroblasts 
were transfected with control siRNA before co-culture with tumour cells. RNA was isolated from co-cultured 
cells and used to determine relative Smad7 (A) and CCN2 (B) mRNA levels.  (C) The effect of inhibiting 
Smad7 on relative COL1A1 and COL1A2 mRNA levels was determined in fibroblast/tumour co-cultures. (D) 
Immunoblotting analysis was performed on Smad7-inhibited fibroblast/tumour co-cultures, using a type I 
collagen antibody. The graphs show the mean ± SD from representative experiments (*p≤0.05, ** p≤0.001; 












































































































































4.3  DISCUSSION 
 
Gene expression analysis, performed to examine the differential expression of adhesion 
and ECM genes, revealed that close contact with MDA-MB-231 tumour cells resulted in 
the down-regulation of type I collagen and CCN2 gene expression, and an up-regulation in 
MMP-1 gene expression in CCD-1068SK fibroblasts.  This suggests that MDA-MB-231 
tumour cells cause the balance of ECM synthesis/degradation to be disturbed by 
decreasing the production of profibrotic type I collagen and CCN2 in neighbouring 
fibroblasts and concurrently causing an increase in the expression of a metalloproteinase 
that degrades type I collagen. Previous studies performed on highly invasive melanomas 
have shown that destabilization and degradation of the type I collagen matrix allows 
melanoma cells to evade the growth arrest and apoptosis that these cells would normally 
undergo in the presence of type I collagen matrix (van Kempen et al. 2005).  Inhibiting 
MMP expression in MDA-MB-231 cells was also shown to inhibit the migration of these 
tumour cells through a bone marrow fibroblast monolayer (Saad et al. 2000).  The results 
obtained in these studies suggest that the decreased type I collagen matrix production and 
increased MMP expression observed in co-cultured CCD-1068SK fibroblasts could 
facilitate MDA-MB-231 tumour cell invasion through the ECM.    
 
Elevated expression of CCN2 has been associated with a number of fibrotic diseases 
(Leask et al. 2002; Liu et al. 2011; Mason 2009; Ponticos et al. 2009; Shi-wen et al. 2000; 
Uchio et al. 2004).  Howe er, the role of CCN2 in cancer is still controversial, with both 
positive and negative associations between tumour growth and CCN2 expression being 
observed (Chu et al. 2008; Cicha & Goppelt-Struebe 2009). This may suggest that CCN2 
acts in a context-dependent manner in cancers (Oliver et al. 2010).  In a study by Jiang et 
al. (2004) significantly lower than normal CCN2 mRNA and protein levels were detected 
in breast tumour samples and this was correlated with poor prognosis, with increased risk 
of metastasis and higher mortality rates.  In our co-culture system, CCN2 mRNA and 
protein levels were decreased only in CCD-1068SK fibroblasts in close proximity to 
MDA-MB-231 tumour cells, with no change in CCN2 levels in MDA-MB-231 tumour 
cells.   This suggests that the decrease in CCN2 gene expression observed in breast tumour 













Existing evidence suggests that CCN2 facilitates TGFβ-induced type I collagen gene 
expression and that inhibition of CCN2 gene expression leads to a decrease in type I 
collagen protein and mRNA levels in normal skin fibroblasts  (Duncan et al. 1999; Quan et 
al. 2009; Shi-wen et al. 2000; Shi-wen et al. 2006).  In our study, silencing CCN2 
expression in CCD-1068SK fibroblasts also led to a decrease in α1(I) and α2(I) 
procollagen mRNA and protein levels, although the effect on COL1A1 basal transcription 
was more pronounced than the effect on  COL1A2 transcription.  These results suggest that 
the tumour-mediated down-regulation of type I collagen gene expression observed in co-
cultured fibroblasts could be a consequence of the decrease in CCN2 gene expression also 
observed in these fibroblasts.     
 
Our investigations also identified Smad7 as a putative regulator of both CCN2 and type I 
collagen gene expression in fibroblasts, since Smad7 mRNA and protein levels were 
increased in CCD-1068SK fibroblasts after co-culture with tumour cells.  This protein is 
known to act as a negative feedback regulator of TGFβ/Smad signalling (Gersdorff et al. 
2000), but may also be induced by other factors such as TNFα/NFκB, EGF and IFNγ/Stat 
signalling (Dooley et al. 2006; Ulloa et al. 1999; Zhang et al. 2007b).  Previously in this 
study we showed that MDA-MB-231 tumour cell co-culture caused the JAK/Stat1 
signalling pathway to be activated in neighbouring CCD-1068SK fibroblasts, and it is 
therefore possible that activated JAK/Stat signalling could stimulate Smad7 gene 
expression.  Although IFNγ mediated JAK/Stat signalling was previously shown to have 
no effect on Smad7 gene expression in fibroblasts specifically (Ghosh et al. 2001), our co-
culture system involves JAK/Stat1 signalling via type I IFNs, and the mechanism of 
Smad7 regulation may therefore differ from that involved in IFNγ induction. 
 
If the overexpression of Smad7 observed in CCD-1068SK fibroblasts during tumour co-
culture did indeed occur via a TGFβ-independent mechanism, there are a number of 
implications in terms of the effect on tumour progression.  Since Smad7 negatively 
regulates the cellular response to TGFβ, overexpression of Smad7 may result in 












indicates that fibroblasts unable to respond to TGFβ may facilitate tumour growth 
(Bhowmick et al. 2004).  By transplanting fibroblasts lacking the TGF-β receptor into mice 
together with mammary carcinoma cells, the aggressiveness and metastatic ability of the 
resulting tumours was increased when compared to that observed in tumour cells 
transplanted together with normal fibroblasts. The altered fibroblasts produced TGFα and 
hepatocyte growth factor (HGF) which resulted in accelerated tumour cell growth.  Since 
TGFβ also usually suppresses destructive immune and inflammatory responses (Kunz-
Schughart & Knuechel 2002b; Massague 2008), preventing the action of this tumour 
suppressor in breast cancer could result in tumour-promoting inflammatory conditions 
(Bierie & Moses 2006; Mantovani et al. 2008).  
 
The important role of Smad7 in regulating basal levels of CCN2 gene expression was 
revealed as a result of Smad7 inhibition studies in CCD-1068SK fibroblasts, with 
decreased Smad7 expression resulting in a significant increase in CCN2 mRNA and 
protein levels. To our knowledge, this is the first study to examine the effect of Smad7 
inhibition on CCN2 gene expression.  Previous studies have shown that overexpression of 
Smad7 reduces TGFβ-stimulated CCN2 gene expression, but has no effect on the basal 
expression of CCN2 (Holmes et al. 2001).  However, since we have shown earlier that 
CCD-1068SK fibroblasts produce TGFβ in monocultures (3.2.1), it is possible that Smad7 
plays a role in negatively regulating autocrine TGFβ signalling in these fibroblasts and that 
removal of this regulation results in increased CCN2 gene transcription.  Smad7 inhibition 
in CCD-1068SK fibroblasts also caused an increase in type I procollagen levels, although a 
less pronounced effect was observed at an mRNA level.  The reason for this is not known, 
but may indicate that Smad7 regulates basal type I collagen gene expression by decreasing 
COL1A1 and COL1A2 mRNA stability rather than controlling gene expression at a 
promoter level.  Inhibition of Smad7 gene expression in co-cultured fibroblasts resulted in 
a significant increase in CCN2 gene expression compared to that observed in control co-
cultures.  However, the level of reversion in CCN2 mRNA levels observed in Smad7-
inhibited co-cultures may not account for the total negative effect of tumour cells on CCN2 
gene expression, since there was originally more than a 5-fold decrease in CCN2 mRNA 












revert the negative regulatory effect of tumour cells on type I collagen gene expression.  
These results suggest that Smad7 may at least partially be involved in negatively regulating 
CCN2 gene expression during tumour co-culture, but that other factors may also be 
involved in tumour-mediated suppression of both CCN2 and type I collagen gene 
expression.   
 
In this study we suggest a potential role for CCN2 in the tumour-mediated regulation of 
type I collagen, with at least partial regulation of CCN2 by tumour cells occurring via a 
Smad7-dependent mechanism.  We also show that invasive MDA-MB-231 tumour cells 
cause normal fibroblasts to decrease their expression of profibrotic genes while increasing 
collagenase production when there is close contact between tumour cells and fibroblasts.  
This tumour-mediated initiation of matrix degradation by neighbouring normal fibroblasts 
could allow the tumour cells to escape the inhibitory effects of the matrix and promote 
further tumour migration and invasion.   
 



























CHAPTER FIVE     
CONCLUSION 
 
It has recently been shown that genetic mutations are not the only factors that play a role in 
the progression of the transformed epithelial cells to an invasive tumour cells, but that 
continuous communication with the surrounding stroma may also facilitate tumour 
development.  If tumours progress to the invasive stage, the basement membrane which 
usually separates the tumour cells from the fibroblasts in degraded, allowing tumour cells 
to invade into the surrounding stroma where they come into close contact with stromal 
fibroblasts.  Since these fibroblasts are the main producers of the components making up 
the ECM, close interactions with tumour cells could influence ECM production by 
fibroblasts with further consequences for tumour migration and invasion.   
 
Type I collagen is the main constituent of the ECM, and previous studies have shown that 
type I collagen gene expression is decreased in stage II and stage III breast tumours when 
compared to levels in normal tissue (Fenhalls et al. 1999).  Since further in vivo studies 
showed that breast tumour cells had a negative regulatory effect on type I collagen gene 
expression in neighbouring fibroblasts, we aimed to determine the mechanisms involved in 
this regulation.  The role of the MDA-MB-231 breast tumour cell line in regulating type I 
collagen gene expression in normal breast skin (CCD-1068SK) and lung (WI38) 
fibroblasts was determined using direct and indirect co-culturing systems.  The role of 
tumour-secreted factors and fibroblast signalling pathways in mediating the effects on type 
I collagen gene expression in normal fibroblasts was also further investigated.  Microarray 
analysis was performed to determine the effect of close contact with tumour cells on the 
expression of cell adhesion and ECM molecules in fibroblasts.        
 
The results of our study show that MDA-MB-231 tumour cells require close contact with 
normal CCD-1068SK and WI38 fibroblasts to negatively regulate type I collagen gene 
expression.  This negative regulation is specifically a result of a factor produced by the 
tumour cells, and is not observed in co-cultures with non-tumourigenic MCF12A epithelial 












with specific involvement of the -375/+54 region of the COL1A2 promoter, suggesting 
that tumour cells regulate type I collagen gene expression at a transcriptional level in co-
cultured fibroblasts.  Type I collagen mRNA levels were decreased as early as four hours 
after co-culture and, since tumour-mediated repression of type I collagen mRNA and 
protein levels was still observed six days after co-culture, the tumour-produced factor 
responsible for this regulation was not only transiently expressed during co-cultures. 
 
Tumour-mediated regulation of type I collagen gene expression in fibroblasts may occur 
via secreted factors and/or cell surface adhesion molecules.  Previous studies have shown 
that factors (TNFα, IFNγ and IL-1) secreted by keratinocyte and T-cells can negatively 
regulate type I collagen gene expression in fibroblasts, but that close contact between cells 
was required.  Our investigations revealed that TNFα, IFNγ and IL-1 were not secreted 
during MDA-MB-231/CCD-1068SK co-cultures, but that the expression of IFNα and 
IFNβ was significantly increased under these conditions.  These type I IFNs appeared to 
mediate their effect through the JAK/Stat signalling pathway, with increased gene 
expression and activation of Stat1 observed in both fibroblasts and tumour cells after co-
culture.  Since the increase in Stat1 levels observed in the fibroblasts was shown to occur 
only in response to factors secreted during direct fibroblast/tumour co-cultures, we suggest 
that a tumour cell factor(s) triggers fibroblasts to produce type I IFNs during direct co-
culture and that the secreted type I IFNs signal in both an autocrine and paracrine manner, 
resulting in JAK/Stat activation in both cell types as well as a further increase in type I IFN 
gene expression.   Stat1 gene expression has previously been shown to be specifically up-
regulated at the tumour-stroma border in certain breast tumours (Buess et al. 2007) and our 
results suggest that it is specifically the close association of tumour cells with stromal 
fibroblasts that leads to increased Stat1 gene expression and activation.  The increase in 
Stat1 gene expression has also been inversely correlated with poor patient outcome (Buess 
et al. 2007) and since close contact between CCD-1068SK fibroblasts and MDA-MB-231 
tumour cells also increases type I IFN expression by both cell types, the resulting 
recruitment of immune and inflammatory cells to the tumour could result in an 













Further investigation of the role of Stat1 in type I collagen gene expression showed that the 
negative regulatory effect of tumour cells on type I collagen gene expression could not be 
reversed by inhibiting JAK activation and Stat1 gene expression. However, indirect co-
culture results did suggest that type I collagen gene expression was not affected by factors 
secreted as a result of fibroblast/tumour co-culture.  Type I collagen down-regulation 
therefore occurs as a result of a tumour cell factor(s) that only has an effect on fibroblasts 
in close contact with these tumour cells.   
 
Since MAPK signalling pathways are often deregulated in tumours, the role of the 
MEK/ERK, JNK and p38 MAPK signalling pathways in tumour-mediated negative 
regulation of type I collagen gene expression was also investigated.  Inhibition studies 
performed on co-cultured cells using U0126 and SP600125 showed that MEK/ERK and 
JNK signalling pathways were not involved.  However, results of studies using SB203580 
suggests that the p38 MAPK signalling pathway may at least be partially involved in 
regulating type I collagen gene expression in response to tumour cell co-culture.   
 
Since none of the secreted factors known to negatively regulate type I collagen gene 
expression were produce during tumour/fibroblast co-cultures, the role of cell adhesion and 
ECM molecules in type I collagen regulation were investigated. MMP-1 (collagenase-1) 
was shown to be overexpressed in CCD-1068SK fibroblast as a result of tumour co-
culture, while CCN2 gene expression was down-regulated.  CCN2 is a matricellular 
protein that is thought to play a role in regulating type I collagen gene expression in 
fibroblasts and is regarded as a reliable marker of fibrosis (Shi-wen et al. 2000).  Silencing 
CCN2 gene expression in CCD-1068SK fibroblasts led to a decrease in type I collagen 
gene expression, which suggests that the tumour-mediated down-regulation of CCN2 
levels observed in co-cultured fibroblasts could be resulting in the decrease in type I 
collagen gene expression. 
 
The role of Smad7 as a possible tumour cell-induced negative regulator of CCN2 and type 
I collagen gene expression was also investigated.  Protein and mRNA levels of this 












fibroblasts as a result of direct co-culture with tumour cells.  Increased Smad7 gene 
expression is known to suppress TGFβ-stimulated Smad signalling, and fibroblasts unable 
to respond to TGFβ appear to facilitate tumour growth (Bhowmick et al. 2004).  Therefore, 
any down-stream effects of inhibiting Smad pathway activation may be involved in 
facilitating tumour growth.  Smad7 inhibition in fibroblasts resulted in a down-regulation 
of basal CCN2 gene expression and was also able to at least partially reverse the tumour-
suppressive effect on CCN2 gene expression.  Basal expression of type I procollagen was 
also increased as a result of Smad7 inhibition in fibroblasts.  However, no effect on type I 
collagen gene expression was observed in Smad7-inhibited fibroblasts co-cultured with 
tumour cells.  These results suggest that the tumour-stimulated increase in Smad7 gene 
expression plays a role in negatively regulating CCN2 gene expression, possibly by 
inhibiting Smad signalling, but that other signalling pathways and/or transcription factors 
may also contribute to tumour-mediated suppression of CCN2 and type I collagen gene 
expression.   
 
Since tumour cells need close contact with fibroblasts to suppress type I collagen gene 
expression, cell-membrane associated adhesion molecule may also be involved in this 
regulation.  Although our microarray analysis did not reveal any changes in the expression 
of integrins or other cell adhesion molecules, tumour-mediated regulation might not affect 
gene expression but could rather involve conformational changes to the integrin subunits, 
redistribution of adhesion molecules on the cell surface and/or association of cell adhesion 
molecules with growth factor or cytokine receptors (Comoglio et al. 2003; Danen & 
Sonnenberg 2003; Ivaska & Heino 2011).  Recent studies have shown that TGFβ-mediated 
up-regulation of both CCN2 and type I collagen in fibroblasts requires activation of 
Alk1/Smad1 and ERK1/2 signalling (Pannu et al. 2007) and that the association of CCN2 
with β3 integrin is required for TGFβ-mediated Smad1 phosphorylation (Nakerakanti et al. 
2011).  Silencing Smad1 gene expression resulted in a decrease in the expression of both 
TGFβ-stimulated CCN2 and type I collagen gene expression as well as basal type I 
collagen expression (Pannu et al. 2007).  CCN2-deficient embryonic fibroblasts have also 
shown an impaired ability to induce adhesive signals and type I collagen gene expression 












adhesion kinase) and Src kinase (Nakerakanti et al. 2011; Shi-wen et al. 2006).  Further 
studies would therefore need to be undertaken to examine the role of cell adhesion 
molecules and downstream signalling pathways in tumour-fibroblast interactions and, 
more specifically, their role in regulating CCN2 and type I collagen gene expression by 
tumour cells.   
 
The results obtained in this study suggest that tumour cells are able to down-regulate the 
expression of profibrotic genes such as type I collagen and CCN2, while up-regulating the 
expression of collagenases such as MMP-1 in neighbouring fibroblasts when in close 
contact. Since this type of close contact between tumour cells and fibroblasts is only 
possible in the later stages of breast cancer progression, the resulting decrease in fibroblast-
mediated production of the surrounding extracellular matrix could facilitate further tumour 
invasion and metastasis.  The contribution we have made to better understanding the 
communication occurring between tumour cells and fibroblasts during tumour invasion, 
including how this affects ECM synthesis and degradation, may therefore assist in the 
identification of key mediators of tumour invasion with implications for the development 


























CHAPTER SIX  
MATERIALS AND METHODS 
 
6.1 CELL CULTURE 
CCD-1068SK breast fibroblasts, WI38 lung fibroblasts, MDA-MB-231 breast tumour cells 
and MCF12A non-tumorigenic epithelial cells were purchased from the American Type 
Culture Collection (ATCC).  All cells, apart from MCF12As, were grown in complete 
medium containing Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 
% fetal calf serum (FCS), 100 μg/ml streptomycin and 100 U penicillin. MCF12A cells 
were grown in a 1:1 mixture of DMEM and Ham’s F12 medium containing 5 % FCS, 20 
ng/ml human epidermal growth factor (EGF), 100 ng/ml cholera toxin, 0.01 mg/ml bovine 
insulin and 500 ng/ml hydrocortisone.  
6.2 DIRECT CO-CULTURE 
Fibroblasts were mixed with an equal number of MDA-MB-231 tumour cells and seeded 
into dishes or plates.  As controls, fibroblast were co-cultured with an equal numbers of 
MCF12A cells and each cell type was cultured on its own.  Cells were allowed to settle in 
complete medium for at least 12 hours.  Cells were then washed twice with 1 X PBS and 
incubated in serum-free DMEM containing 50 μg/ml ascorbic acid for a further 48 hours, 
unless otherwise indicated.  All experiments were performed in triplicate and experiments 
were repeated at least once. 
6.3 INDIRECT CO-CULTURE 
CCD-1068SK or WI38 fibroblasts were seeded into 6-well plates and on transwell inserts 
(NUNC) in separate 6-well plates.  An equal number of MDA-MB-231 or MCF12A cells 
were also seeded on transwell inserts in separate 6-well plates.  The pore size of the insert 
membrane was 0.2 μm. In certain cases mixed MDA-MB-231/CCD-1068SK cells were 
also seeded in transwell inserts. Cells were allowed to settle in complete medium for at 
least 12 hours before inserts were transferred into the 6-well plates containing fibroblasts.  
Medium was removed, cells were washed twice with 1 X PBS and serum-free DMEM 












hours. All experiments were performed in triplicate and experiments were repeated at least 
once.     
6.4 FLUORESCENT CELL LABELLING 
Fibroblasts were labelled with PKH67 green fluorescent dye (Sigma) according to the 
manufacturer’s instructions.  Cells were removed from dishes using trypsin/EDTA and 
pooled.  Approximately 2 X 107 cells were placed in a conical polypropylene tube and 
washed once with serum-free medium.  The supernatant was removed after centrifugation 
and cells were resuspended in 1ml of Diluent C.  A 2x dilution of PKH67 dye (4 X 10-6 
molar) was made up in 1ml of Diluent C and added to the cell suspension. Cells were 
mixed well and incubated at room temperature for 5 minutes.  The reaction was stopped by 
adding an equal volume of serum and incubated for a further minute.  An equal volume of 
complete medium was added and samples were centrifuged at 400 x g for 10 minutes.  The 
pellet was resuspended in 10 ml of complete medium, transferred to a new tube and 
washed at least three times before seeding 1.4 X 106 cells per 150mm dish.  An equal 
number of MDA-MB-231 cells were added, and incubated as for direct co-cultures.  CCD-
1068SK and MDA-MB-231 monocultures were used as controls. 
6.5 FLUORESCENCE-ACTIVATED CELL SORTING 
Co-cultured cells were trypsinized, centrifuged and resuspended in DMEM with 2 % FCS.  
Cell types were sorted based on green fluorescence using the BD FACS VANTAGE.  The 
separated cells were collected in tubes containing DMEM with 2% FCS and used for 
further RNA and protein analysis. 
6.6 RNA ISOLATION  
Qiazol (Qiagen) was used to extract RNA from cells according to the manufacturer’s 
instructions.  After removing the medium, cells were washed twice with ice-cold 1 X PBS.  
All further steps were performed on ice.  Qiazol was added to cells and the lysate was 
resuspended and transferred to 1.5 ml tubes.  Chloroform was added to each tube, the 
suspension was mixed vigorously and then centrifuged at 12 000 x g for 15 minutes at 4 
°C.  The aqueous phase containing the RNA was transferred to new tubes and isopropyl 
alcohol was added.  RNA was precipitated overnight at -20 °C and pellets were collected 












75 % EtOH and air dried for 5 to 10 minutes.  The RNA was dissolved in RNase-free 
water and the concentration was determined by means of spectrometry at 260 nm.  RNA 
quality was checked by running 1 μg of sample on a 2.5 % MOPS agarose gel and 
visualizing ethidium bromide under UV light.  Samples were stored at -80 °C.      
6.7 REVERSE TRANSCRIPTION 
The ImPromTM-II Reverse Transcription System (Promega) was used to synthesize cDNA 
according to the manufacturer’s protocol.  Firstly, 1 μg of RNA was made up to a total 
volume of 7 μl and 1 μl of Oligo(dT)15 (500ng) was added.  Samples were incubated at 70 
°C for 10 minutes and then on ice for 5 minutes.  The reverse transcription reaction mix 
was made up by adding together 1 μl of ImProm-IITM Reverse Transcriptase, 4 μl of 
ImProm-IITM 5X Reaction Buffer, 2.4 μl of MgCl2 (3 mM) , 1 μl dNTPs (0.5mM of each 
dNTP), 0.5ul RNasin® ribonuclease inhibitor (20U) and RNase-free water to a total volume 
of 12 μl.  The  reverse transcription reaction mix was then added to the RNA/Oligo(dT)15 
mix and incubated for 5 minutes at room temperature to allow primer annealing, and then 
at 42 °C for 90 minutes to allow reverse transcription.  The reverse transcriptase was 
inactivated by incubation of samples at 70 °C for 10 minutes.  Samples were stored at –80 
°C until further use. 
6.8 REAL-TIME PCR 
For each real-time PCR reaction 2 μl of cDNA was added to 12.5 μl KAPA SYPR green, 1 
μl of forward and reverse primer and 8.5 μl of water.   Real-time PCR reactions were 
performed on a MiniOpticonTM Real-Time PCR Detection System (BIO-RAD) or the 
Roche LightCycler® 480. GAPDH was used to normalize results and the 2-ΔΔCT method 
























































Sengupta et al., 2003 
IFNα 
F: 5’- CCTCGCCCTTTGCTTTACTG-3’ 
R: 5’-GCCCAGAGAGCAGCTTGACT-3’ 
65 ºC 65 bp Buess et al., 2007  
IFNβ1 F: 5’-ACCTCCGAAACTGAAGATCTCCTA-3’ 
R: 5’- TGCT- GGTTGAAGAATGCTTGA-3’ 
65 ºC 74 bp Buess et al., 2007 
Stat1 
F: 5’- ATGGCAGTCTGGCGGCTGAATT-3’ 
R: 5’- CCAAACCAGGCTGGCACAATTG-3’ 












60 ºC 137 bp Koinuma et al 2003 
6.9 PROTEIN ISOLATION 
After removing the medium, cells were washed twice with 1 X PBS and an appropriate 
volume of 1 X RIPA buffer (Cell Signaling) containing 1 X Protease inhibitor (Roche) and 
1 X phosphatase inhibitor (Roche) was added.  Cells were scraped off the dish, and the 
lysate was transferred to 1.5ml tubes.  Samples were sonicated for 10 seconds and 
centrifuged at 10 000 rpm for 10 minutes at 4 °C to remove cell debris.  The supernatant 
was transferred to a new tube and stored at -20 °C. 
6.10 PROTEIN QUANTIFICATION 
The BCATM Protein assay kit (Pierce) was used to quantify protein levels.  Protein sample 
(2.5 μl) was added to 22.5μl of water in a 96-well plate.  BSA Concentration Standards (2 
000 μg/ml to 0 μg/ml) were added to separate wells. Two hundred microliters of BCA 
Working Reagent (50:1 reagent A:reagent B) was then added to samples and concentration 
96-well plate reader.  A standard curve of BSA standards was drawn up and used to 












6.11 SDS-PAGE AND IMMUNOBLOTTING ANALYSIS 
Between 6 and 15 % SDS-Page separating gels were made with a 4 % stacking gel.  
Approximately 20 to 30ug of protein was denatured by incubation at 95 °C for 10 minutes 
in protein loading buffer and then loaded on SDS-Page gels.  Gels were run at 160 V for 90 
minutes and then transferred to nitrocellulose membranes for a further 90 minutes at 100 
V.  Membranes were blocked in 5 % milk for 1 hour.  After 3 washes with TBST, primary 
antibody resuspended in the appropriate buffer (table 6.2) was added to membranes and 
incubated at 4 °C, overnight with shaking.  Three further TBST washes were performed 
before incubating membranes in secondary antibody in appropriate buffer (table 6.3) for 1 
hour at room temperature. After 5 washes with TBST, membranes were incubated with 
LumiGlo Reserve (KPL) for one minute.  Chemiluminscence was detected on X-ray film 
or using a UVP GelDoc-It® TS imaging system.    
 
Table 6.2  Primary antibody information for immunoblotting. 
Primary antibody WB conditions Product size (kDa) Company 
Anti-Type I collagen 1:1000 in 5% milk 130-250 Southern biotech 
Β-tubulin 1:1000 in 5% milk 55 Santa Cruz 
p-STATI (Tyr 701) 1:1000 in 2.5% BSA 84 & 91 Cell Signaling 
STATI 1:1000 in 1% BSA 84 & 91 Cell Signaling 
cJun 1:1000 in 1% BSA 39 Santa Cruz 
p-cJun (Ser63/73) 1:1000 in 1% BSA 46 & 54 Santa Cruz 
p-Erk 1,2 1:500 in 1% BSA 44 & 42 Cell Signaling 
Erk2 1:1000 in 1% milk 42 Santa Cruz 
p-p38 (Thr 180/Tyr 182) 1:1000 in TBST 43 Cell Signaling 
p38 1:5000 in TBST 38 Sigma 
CCN2 1:1000 in 5% BSA 36-38 Santa Cruz 
Smad7 1:500 in 5% BSA 46 Santa Cruz 
 
Table 6.3  Secondary antibody information for immunoblotting. 
Secondary antibody WB conditions Company 
Donkey anti-goat 1:3000 in 5% milk Southern biotech 
Goat anti-rabbit 1:5000 in 5% milk Bio-rad 













6.12 ANALYSING THE INCORPORATION OF [3H]-PROLINE INTO 
SECRETED α1(I) AND α2(I) PROCOLLAGEN. 
CCD-1068SK or WI38 fibroblasts were mixed with an equal number of MCF12A or 
MDA-MB-231 cells, seeded into 6-well plates and allowed to settle overnight.  Cells were 
then washed twice with 1 X PBS, after which 2 ml serum-free DMEM with 20 μCi/ml 
[3H]-proline (American Radiolabeled Chemicals Inc), 50 mg/ml ascorbic acid and 50 
mg/ml β-aminopropionitrile was added to each well and incubated for 20 hours. 
 
Medium was removed from cells and transferred to 2ml microfuge tubes.  Acetic acid was 
added to a final concentration of 0.5M.  Medium proteins were then digested with 100 
μg/ml pepsin for 4 h at 20 °C, with rotation.  Digested medium was transferred to dialysis 
tubing and dialyzed overnight against 50mM Tris, pH 7.5, with one buffer change after 2 
hours.  Medium was transferred back into microfuge tubes and precipitated with TCA 
overnight at 4 °C.  The samples were centrifuged at 11 000 rpm for 15 minutes, washed 
twice with acetone, air-dried and dissolved in 40 μl of SDS-Page loading buffer.  Ten 
microliters of sample was added to 1 ml of scintillation fluid and radioactivity was 
determined using a Packard scintillation counter.  An equal volume of each sample was 
heat-denatured at 95 °C for 5 minutes and run on a 7% SDS-Page gel (with 4 % stacking 
gel) for 80 minutes at 180 V.  The gel was soaked in 1M sodium salicylate for 1 hour and 
then washed in distilled water for another hour.  The gel was then placed on 3mm 
whatmann paper, covered with saran wrap and vacuum dried at 70 °C for 2 hours.  The 
dried gel was placed in a cassette and exposed to film for 7 days at -80 °C, after which it 
was developed and fixed. 
6.13 PLASMID TRANSFECTIONS  
WI38 or CCD-1068SK fibroblasts were seeded into 10cm dishes and allowed to settle 
overnight to obtain a final confluence of 60 %.  The next morning, the transfection mix 
was made up according to the manufacturer’s instructions (Polyplus transfection) by 
diluting 10ug of the plasmid of interest in 500 μl of 150mM NaCl.  One microgram of 
CMV-βgal plasmid, containing a β-galactosidase gene driven by a CMV promoter, was 
added as an internal control.  In a separate tube, 20 μl of jetPEITM transfection reagent was 












vortexed briefly and incubated at room temperature for 30 min.  Medium was changed on 
the WI38 cells, the jetPEITM/plasmid mixture was added drop-wise to the cell medium, and 
cells were incubated for 24 hours.  After 24 hours, the transfected fibroblasts were 
trypsinized and counted.  The cells were split into 9 wells of 6-well plates and an equal 
number of MDA-MB-231 or MCF12A cells (if applicable) were added to three wells each.  
Co-cultures were incubated for 12 hours in complete medium and a further 12 hours in 
serum-free medium before undergoing further analysis.   
6.14 LUCIFERASE ASSAYS 
The Promega Luciferase Assays System was used to determine luciferase levels.  Briefly, 
cell were washed with 1X PBS, actively lysed in 1X passive lysis buffer and the 
supernatant was transferred to white, 96-well plates for analysis.  Luciferase Assay 
Reagent II (LARII) was added to the lysate and luciferase levels were quantified using a 
luminometer.  To determine β-galactosidase levels for normalization, Beta-Glo® was added 
to a separate aliquot of the lysate, incubated for 30 minutes at room temperature and 
analysed with a luminometer.  Luciferase and β-galactosidase values were corrected by 
subtracting the background values obtained for each cell type (untransfected).  The 
corrected luciferase value for each sample was subtracted from the corrected β-
galactosidase value to obtain relative luciferase activity.      
6.15 CYTOKINE ELISA 
The Multi-Analyte Profiler ELISarray kit (SABioscience) was used to determine the levels 
of the following 12 cytokines in culture medium:  IL-1b, IL-4, IL-6, IL-10, IL-12, IL-17A, 
IFNγ, TNFα, TGF-β1, MCP1, MIP-1a, and MIP-1b.  Experiments were performed 
according to the manufacturer’s instructions.  Briefly, 50 μl of assay buffer were added 
into each well of the ELISarray plate.  A further 50 μl of sample (culture medium) was 
added to the appropriate wells.  Antigen standards were made up and added to the 
appropriate well in row A.  Medium was added to the last row as a negative control.  After 
a two hour incubation the plate was washed 3 times with the provided wash buffer.  
Detection Antibody Solution (100 μl) was added to all wells and the plate was incubated 
for 1 hour.  After 3 washes, 100 μl of Avidin-HRP was added and incubated for 30 












The plate was incubated in the dark for 15 minutes and 100 μl of Stop Solution was added 
to all wells.  The plate was read at OD 450 and OD 570 within 30 minutes of adding Stop 
Solution.  Values were normalized by subtracting the OD570 values from OD450 values 
and dividing this value by total cell number. 
6.16 CO-CULTURES WITH SIGNALLING PATHWAY INHIBITORS  
For co-cultures, CCD-1068SK fibroblasts were mixed with an equal number of MCF12A 
or MDA cells or seeded alone in 6-well plates and allowed to settle overnight.  Cells were 
washed with 1X PBS and serum-free medium was added to cells and incubated for 24h.  
Fresh serum-free medium containing the appropriate volume of inhibitor was added to 
cells and incubated for a further 24 hours.  U0126, SP600125 and SB203580 were 
obtained from Merck, while JAK inhibitor I was a Santa Cruz product. Control cells were 
incubated with 0.1 % DMSO in serum-free medium. RNA and protein was then isolated 
and used for further analysis as previously described.        
6.17 siRNA TRANSFECTIONS 
CCD-1068SK or WI38 fibroblasts were plated in 6-well plates and allowed to settle 
overnight, to reach a final confluence of 50%. Transfectin lipid reagent (Bio-Rad) was 
added to the appropriate volume of siRNA in DMEM and incubated at room temperature 
for 20 minutes before being added dropwise to cell medium.  Stat1, CCN2 and Smad7 
siRNA pools were all Dharmacon products (Thermo Scientific).  Cells were then incubated 
overnight with the transfection mix.  The next day, medium was changed and an equal 
number of MDA-MB-231 cells were added and allowed to settle overnight.  Serum-free 
medium was added to co-cultured cells and incubated for a further 24 hours before 
continuing with RNA and protein extraction as previously described. 
6.18 OLIGO GEarray® HUMAN EXTRACELLULAR AND ADHESION 
MOLECULES MICROARRAY ANALYSIS. 
CCD-1068SK fibroblasts were fluorescently labelled, directly co-cultured with an equal 
number of MDA-MB-231 for 48 hours and separated by means of FACS, as previously 
described (see 6.4 & 6.5).  RNA was extracted from CCD-1068SK fibroblast and the 
RNeasy® MinElute™ Cleanup Kit (Qiagen) was used to purify the RNA (according to the 












was used for cDNA and cRNA synthesis, using the TrueLabeling-AMP™ 2.0 kit 
(SABiosciences). cRNA was purified using the ArrayGrade™ cRNA Cleanup Kit 
(SABiosciences) and quantified.   
 
The Oligo GEArrays® nylon membranes were pre-wet with deionized water.  Prewarmed 
GEAhyb Hybridization Solution was added and the membranes were prehybridized at 60 
°C, with rotation, in a hybridization oven for more than one hour.  Approximately 6 μg of 
cRNA was added to 0.75 ml of prewarmed GEAhyb Hybridization Solution and added to 
the hybridization tube after discarding the prehybridization solution.  Membranes were 
hybridized at 60 °C, with continuous rotation, overnight.  A low stringency wash was 
followed by high stringency wash of the membranes, performed at 60 °C for 15 minutes 
each.  Tubes were then allowed to reach room temperature in the hybridization oven. 
 
The Chemiluminescent Detection Kit (SABiosciences) was used for binding of the alkaline 
phosphatase-conjugated streptavidin and for detection of biotinylated cRNA probes.  After 
adding CDP-Star chemiluminescent substrate to the membranes the array images were 
detected using the Syngene G:Box Chemi system. The images were uploaded onto the 
web-based GEArray Expression Analysis Suite for further evaluation.  The background 
was normalized against two empty spots on each array and gene expression was 
normalized against ribosomal protein S27a (RPS27A) and beta actin (ACTB) gene 
expression.      
6.19 IMMUNOBLOTTING ANALYSIS OF CCN2 IN CELL MEDIUM 
CCD-1068SK fibroblasts were directly co-cultured with MDA-MB-231 tumour cells for 
48 hours in serum-free medium as previously described.   Medium was removed from cells 
and dialyzed against distilled water, overnight at 4 °C.  Samples were then lyophilized 
overnight and resuspended in sterile water.  An equal concentration of sample protein was 
then run on a 15% SDS-Page gel and used for immunoblotting analysis as previously 















6.20 STATISTICAL ANALYSIS 
All experiments were performed in triplicate and repeated at least twice.  Standard 
deviations (SD) were calculated from triplicate samples by means of the two-tailed 
















Abraham, D. 2008. “Connective tissue growth factor: growth factor, matricellular 
organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?” 
Rheumatology 47: v8-v9. 
Abreu, J G, N I Ketpura, B Reversade, and E M D Robertis. 2002. “Connective-tissue 
growth factor (CTGF) modulates cell signalling by BMP and TGF-β.” Nature Cell 
Biology 4:599-604.  
Abécassis, L, E Rogier, A Vazquez, A Atfi, and M-F Bourgeade. 2004. “Evidence for a 
role of MSK1 in transforming growth factor-beta-mediated responses through p38α 
and Smad signaling pathways.” The Journal of biological chemistry 279(29):30474-9.  
Alattia, J R, H Kurokawa, and M Ikura. 1999. “Review Structural view of cadherin-
mediated cell-cell adhesion.” Cellular and Molecular Life Sciences 55:359-367. 
Allinen, M, R Beroukhim, L Cai, C Brennan, J Lahti-Domenici, H Huang, D Porter, M Hu, 
L Chin, A Richardson, S. Schnitt, W R Sellers, K Polyak. 2004. “Molecular 
characterization of the tumor microenvironment in breast cancer.” Cancer Cell 6:17-
32. 
 
Alpaugh, M L, M C Lee, M Nguyen, M Deato, L Dishakjian, S Barsky. 2000. 
“Myoepithelial-Specific CD44 Shedding Contributes to the Anti-invasive and 
Antiangiogenic Phenotype of Myoepithelial Cells.” Experimental Cell Research 
261:150 -158. 
 
Andarawewa, K L, E R Motrescu, M-P Chenard, A Gansmuller, I Stoll, C Tomasetto, M-C  
Rio. 2005. “Stromelysin-3 is a potent negative regulator of adipogenesis participating 
to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front.” Cancer 
research 65(23):10862-71. 
Arnaout, M Amin, S L Goodman, and J-P Xiong. 2007. “Structure and mechanics of 
integrin-based cell adhesion.” Current opinion in cell biology 19(5):495-507. 
Artlett, C M, S-J Chen, J Varga, and S A Jimenez. 1998. “Modulation of Basal Expression 
of the Human a1(I) Procollagen Gene (COLIA1) by Tandem NF-I/Sp1 Promoter 
Elements in Normal Human Dermal FibrobLasts.” Matrix Biology 17:425-434. 
Ball, D K, E E-D A Moussad, M A E Rageh, S A Kemper, and D R Brigstock. 2003. 
“Establishment of a recombinant expression system for connective tissue growth 
factor (CTGF) that models CTGF processing in utero.” Reproduction 125: 271-284. 
Bardwell, L. 2006. “Mechanisms of MAPK signalling specificity.” Biochemical Society 












Barsky, S H. 2003. “Myoepithelial mRNA expression profiling reveals a common tumor-
suppressor phenotype.” Experimental and Molecular Pathology 74:113-122. 
Basset, P, J P Bellocq, C Wolf, I Stoll, P Hutin, J M Limacher, O L Podhajcer, M P 
Chenard, M C Rio and, P Chambon. 1990. “A novel metalloproteinase gene 
specifically expressed in stromal cells of breast carcinomas.” Nature 348(6303):699-
704. 
Beacham, D A, and E Cukierman. 2005. “Stromagenesis : The changing face of 
fibroblastic microenvironments during tumor progression.” Seminars in Cancer 
Biology 15:329-341. 
Bergamaschi, A, E Tagliabue, T Sorlie, B Naume, T Triulzi, R Orlandi, H G Russnes, J M 
Nesland, R Tammi, P Auvinen, V-M Kosma, S Menard, and A-L Borresen-Dale. 
2008. “Extracellular matrix signature identifies breast cancer subgroups with different 
clinical outcome.” Journal of Pathology, The 214:357-367. 
Bernstein, C. 1998. “β2 Integrin/ICAM Expression in Crohn’s Disease.” Clinical 
Immunology and Immunopathology 86(2):147-160.  
Bhogal, R K, C M Stoica, T L McGaha, and C A Bona. 2005. “Molecular Aspects of 
Regulation of Collagen Gene Expression in Fibrosis.” Journal of Clinical 
Immunology 25(6):592-603. 
Bhogal, R K, and C A Bona. 2008. “Regulatory Effect of Extracellular Signal-Regulated 
Kinases (ERK) on Type I Collagen Synthesis in Human Dermal Fibroblasts 
Stimulated by IL-4 and IL-13.” International Reviews of Immunology 27(6):472-496. 
Bhowmick, N A, E G Neilson, and H L Moses. 2004a. “Stromal fibroblasts in cancer 
initiation and progression.” Nature 432:332-337. 
Bhowmick, N A, A Chytil, D Plieth, A E Gorska, N Dumont, S Shappell, M K 
Washington, E G Neilson, H L Moses. 2004b. “TGFβ signaling in fibroblasts 
modulates the oncogenic potential of adjacent epithelia.” Science 303: 848-851. 
Bierie, B, and H L Moses. 2006. “TGF-β and cancer.” Cytokine & Growth Factor Reviews 
17:29-40. 
Bissell, M J, D C Radisky, A Rizki, V M Weaver, and O W Petersen. 2002. “The 
organizing principle: microenvironmental influences in the normal and malignant 
breast.” Differentiation 70:537-46.  
Blom, I E, R Goldschmeding, and A Leask. 2002. “Gene regulation of connective tissue 












Boast, S, M-W Su, F Ramirez, M Sanchez, and E V Avvedimentoii. 1990. “Functional 
Analysis of cis-Acting DNA Sequences Controlling Transcription of the Human Type 
I Collagen Genes.” Journal of Biological Chemistry 265(22):13351-13356. 
Bornstein, P. 2009. “Matricellular proteins: an overview.” Journal of Cell Communication 
and Signaling 3(3-4):163-5.  
Bornstein, P, and J Mckay. 1988. “The first intron of the a1(I) collagen gene contains 
several transcriptional regulatory elements.” The Journal of Biological Chemistry 
263(4):1603-1606. 
Bornstein, P, and E H Sage. 2002. “Matricellular proteins: extracellular modulators of cell 
function.” Current Opinion in Cell Biology 14(5):608-16.   
Bosman, F T, and I Stamenkovic. 2003. “Functional structure and composition of the 
extracellular matrix.” The Journal of Pathology 200:423-428. 
Buess, M, D S A Nuyten, T Hastie, T O Nielsen, R Pesich, P O Brown. 2007. 
“Characterization of heterotypic interaction effects in vitro to deconvolute global gene 
expression profiles in cancer.” Genome Biology 8:R191. 
Büttner, C, A Skupin, and E P Rieber. 2004. “Transcriptional activation of the type I 
collagen genes COL1A1 and COL1A2 in fibroblasts by interleukin-4: analysis of the 
functional collagen promoter sequences.” Journal of Cellular Physiology 198(2):248-
58.  
Chang, H Y, D S Nuyten, J B Sneddon, T Hastie, R Tibshirani, T Sorlie, H Dai, Y D He, L 
J van't Veer, H Bartelink, M van de Rijn, P O Brown, M J van de Vijver. 2005. 
“Robustness, scalability, and integration of a wound-response gene expression 
signature in predicting breast cancer survival.” Proc Natl Acad Sci USA 102:3738-
3743. 
Chang, H Y, J B Sneddon, A A Alizadeh, R Sood, R B West, K Montgomery, J-T Chi, M 
van De Rijn, D Botstein, P O Brown. 2004. “Gene Expression Signature of Fibroblast 
Serum Response Predicts Human Cancer Progression: Similarities between Tumors 
and Wounds.” PLOS Biology 2(2):206-214. 
Chauhan, H, A Abraham, J R A Phillips, J H Pringle, R A Walker, J L Jones. 2003. “There 
is more than one kind of myofibroblast: analysis of CD34 expression in benign, in 
situ, and invasive breast lesions.” Journal of Clinical Pathology 56(4):271-6. 
Chen, C-C, N Chen, and L F Lau. 2001. “The Angiogenic Factors Cyr61 and Connective 
Tissue Growth Factor Induce Adhesive Signaling in Primary Human Skin 












Chen, C-C, and L F Lau. 2009. “Functions and mechanisms of action of CCN matricellular 
proteins.” International Journal of Biochemistry & Cell Biology 41:771-783. 
Chen, S J, C M Artlett, S A Jimenez, and J Varga. 1998. “Modulation of human α1(I) 
procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in 
vitro.” Gene 215(1):101-10.  
Chen, S J, W Yuan, Y Mori, A Levenson, M Trojanowska, J Varga. 1999. “Stimulation of 
type I collagen transcription in human skin fibroblasts by TGF-β: involvement of 
Smad 3.” The Journal of Investigative Dermatology 112(1):49-57.  
Chen, Y, P Segarini, F Raoufi, D Bradham, and A Leask. 2001. “Connective tissue growth 
factor is secreted through the Golgi and is degraded in the endosome.” Experimental 
Cell Research 271(1):109-17.  
Chenard, M P, L O'Siorain, S Shering, N Rouyer, Y Lutz, C Wolf, P Basset, J P Bellocq, 
M J Duffy. 1996. “High levels of stromelysin-3 correlate with poor prognosis in 
patients with breast carcinoma.” International Journal of Cancer 69(6):448-51.  
Chu, C-Y, C-C Chang, E Prakash, and M-L Kuo. 2008. “Connective tissue growth factor 
(CTGF) and cancer progression.” Journal of Biomedical Science 15(6):675-85.  
Chung, K Y, A Agarwal, J Uitto, and A Mauviel. 1996. “An AP-1 binding sequence is 
essential for regulation of the human α2(I) collagen (COL1A2) promoter activity by 
transforming growth factor-beta.” The Journal of Biological Chemistry 271(6):3272-
3278.  
Chung, L W K, A Baseman, V Assikis, and H E Zhau. 2005. “Molecular insights into 
prostate cancer progression: the missing link of tumor microenvironment.” The 
Journal of Urology 173(1):10-20. 
Cicha, I, and M Goppelt-Struebe. 2009. “Connective tissue growth factor: Context-
dependent functions and mechanisms of regulation.” BioFactors 35(2):200-208. 
Comoglio, P M, C Boccaccio, and L Trusolino. 2003. “Interactions between growth factor 
receptors and adhesion molecules: breaking the rules.” Current Opinion in Cell 
Biology 15(5):565-571.  
Curino, A C, L H Engelholm, S S Yamada, K Holmbeck, L R Lund, A A Molinolo, N 
Behrendt, B S Nielsen, and T H Bugge. 2005. “Intracellular collagen degradation 
mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover 
during malignancy.” The Journal of Cell Biology 169(6):977-85. 
Czuwara-Ladykowska, J, V I Sementchenko, D K Watson, and M Trojanowska. 2002. 












and an antagonist of the profibrotic effects of TGF-β.” The Journal of Biological 
Chemistry 277(23):20399-408.  
Danen, E H J. 2005. “Integrins: regulators of tissue function and cancer progression.” 
Current Pharmaceutical Design 11(7):881-91.  
Danen, E H J, and A Sonnenberg. 2003. “Integrins in regulation of tissue development and 
function.” Journal of Pathology, The 200:471-480. 
Davis, R J. 2000. “Signal transduction by the JNK group of MAP kinases.” Cell 
103(2):239-52.  
Debnath, J, and J S Brugge. 2005. “Modelling glandular epithelial cancers in three-
dimensional cultures.” Nature Reviews Cancer 5(9):675-688.  
Dennler, S, C Prunier, N Ferrand, J M Gauthier, and A Atfi. 2000. “c-Jun inhibits 
transforming growth factor beta-mediated transcription by repressing Smad3 
transcriptional activity.” The Journal of Biological Chemistry 275(37):28858-65.  
De Visser, K E, A Eichten, and L M Coussens. 2006. “Paradoxical roles of the immune 
system during cancer development.” Nature Reviews Cancer 6(1):24-37.  
De Wever, O, P Demetter, M Mareel, and M Bracke. 2008. “Stromal myofibroblasts are 
drivers of invasive cancer growth.” International Journal of Cancer 123(10):2229-38. 
De Wever, O, and M Mareel. 2003. “Role of tissue stroma in cancer cell invasion.” The 
Journal of Pathology 200(4):429-47.  
Dhanasekaran, D N, and G L Johnson. 2007. “MAPKs: function, regulation, role in cancer 
and therapeutic targeting.” Oncogene 26(22):3097-9.  
Dhillon, A S, S Hagan, O Rath, and W Kolch. 2007. “MAP kinase signalling pathways in 
cancer.” Oncogene 26(22):3279-90.  
Dijke, P, and C S Hill. 2004. “New insights into TGF-β-Smad signalling.” Trends in 
Biochemical Sciences 29(5):265-273.  
Ding, Q, C L Gladson, H Wu, H Hayasaka, and M A Olman. 2008. “Focal adhesion kinase 
(FAK)-related non-kinase inhibits myofibroblast differentiation through differential 
MAPK activation in a FAK-dependent manner.” The Journal of Biological Chemistry 
283(40):26839-49. 
Dooley, S, H M Said, A M Gressner, J Floege, A En-nia, and P R Mertens. 2006. “Y-box 
protein-1 is the crucial mediator of antifibrotic interferon-gamma effects.” The 












Du, X, E F Plow, A L Frelinger, T E O'Toole, J C Loftus, and M H Ginsberg. 1991. 
“Ligands ‘activate’ integrin αIIbβ3 (platelet GPIIb-IIIa).” Cell 65(3):409-416.  
Duncan, M R, K S Frazier, S Abramson, S Williams, H Klapper, X Huang, and G 
Grotendorst. 1999. “Connective tissue growth factor mediates transforming growth 
factor B-induced collagen synthesis: down-regulation by cAMP.” FASEB 13:1774-
1786. 
Duncan, M R, and B Berman. 1985. “Gamma interferon is the lymphokine and beta 
interferon the monokine responsible for inhibition of fibroblast collagen production 
and late but not early fibroblast proliferation.” Journal of Experimental Medicine 
162:516-527. 
Eckes, B , P Zigrino, D Kessler, O Holtkötter, P Shephard, C Mauch, T Krieg. 2000. 
“Fibroblast-matrix interactions in wound healing and fibrosis.” Matrix Biology 
19(4):325-32.  
Egeblad, M, LE Littlepage, and Z Werb. 2005. “The fibroblastic coconspirator in cancer 
progression.” Cold Spring Harbour Symposia on Quantitative Biology 70:383-388. 
Egeblad, M, E S Nakasone, and Z Werb. 2010. “Tumors as organs: complex tissues that 
interface with the entire organism.” Developmental Cell 18(6):884-901.  
Elenbaas, B, and R A Weinberg. 2001. “Heterotypic signaling between epithelial tumor 
cells and fibroblasts in carcinoma formation.” Experimental Cell Research 264:169-
184. 
Eliceiri, B. P. 2001. “Integrin and Growth Factor Receptor Crosstalk.” Circulation 
Research 89(12):1104-1110.  
Eyden, B, S S Banerjee, P Shenjere, and C Fisher. 2009. “The myofibroblast and its 
tumours.” Journal of Clinical Pathology 62(3):236-49. 
Eyden, B. 2009. “The myofibroblast, electron microscopy and cancer research.” 
International Journal of Cancer 125(7):1743-5 
Fagotto, F, and B M Gumbiner. 1996. “Cell Contact-Dependent Signaling.” 
Developmental Biology 180:445 -454. 
Fang, M, X Kong, P Li, F Fang, X Wu, H Bai, X Qi, Q Chen, and Y Xu. 2009. “RFXB and 
its splice variant RFXBSV mediate the antagonism between IFNγ and TGFβ on 













Fenhalls, G, M Geyp, D M Dent, and M I Parker. 1999. “Breast tumour cell-induced 
down-regulation of type I collagen mRNA in fibroblasts.” British Journal of Cancer 
81(7):1142-9.  
Ferlay, J, HR Shin, F Bray, D Forman, C Mathers, D M Parkin. 2008. “GLOBOCAN 2008 
v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 
[Internet].” Lyon, France: International Agency for Research on Cancer; 2010. 
Available from: http://globocan.iarc.fr. 
Finak, G, N Bertos, F Pepin, S Sadekova, M Souleimanova, H Zhao, H Chen, G 
Omeroglu, S Meterissian, A Omeroglu, M Hallett, M Park. 2008. “Stromal gene 
expression predicts clinical outcome in breast cancer.” Nature Medicine 14(5):518-27.  
Forbes, S J, F P Russo, V Rey, P Burra, M Rugge, N A Wright, M R Alison. 2004. “A 
Significant Proportion of Myofibroblasts Are of Bone Marrow Origin in Human Liver 
Fibrosis.” Gastroenterology 126:955-963. 
Franco, O E, A K Shaw, D W Strand, and S W Hayward. 2010. “Cancer associated 
fibroblasts in cancer pathogenesis.” Seminars in Cell & Developmental Biology 
21(1):33-9.  
Gaggioli, C. 2008. “Collective invasion of carcinoma cells: when the fibroblasts take the 
lead.” Cell Adhesion & Migration 2(1):45-7. 
Gaggioli, C, S Hooper, C Hidalgo-Carcedo, R Grosse, J F Marshall, K Harrington, and E 
Sahai. 2007. “Fibroblast-led collective invasion of carcinoma cells with differing 
roles for RhoGTPases in leading and following cells.” Nature Cell Biology 
9(12):1392-1400.  
Gaidarova, S, and S A Jiménez. 2002. “Inhibition of basal and transforming growth factor-
β-induced stimulation of COL1A1 transcription by the DNA intercalators, 
mitoxantrone and WP631, in cultured human dermal fibroblasts.” The Journal of 
Biological Chemistry 277(41):38737-45.  
Gersdorff, G V, K Susztak, F Rezvani, M Bitzer, D Liang, and E P Bottinger. 2000. 
“Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter 
by transforming growth factor β.” The Journal of Biological Chemistry 275:11320-
11326. 
Ghosh, A K. 2002. “Factors involved in the regulation of type I collagen gene expression: 
implication in fibrosis.” Experimental Biology and Medicine 227(5):301-14.  
Ghosh, A K, W Yuan, Y Mori, S-J Chen, and J Varga. 2001. “Antagonistic Regulation of 
Type I Collagen Gene Expression by Interferon-gamma and Transforming Growth 












Goh, K C, S J Haque, and B R G Williams. 1999. “p38 MAP kinase is required for STAT1 
serine phosphorylation and transcriptional activation induced by interferons.” EMBO 
Journal 18(20):5601-5608. 
Gomm, J J, R C Coope, P J Browne, and R C Coombes. 1997b. “Separated Human Breast 
Epithelial and Myoepithelial Cells Have Different Growth Factor Requirements In 
Vitro But Can Reconstitute Normal Breast Lobuloalveolar Structure.” Journal of 
Cellular Physiology 171:11-19. 
Greenwel, P, S Tanaka, D Penkov, W Zhang, M Olive, J Moll, C Vinson, M Di Liberto, 
and F Ramirez. 2000. “Tumor necrosis factor alpha inhibits type I collagen synthesis 
through repressive CCAAT/enhancer-binding proteins.” Molecular and Cellular 
Biology 20(3):912-8.  
Grotendorst, G R, H Okochi, and N Hayashi. 1996. “Growth Transforming Growth Factor 
β Response Element Controls the Expression of the Connective Tissue Factor Gene.” 
Cell Growth & Differentiation 7:469-480. 
Grotendorst, G R, H Rahmanie, and M R Duncan. 2004. “Combinatorial signaling 
pathways determine fibroblast proliferation and myofibroblast differentiation.” The 
FASEB Journal 18(3):469-79.  
Grotendorst, G R, and M R Duncan. 2005. “Individual domains of connective tissue 
growth factor regulate fibroblast proliferation and myofibroblast differentiation.” The 
FASEB Journal 19:729-738. 
Gudjonsson, T, L Ronnov-Jessen, R Villadsen, F Rank, M J Bissell, and O W Petersen. 
2002. “Normal and tumor-derived myoepithelial cells differ in their ability to interact 
with luminal breast epithelial cells for polarity and basement membrane deposition.” 
Journal of Cell Science 115:39-50. 
Gudjonsson, T, M C Adriance, M D Sternlicht, O W Petersen, and M J Bissell. 2006. 
“Myoepithelial Cells : Their Origin and Function in Breast Morphogenesis and 
Neoplasia.” Journal of Mammary Gland Biology and Neoplasia 10(3):261-271. 
Hanafusa, H, J Ninomiya-Tsuji, N Masuyama, M Nishita, J Fujisawa, H Shibuya, K 
Matsumoto, and E Nishida. 1999. “Involvement of the p38 mitogen-activated protein 
kinase pathway in transforming growth factor-beta-induced gene expression.” The 
Journal of Biological Chemistry 274(38):27161-7.  
Hayashi, H, S Abdollah, Y Qiu, J Cai, Y Y Xu, B W Grinnell, M A Richardson, J Topper, 
M A Gimbrone, J L Wrana, and D Falb. 1997. “The MAD-related protein Smad7 
associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling.” 












Heino, J. 2000. “The collagen receptor integrins have distinct ligand recognition and 
signaling functions.” Matrix Biology 19:319-323. 
Heldin, C-H, M Landström, and A Moustakas. 2009. “Mechanism of TGF-beta signaling 
to growth arrest, apoptosis, and epithelial-mesenchymal transition.” Current Opinion 
in Cell Biology 21(2):166-76. 
Higashi, K, Y Inagaki, K Fujimori, A Nakao, H Kaneko, and I Nakatsuka. 2003. 
“Interferon-γ interferes with transforming growth factor-β signaling through direct 
interaction of YB-1 with Smad3.” The Journal of Biological Chemistry 
278(44):43470-43479. 
Higashi, K, Y Inagaki, N Suzuki, S Mitsui, A Mauviel, H Kaneko, and I Nakatsuka. 2003. 
“Y-box-binding protein YB-1 mediates transcriptional repression of human alpha 2(I) 
collagen gene expression by interferon-gamma.” The Journal of Biological Chemistry 
278(7):5156-62.  
Higashi, K, D J Kouba, Y-J Song, J Uitto, and A Mauviel. 1998. “A Proximal ELement 
within the Human Collagen ( COLIA2 ) Promoter , Distinct from the Tumor Necrosis 
Factor-α Response Element , Mediates Transcriptional Repression by Interferon-
gamma.” Matrix Biology 16:447-456. 
Hinz, B, S H Phan, V J Thannickal, A Galli, M-L Bochaton-Piallat, and G Gabbiani. 2007. 
“The Myofibroblast: One Function, Multiple Origins.” American Journal Of 
Pathology 170(6):1807-1816.  
Hishikawa, K, T Nakaki, and T Fujii. 1999. “Transforming growth factor-β1 induces 
apoptosis via connective tissue growth factor in human aortic smooth muscle cells.” 
European Journal of Pharmacology 385(2-3):287-290.  
Hitraya, E G, and S A Jiménez. 1996. “Transcriptional activation of the alpha 1(I) 
procollagen gene n systemic sclerosis dermal fibroblasts. Role of intronic 
sequences.” Arthritis and Rheumatism 39(8):1347-54. 
Holbourn, K P, K R Acharya, and B Perbal. 2008. “The CCN family of proteins : structure 
– function relationships.” Trends in Biochemical Sciences 33:461-473. 
Holmes, A M, D J Abraham, S Sa, X Shiwen, C M Black, and A Leask. 2001. “CTGF and 
SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling.” 
The Journal of Biological Chemistry 276:10594-10601. 
Honda, K, A Takaoka, and T Taniguchi. 2006. “Type I interferon gene induction by the 
interferon regulatory factor family of transcription factors.” Immunity 25(3):349-60.  
Hu, M, and K Polyak. 2008. “Molecular characterisation of the tumour microenvironment 












Huang, G, L Z Shi, and H Chi. 2009. “Regulation of JNK and p38 MAPK in the immune 
system: signal integration, propagation and termination.” Cytokine 48(3):161-9. 
Igarashi, A, H Okochi, D M Bradham, and G R Grotendorst. 1993. “Regulation of 
connective tissue growth factor gene expression in human skin fibroblasts and during 
wound repair.” Molecular Biology of the Cell 4:637-645. 
Ihle, J N, and I M Kerr. 1995. “Jaks and Stats in signaling by the cytokine receptor 
superfamily.” Trends in Genetics  11(2):69-74. 
Ihn, H, K Ohnishi, T Tamaki, E C LeRoy, and M Trojanowska. 1996. “Transcriptional 
Regulation of the Human α 2(I) Collagen Gene.” The Journal of Biological Chemistry 
271(43):26717-26723. 
Ilina, O, and P Friedl. 2009. “Mechanisms of collective cell migration at a glance.” Journal 
of Cell Science 122:3203-8.  
Inagaki, Y, and I Okazaki. 2007. “Emerging insights into Transforming growth factor beta 
Smad signal in hepatic fibrogenesis.” Gut 56(2):284-92. 
Inagaki, Y, T Nemoto, Z M Kushida, Y Sheng, K Higashi, K Ikeda, N Kawada, F 
Shirasaki, K Takehara, K Sugiyama, M Fujii, H Yamauchi, A Nakao, B de 
Crombrugghe, T Watanabe, and I Okazaki. 2003. “Interferon alfa down-regulates 
collagen gene transcription and suppresses experimental hepatic fibrosis in mice.” 
Hepatology 38:890-899. 
Inagaki, Y, S Truter, S Tanaka, M Di Liberto, and F Ramirez. 1995. “Overlapping 
pathways mediate the opposing actions of tumor necrosis factor-alpha and 
transforming growth factor-beta on α2(I) collagen gene transcription.” The Journal of 
Biological Chemistry 270(7):3353-3358. 
Inagaki, Y, S Truter, and F Ramirez. 1994. “Transforming Growth Factor-β stimulates 
α2(I) Collagen Gene Expression through a cis-Acting Element That Contains an Sp1-
binding Site.” The Journal of Biological Chemistry 269(20):14828-14834. 
Ishida, Y, T Kondo, T Takayasu, Y Iwakura, and N Mukaida. 2004. “The Essential 
Involvement of Cross-Talk between IFN-γ and TGF-β in the Skin Wound-Healing 
Process.” The Journal of Immunology 172:1848-1855.  
Ishii, G. 2003. “Bone-marrow-derived myofibroblasts contribute to the cancer-induced 
stromal reaction.” Biochemical and Biophysical Research Communication 309:232-
240. 
Itoh, S, and P ten Dijke. 2007. “Negative regulation of TGF-β receptor/Smad signal 












Ivaska, J, and J Heino. 2011. “Cooperation Between Integrins and Growth Factor 
Receptors in Signaling and Endocytosis.” Annual Review of Cell and Developmental 
Biology 27:1-30.  
Ivkovic, S. 2003. “Connective tissue growth factor coordinates chondrogenesis and 
angiogenesis during skeletal development.” Development 130(12):2779-2791.  
Javelaud, D, and A Mauviel. 2005. “Crosstalk mechanisms between the mitogen-activated 
protein kinase pathways and Smad signaling downstream of TGF-beta: implications 
for carcinogenesis.” Oncogene 24(37):5742-50. 
Jiang, W G, G Watkins, O Fodstad, A Douglas-Jones, K Mokbel, and R E Mansel. 2004. 
“Differential expression of the CCN family members Cyr61, CTGF and Nov in 
human breast cancer.” Endocrine-Related Cancer 11(4):781-91.  
Jimenez, S A, and B Saitta. 1999. “Alterations in the regulation of expression of the α1(I) 
collagen gene (COL1A1) in systemic sclerosis (scleroderma).” Springer Seminars in 
Immunopathology 21(4):397-414. 
Jimenez, S A, J Varga, A Olsen, L Li, A Diaz, J Herhal, and J Koch. 1994. “Functional 
Analysis of Human α1(1) Procollagen Gene Promoter.” The Journal of Biological 
Chemistry 269(17):12684-12691. 
Johnson, G L, and R Lapadat. 2002. “Mitogen-activated protein kinase pathways mediated 
by ERK, JNK, and p38 protein kinases.” Science 298(5600):1911-2. 
Joyce, J A, and J W Pollard. 2009. “Microenvironmental regulation of metastasis.” Nature 
Reviews. Cancer 9(4):239-52. 
Kalluri, R, and M Zeisberg. 2006. “Fibroblasts in cancer.” Nature Reviews Cancer 
6(5):392-401.  
Kang, Y, P M Segel, W Shu, M Drobnjak, S M Kakonen, C Cordon-Cardo, T A Guise, and 
J Massague. 2003. “A multigenic program mediating breast cancer metastasis to 
bone.” Cancer Cell 3:537-549. 
Karnoub, A E, A B Dash, A P Vo, A Sullivan, M W Brooks, G W Bell, A L Richardson, K 
Polyak, R Tubo, and R A Weinberg. 2007. “Mesenchymal stem cells within tumour 
stroma promote breast cancer metastasis.” Nature 449(7162):557-63. 
Katsoulidis, E, Y Li, H Mears, and L C Platanias. 2005. “The p38 mitogen-activated 
protein kinase pathway in interferon signal transduction.” Journal of Interferon & 
Cytokine Research 25(12):749-56. 
Kenny, P A, G Y Lee, and M J Bissell. 2007. “Targeting the tumor microenvironment.” 












Khoo, Y T, C T Ong, A Mukhopadhyay, H C Han, D V Do, I J Lim, and T T Phan. 2006. 
“Upregulation of Secretory Connective Tissue Growth Factor (CTGF) in 
Keratinocyte-Fibroblast Coculture Contributes to Keloid Pathogenesis.” Journal of 
Cellular Physiology 208:336-343. 
Kim, C, F Ye, and M H Ginsberg. 2011. “Regulation of Integrin Activation.” Annual 
Review of Cell and Developmental Biology 27:1-25.  
Kim, K K, M C Kugler, P J Wolters, L Robillard, M G Galvez, A N Brumwell, D 
Sheppard, and H A Chapman. 2006. “Alveolar epithelial cell mesenchymal transition 
develops in vivo during pulmonary fibrosis and is regulated by the extracellular 
matrix.” PNAS,the United States of America 103(35):13180-5.  
Kojima, Y, A Acar, E N Eaton, K T Mellody, C Scheel, I Ben-Porath, T T Onder, Z C 
Wang, A L Richardson, R A Weinberg, and A Orimo. 2010. “Autocrine TGF-β and 
stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-
promoting mammary stromal myofibroblasts.” Proc Natl Acad Sci USA 
107(46):20009-14. 
Koliopanos, A, H Friess, F F di Mola, W-H Tang, D Kubulus, D Brigstock, A 
Zimmermann, and M W Büchler. 2002. “Connective tissue growth factor gene 
expression alters tumor progression in esophageal cancer.” World Journal of Surgery 
26(4):420-7.  
Kouba, D J, K-Y Chung, T Nishiyama, L Vindevoghel, A Kon, J F Klement, J Uitto, and 
A Mauviel. 1999. “Nuclear Factor-kB Mediates TNF-α Inhibitory Effect on α2(I) 
Collagen (COL1A2) Gene Transcription in Human Dermal Fibroblasts.” Journal of 
Immunology 162:4226-4234. 
Kreike, B, M van Kouwenhove, H Horlings, B Weigelt, H Peterse, H Bartelink, and M J 
van de Vijver. 2007. “Gene expression profiling and histopathological 
characterization of triple-negative / basal-like breast carcinomas.” Breast Cancer 
Research 9:R65. 
Kubo, M, K Kikuchi, K Nashiro, T Kakinuma, N Hayashi, H Nanko, and K Tamaki. 1998. 
“Expression of fibrogenic cytokines in desmoplastic malignant melanoma.” The 
British Journal of Dermatology 139(2):192-7.  
Kubo, M, J Czuwara-Ladykowska, O Moussa, M Markiewicz, E Smith, R M Silver, S 
Jablonska, M Blaszczyk, D K Watson, and M Trojanowska. 2003. “Persistent Down-
Regulation of Fli1 , a Suppressor of Collagen Transcription , in Fibrotic Scleroderma 
Skin.” American Journal of Pathology 163(2):571-581. 
Kunz-Schughart, L A, P Heyder, J Schroeder, and R Knuechel. 2001. “A Heterologous 3-
D Coculture Model of Breast Tumor Cells and Fibroblasts to Study Tumor-












Kunz-Schughart, L A, and R Knuechel. 2002. “Tumor-associated fibroblasts (Part I ): 
active stromal participants in tumor development and progression ?” Histology & 
Histopathology 17:599-621. 
Kunz-Schughart, LA, and R Knuechel. 2002. “Tumor-associated fibroblasts ( Part II ): 
functional impact on tumor tissue.” Histology & Histopathology 17:623-637. 
Kunz-Schughart, L A, S Wenninger, T Neumeier, P Seidl, and R Knuechel. 2003. “Three-
dimensional tissue structure affects sensitivity of fibroblasts to TGF-B1.” American 
Journal of Physiology - Cell Physiology 284:C209-C219. 
Kuperwasser, C, T Chavarria, M Wu, G Magrane, J W Gray, L Carey, A Richardson, and 
R A Weinberg. 2004. “Reconstruction of functionally normal and malignant human 
breast tissues in mice.” Proc Natl Acad Sci USA 101(14):4966-71. 
Lacroix, M, R-A Toillon, and G Leclercq. 2004. “Stable ‘portrait’ of breast tumors during 
progression: data from biology, pathology and genetics.” Endocrine-Related Cancer 
11:497-522. 
Lakos, G, S Takagawa, S-J Chen, A M Ferreira, G Han, K Masuda, X-J Wang, L A 
Dipietro, and J Varga. 2004. “Targeted Disruption of TGF-β /Smad3 Signaling 
Modulates Skin Fibrosis in a Mouse Model of Scleroderma.” American Journal of 
Pathology 165(1):203-217. 
Leaner, V D, A Masemola, and M I Parker. 2005. “Species-specific regulation of the 
alpha-2(I) procollagen gene by proximal promoter elements.” IUBMB life 57(4-
5):363-70.  
Leask, A, A M Holmes, C M Black, and D J Abraham. 2003. “Connective tissue growth 
factor gene regulation. Requirements for its induction by transforming growth factor-
β2 in fibroblasts.” The Journal of Biological Chemistry 278(15):13008-15.  
Leask, A, A M Holmes, and D J Abraham. 2002. “Connective tissue growth factor: a new 
and important player in the pathogenesis of fibrosis.” Current Rheumatology Reports 
4(2):136-42. 
Leask, A, S K Parapuram, X Shi-wen, and D J Abraham. 2009. “Connective tissue growth 
factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of 
fibroproliferative disease?” Journal of Cell Communication and Signaling 3(2):89-94. 
Leask, A, and D J Abraham. 2004. “TGF-β signaling and the fibrotic response.” FASEB 
Journal 18:816-827. 
Li, F, B Zeng, Y Chai, P Cai, C Fan, and T Cheng. 2009. “The linker region of Smad2 
mediates TGF-β-dependent ERK2-induced collagen synthesis.” Biochemical and 












Li, G, K Satyamoorthy, and M Herlyn. 2001. “N-Cadherin-mediated Intercellular 
Interactions Promote Survival and Migration of Melanoma Cells.” Cancer Research 
61:3819-3825. 
Lin, J, B Liliensiek, M Kanitz, U Schimanski, H Bohrer, R Waldherr, E Martin, G 
Kaufmann, R Ziegler, and P P Nawroth. 1998. “Molecular cloning of genes 
differentially regulated by TNF-α in bovine aortic endothelial cells, fibroblasts and 
smooth muscle cells.” Cardiovascular Research 38:802.  
Liu, S, X Shi-wen, D J Abraham, and A Leask. 2011. “CCN2 Is Required for Bleomycin-
Induced Skin Fibrosis in Mice.” Arthritis & Rheumatism 63(1):239-246. 
Liu, S, X Shi-wen, L Kennedy, D Pala, Y Chen, M Eastwood, D E Carter, C M Black, D J 
Abraham, and A Leask. 2007. “FAK Is Required for TGFβ-induced JNK 
Phosphorylation in Fibroblasts : Implications for Acquisition of a Matrix-remodeling 
Phenotype.” Molecular Biology of the Cell 18:2169 -2178. 
Livak, K J, and T D Schmittgen. 2001. “Analysis of Relative Gene Expression Data Using 
Real- Time Quantitative PCR and the 2 delta delta CT Method.” Methods 25:402-408. 
Lu, X, and Y Kang. 2007. “Organotropism of Breast Cancer Metastasis.” Journal of 
Mammary Gland Biology and Neoplasia 12:153-162. 
Madsen, D H, L H Engelholm, S Ingvarsen, T Hillig, R A Wagenaar-Miller, L Kjøller, H 
Gårdsvoll, G Høyer-Hansen, K Holmbeck, T H Bugge, and N Behrendt. 2007. 
“Extracellular collagenases and the endocytic receptor, urokinase plasminogen 
activator receptor-associated protein/Endo180, cooperate in fibroblast-mediated 
collagen degradation.” The Journal of Biological Chemistry 282(37):27037-45. 
Mantovani, A, P Allavena, A Sica, and F Balkwill. 2008. “Cancer-related inflammation.” 
Nature 454(7203):436-444. 
Marchionni, L, R F Wilson, A C Wolff, S Marinopoulos, G Parmigiani, E B Bass, and S N 
Goodman. 2008. “Gene Expression Profiling Assays in Early-Stage Breast Cancer.” 
Annals of Internal Medicine 148:358-369. 
Mason, J M, H-P Xu, S K Rao, A Leask, M Barcia, J Shan, R Stephenson, and S 
Tabibzadeh. 2002. “Lefty Contributes to the Remodeling of Extracellular Matrix by 
Inhibition of Connective Tissue Growth Factor and Collagen mRNA Expression and 
Increased Proteolytic Activity in a Fibrosarcoma Model.” The Journal of Biological 
Chemistry 277(1):407-415. 
Mason, R M. 2009. “Connective tissue growth factor(CCN2), a pathogenic factor in 
diabetic nephropathy. What does it do? How does it do it?” Journal of Cell 












Massagué, J, and D Wotton. 2000. “Transcriptional control by the TGF-β / Smad signaling 
system.” EMBO Journal 19(8):1745-1754. 
Massagué, J. 2008. “TGFβ in Cancer.” Cell 134(2):215-30.  
Massagué, J, J Seoane, and D Wotton. 2005. “Smad transcription factors.” Genes & 
Development 19(23):2783-810.  
Matzinger, P. 1994. “Tolerance, Danger, and the Extended Family.” Annual Review of 
Immunology 12(1):991-1045.  
Matzinger, P. 2007. “Friendly and dangerous signals: is the tissue in control?” Nature 
Immunology 8(1):11-13. 
Mauviel, A, J Heino, V-M Kahari, D-J Hartmann, G Loyau, J-P Pujol, and E Vuorio. 1991. 
“Comparative effects of interleukin-1 and tumor necrosis factor-α on collagen 
production and corresponding procollagen mRNA levels in human dermal 
fibroblasts.” Journal of Investigative Dermatology 96:243-249. 
McAnulty, R J. 2007. “Fibroblasts and myofibroblasts: their source, function and role in 
disease.” The International Journal of Biochemistry & Cell Biology 39(4):666-71.  
Mimura, Y, H Ihn, M Jinnin, Y Asano, K Yamane, and K Tamaki. 2006. “Epidermal 
growth factor affects the synthesis and degradation of type I collagen in cultured 
human dermal fibroblasts.” Matrix Biology 25:202 - 212. 
Morgan, H, and P A Hill. 2005. “Human breast cancer cell-mediated bone collagen 
degradation requires plasminogen activation and matrix metalloproteinase activity.” 
Cancer Cell International 5:1. 
Mori, K, A Hatamochi, H Ueki, A Olsen, and S A Jimenez. 1996. “The transcription of 
human α1(I) procollagen gene (COL1A1) is suppressed by tumour necrosis factor-α 
through proximal short promoter elements : evidence for suppression mechanisms 
mediated by two nuclear-factor-binding sites.” Journal of Biochemistry 319:811-816. 
Mueller, M M, and N E Fusenig. 2002. “Tumor-stroma interactions directing phenotype 
and progression of epithelial skin tumor cells.” Differentiation 70(9-10):486-97. 
Nakao, A, M Afrakhte, A Moren, T Nakayama, J L Christian, R Heuchel, S Itoh, M 
Kawabata, N-E Heldin, C-H Heldin, and P ten Dijke. 1997. “Identification of Smad7 , 
a TGFβ-inducible antagonist of TGF-β signalling.” Nature 389:631-635. 
Nakerakanti, S S, A M Bujor, and M Trojanowska. 2011. “CCN2 Is Required for the TGF-












Nelson, C M, and M J Bissell. 2006. “Of extracellular matrix, scaffolds, and signaling: 
Tissue architecture regulates development, homeostasis, and cancer.” Annual Review 
of Cell and Developmental Biology 22:287-309. 
Ng, Y-Y, J-M Fan, W Mu, D J Nikolic-Paterson, W-C Yang, T-P Huang, R C Atkins, and 
H Y Lan. 1999. “Glomerular epithelial – myofibroblast transdifferentiation in the 
evolution of glomerular crescent formation.” Nephrology Dialysis Transplantation 
14:2860-2872. 
Nowinski, D, P Höijer, T Engstrand, K Rubin, B Gerdin, and M Ivarsson. 2002. 
“Keratinocytes inhibit expression of connective tissue growth factor in fibroblasts in 
vitro by an interleukin-1α-dependent mechanism.” The Journal of Investigative 
Dermatology 119(2):449-55.  
Nuyten, D S A, and M J van de Vijver. 2007. “Gene Expression Signatures to Predict the 
Development of Metastasis in Breast Cancer.” Breast disease 26:149-156. 
Oberyszyn, T M, C J Conti, M S Ross, A S Oberyszyn, K L Tober, A I Rackoff, and F M 
Robertson. 1998. “β2 integrin/ICAM-1 adhesion molecule interactions in cutaneous 
inflammation and tumor promotion.” Carcinogenesis 19(3):445-55.  
Oliver, N, M Sternlicht, K Gerritsen, and R Goldschmeding. 2010. “Could aging human 
skin use a connective tissue growth factor boost to increase collagen content?” The 
Journal of Investigative Dermatology 130(2):338-41.  
Ono, K, T Ohtomo, J Ninomiya-Tsuji, and M Tsuchiya. 2003. “A dominant negative 
TAK1 inhibits cellular fibrotic responses induced by TGF-β.” Biochemical and 
Biophysical Research Communications 307:332-337. 
Orimo, A, P B Gupta, D C Sgroi, F Arenzana-Seisdedos, T Delaunay, R Naeem, V J 
Carey, A L Richardson, and R A Weinberg. 2005. “Stromal fibroblasts present in 
invasive human breast carcinomas promote tumor growth and angiogenesis through 
elevated SDF-1/CXCL12 secretion.” Cell 121:335-348. 
Ovington, L G, and GS Schultz. 2004. The physiology of wound healing. In: Morison MJ, 
Ovington LG, Wilkie K, eds. Chronic wound care: a problem-based learning 
approach. Mosby, London.  
Paget, S. 1989. “The distribution of secondary growths in cancer of the breast. 1889.” 
Cancer Metastasis Reviews 8(2):98-101. 
Pannu, J, S Nakerakanti, E Smith, P ten Dijke, and M Trojanowska. 2007. “Transforming 
growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via 













Parmar, H., and G R Cunha. 2004. “Epithelial-stromal interactions in the mouse and 
human mammary gland in vivo.” Endocrine Related Cancer 11:437-458. 
Perou, C M, T Sorlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T 
Ross, H Johnsen, L A Akslen, O Fluge, A Pergamenschikov, C Williams, S X Zhu, P 
E Lonning, A-L Borresen-Dale, P O Brown, and D Botstein. 2000. “Molecular 
portraits of human breast tumours.” Nature 406:747-752. 
Perou, C M, S S Jeffrey, M van De Rijn, M B Eisen, D T Ross, A Pergamenschikov, C F 
Williams, S X Zhu, J C F Lee, D Lashkari, D Shalon, P O Brown, and D Botstein. 
1999. “Distinctive gene expression patterns in human mammary epithelial cells and 
breast cancers.” PNAS 96:9212-9217. 
Petersen, O W. 2003. “Epithelial to mesenchymal transition in human breast cancer can 
provide a nonmalignant stroma.” American Journal of Pathology 162:391-402. 
Pietras, K, and A Ostman. 2010. “Hallmarks of cancer: interactions with the tumor 
stroma.” Experimental Cell Research 316(8):1324-31.  
Pogulis, R J, and S O Freytag. 1993. “Contribution of specific cis-acting elements to 
activity of the mouse pro-α2(I) collagen enhancer.” The Journal of Biological 
Chemistry 268(4):2493-9. 
Ponticos, M, A M Holmes, X Shi-Wen, P Leoni, K Khan, V S Rajkumar, R K Hoyles, G 
Bou-Gharios, C M Black, C P Denton, D J Abraham, A Leask, and G E Lindahl. 
2009. “Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-
dependent transcriptional activation of type I collagen.” Arthritis and Rheumatism 
60(7):2142-55. 
Quan, T, Y Shao, T He, J J Voorhees, and G J Fisher. 2009. “Reduced Expression of 
Connective Tissue Growth Factor (CTGF/CCN2) Mediates Collagen Loss in 
Chronologically Aged Human Skin.” Journal of Investigative Dermatology 
130(2):415-424. 
Radisky, D C, P A Kenny, and M J Bissell. 2007. “Fibrosis and cancer: do myofibroblasts 
come also from epithelial cells via EMT?” Journal of Cellular Biochemistry 
101(4):830-9.  
Ramirez, F, S Tanaka, and G Bou-Gharios. 2006. “Transcriptional regulation of the human 
α2(I) collagen gene (COL1A2), an informative model system to study fibrotic 
diseases.” Matrix Biology 25:365 - 372. 
Reilly, K M, and T van Dyke. 2008. “It takes a (dysfunctional) village to raise a tumor.” 












Reitamo, S, A Remitz, K Tamai, and J Uitto. 1994. “Interleukin-10 Modulates Type I 
Collagen and Matrix Metalloprotease Gene Expression in Cultured Human Skin 
Fibroblasts.” Journal of Clinical Investigation 94:2489-2492. 
Retief, E, M I Parker, and A E Retief. 1985. “Regional chromosome mapping of human 
collagen genes alpha 2(I) and alpha 1(I) (COLIA2 and COLIA1).” Human Genetics 
69(4):304-8.  
Reunanen, N, M Foschi, J Han, and V M Kahari. 2000. “Activation of extracellular signal-
regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts.” 
The Journal of Biological Chemistry 275(44):34634-9. 
Rezzonico, R, D Burger, and J M Dayer. 1998. “Direct contact between T lymphocytes 
and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen 
production via cell-associated cytokines.” The Journal of Biological Chemistry 
273(30):18720-8. 
Rickelt, S, W W Franke, Y Doerflinger, S Goerdt, J M Brandner, and W K Peitsch. 2008. 
“Subtypes of melanocytes and melanoma cells distinguished by their intercellular 
contacts: heterotypic adherens junctions, adhesive associations, and dispersed 
desmoglein 2 glycoproteins.” Cell and Tissue Research 334(3):401-22.  
Rønnov-Jessen, L, O W Petersen, and M J Bissell. 1996. “Cellular changes involved in 
conversion of normal to malignant breast: importance of the stromal reaction.” 
Physiological Reviews 76:69-125. 
Rønnov-Jessen, L, O W Petersen, V E Koteliansky, and M J Bissell. 1995. “The Origin of 
the Myofibroblasts in Breast Cancer.” Journal of Clinical Investigation 95:859-873. 
Rønnov-Jessen, L, and M J Bissell. 2008. “Breast cancer by proxy : can the 
microenvironment be both the cause and consequence ?” Trends in Molecular 
Medicine 15:5-13.  
Rossert, J, H Eberspaecher, and B de Crombrugghe. 1995. "Separate cis-acting DNA 
elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter 
genes to different type I collagen-producing cells in transgenic mice." The Journal of 
Cell Biology 129: 1421-1432. 
Rowe, R G, and S J Weiss. 2009. “Navigating ECM barriers at the invasive front: the 
cancer cell-stroma interface.” Annual Review of Cell and Developmental Biology 
25:567-95. 
Ruiter, D, T Bogenrieder, D Elder, and M Herlyn. 2002. “Melanoma-stroma interactions: 












Saad, S, L J Bendall, A James, D J Gottlieb, and K F Bradstock. 2000. “Induction of 
matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells 
and bone marrow fibroblasts.” Breast Cancer Research and Treatment 63:105-115. 
Sadlonova, A, Z Novak, M R Johnson, D B Bowe, S R Gault, G P Page, J V Thottassery, 
D R Welch, and A R Frost. 2005. “Breast fibroblasts modulate epithelial cell 
proliferation in three-dimensional in vitro co-culture.” Breast Cancer Research 
7:R46-R59. 
Sadzak, I, M Schiff, I Gattermeier, R Glinitzer, I Sauer, A Saalmüller, E Yang, B Schaljo, 
and P Kovarik. 2008. “Recruitment of Stat1 to chromatin is required for interferon-
induced serine phosphorylation of Stat1 transactivation domain.” Proc Natl Acad Sci 
USA 105(26):8944-9.  
Saitta, B, S Gaidarova, L Cicchillitti, and S A Jimenez. 2000. “CCAAT binding 
transcription factors binds and regulates human COL1A1 promoter activity in human 
dermal fibroblasts.” Arthritis & Rheumatism 43(10):2219-2229. 
Sato, M, D Shegogue, E A Gore, E A Smith, P J McDermott, and M Trojanowska. 2002. 
“Role of p38 MAPK in transforming growth factor beta stimulation of collagen 
production by scleroderma and healthy dermal fibroblasts.” The Journal of 
Investigative Dermatology 118(4):704-11. 
Sato, M, D Shegogue, A Hatamochi, S Yamazaki, and M Trojanowska. 2004. 
“Lysophosphatidic acid inhibits TGF-β-mediated stimulation of type I collagen 
mRNA stability via an ERK-dependent pathway in dermal fibroblasts.” Matrix 
Biology 23:353 - 361. 
Schindler, C, and J E Darnell. 1995. “Transcriptional responses to polypeptide ligands: the 
JAK-STAT pathway.” Annual Review of Biochemistry 64:621-51.  
Schindler, C, D E Levy, and T Decker. 2007. “JAK-STAT signaling: From interferons to 
cytokines.” The Journal of Biological Chemistry 282(28):20059-20063. 
Segarini, P R, J E Nesbitt, D Li, L G Hays, J R Yates, and D F Carmichael. 2001. “The 
low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a 
receptor for connective tissue growth factor.” The Journal of Biological Chemistry 
276(44):40659-67.  
Selman, M, and A Pardo. 2006. “Role of epithelial cells in idiopathic pulmonary fibrosis: 
from innocent targets to serial killers.” Proceedings of the American Thoracic Society 
3(4):364-72. 
Sengupta, P K, J Fargo, and B D Smith. 2002. “The RFX family interacts at the collagen 













Sengupta, P, Y Xu, L Wang, R Widom, and B D Smith. 2005. “Collagen alpha1(I) gene 
(COL1A1) is repressed by RFX family.” The Journal of Biological Chemistry 
280:21004-21014. 
Serpier, H, P Gillery, V Salmon-Ehr, R Garnotel, N Georges, B Kalis, and F-X Maquart. 
1998. “Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast 
cultures.” Journal of Investigative Dermatology 158:158-162. 
Shekhar, M P, R Pauley, and G Heppner. 2003. “Host microenvironment in breast cancer 
development: extracellular matrix-stromal cell contribution to neoplastic phenotype of 
epithelial cells in the breast.” Breast Cancer Research 5:130-135. 
Shekhar, M P V, J Werdell, S J Santner, R J Pauley, and L Tait. 2001. “Advances in Brief 
Breast Stroma Plays a Dominant Regulatory Role in Breast Epithelial Growth and 
Differentiation : Implications for Tumor Development and Progression.” Cancer 
Research 61:1320 -1326. 
Shephard, P, G Martin, S Smola-Hess, G Brunner, T Krieg, and H Smola. 2004. 
“Myofibroblast Differentiation Is Induced in Keratinocyte-Fibroblast Co-Cultures and 
Is Antagonistically Regulated by Endogenous Transforming Growth Factor-β and 
Interleukin-1.” American Journal of Pathology 164(6):2055-2066. 
Shi, W, C Sun, B He, W Xiong, X Shi, D Yao, and X Cao. 2004. “GADD34-PP1c 
recruited by Smad7 dephosphorylates TGFβ type I receptor.” The Journal of Cell 
Biology 164(2):291-300. 
Shi-wen, X, D Pennington, A Holmes, A Leask, D Bradham, J R Beauchamp, C Fonseca, 
R M du Bois, G R Martin, C M Black, D J Abraham. 2000. “Autocrine 
overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in 
systemic sclerosis.” Experimental Cell Research 259(1):213-24.  
Shi-wen, X, A Leask, and D Abraham. 2008. “Regulation and function of connective 
tissue growth factor/CCN2 in tissue repair , scarring and fibrosis.” Cytokine & 
Growth Factor Reviews 19:133-144. 
Shi-wen, X, L A Stanton, L Kennedy, D Pala, Y Chen, S L Howat, E A Renzoni, D E 
Carter, G Bou-Gharios, R J Stratton, J D Pearson, F Beier, K M Lyons, C M Black, D 
J Abraham, and A Leask. 2006. “CCN2 is necessary for adhesive responses to 
transforming growth factor-β1 in embryonic fibroblasts.” The Journal of Biological 
Chemistry 281(16):10715-26.  
Shimoda, M, K T Mellody, and A Orimo. 2010. “Carcinoma-associated fibroblasts are a 
rate-limiting determinant for tumour progression.” Seminars in Cell & Developmental 












Shoulders, M D, and R T Raines. 2009. “Collagen Structure and Stability.” Annual Review 
of Biochemistry 78:929-958. 
Sieg, D J, C R Hauck, D Ilic, C K Klingbeil, E Schaefer, C H Damsky, and D D 
Schlaepfer. 2000. “FAK integrates growth-factor and integrin signals to promote cell 
migration.” Nature Cell Biology 2(5):249-256. 
Siegel, R C, K H Chen, J S Greenspan, and J M Aguiar. 1978. “Biochemical and 
immunochemical study of lysyl oxidase in experimental hepatic fibrosis in the rat.” 
Proc Natl Acad Sci USA 75(6):2945-9.  
Singer, A J, and R A Clark. 1999. “Cutaneous wound healing.” The New England Journal 
of Medicine 341(10):738–746.  
Slack, J L, D Liska, and P Bornstein. 1991. “An Upstream Regulatory Region Mediates 
High-Level, Tissue- Specific Expression of the Human α1(I) Collagen Gene in 
Transgenic Mice.” Molecular and Cellular Biology 11(4):2066-2074. 
Smith, R S, T J Smith, T M Blieden, and R P Phipps. 1997. “Fibroblasts as sentinel cells. 
Synthesis of chemokines and regulation of inflammation.” American Journal of 
Pathology 151(2):317-322. 
Sonnenschein, C, and A M Soto. 2008. “Theories of carcinogenesis : An emerging 
perspective.” Seminars in Cancer Biology 18:372-377. 
Sorlie, T, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M 
van de Rijn, S S Jeffrey, T Thorsen, H Quist, J C Matese, P O Brown, D Botstein, P E 
Lonning, and A-L Borresen-Dale. 2001. “Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications.” Proc Natl Acad 
Sci USA 98(19):10869-10874. 
Sotiriou, C, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, P Farmer, V Praz, B 
Haibe-Kains, C Desmedt, D Larsimont, F Cardoso, H Peterse, D Nuyten, M Buyse, M 
J van de Vijver, J Bergh, M Piccart, and M Delorenzi. 2006. “Gene Expression 
Profiling in Breast Cancer : Understanding the Molecular Basis of Histologic Grade 
To Improve Prognosis.” Journal of the National Cancer Institute 98:262-272. 
Sotiriou, C, and L Pusztai. 2009. “Gene-expression signatures in breast cancer.” The New 
England Journal of Medicine 360(8):790-800. 
Srikrishna, G, and H H Freeze. 2009. “Endogenous Damage-Associated Molecular Pattern 
Molecules at the Crossroads of Inflammation.” Inflammation 11(7):615-628. 
Stefanovic, B. 2005. “New Insights into Regulation of Type I Collagen Gene Expression.” 












Sternlicht, M D, P Kedeshian, Z-M Shao, S Safarians, and S H Barsky. 1997. “The Human 
Myoepithelial Cell is a Natural Tumor Suppressor.” Clinical Cancer Research 
3:1949-1958. 
Straver, M E, A M Glas, J Hanneman, J Wesseling, M J van de Vijver, E J T Rutgers, P 
Vrancken, TFD Marie-Jeanne, H van Tinteren, L J van't Veer, and R Sjoerd. 2010. 
“The 70-gene signature as a response predictor for neoadjuvant chemotherapy in 
breast cancer.” Breast Cancer Research and Treatment 119:551-558. 
Takaoka, A, and H Yanai. 2006. “Interferon signalling network in innate defence.” 
Cellular Microbiology 8(6):907-22. 
Tamaki, T, K Ohnishi, C Hartl, E C LeRoy, and M Trojanowsa. 1995. “Characterisation of 
a GC-rich region containing Sp1 binding site(s) as a constitutive responsive element 
of the α2(I) gene in human fibroblasts.” The Journal of Biological Chemistry 
270(9):4299-4304. 
Tanaka, K. 2003. “Inhibition of induction of myofibroblasts by interferon γ in a human 
fibroblast cell line.” International Immunopharmacology 3(9):1273-1280. 
Tikellis, C, M E Cooper, S M Twigg, W C Burns, and M Tolcos. 2004. “Connective tissue 
growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-
converting enzyme inhibition.” Endocrinology 145(2):860-6.  
Tlsty, T D, and P W Hein. 2001. “Know thy neighbor: stromal cells can contribute 
oncogenic signals.” Current Opinion in Genetics and Development 11:54-59. 
Tran-Thanh, D, and S J Done. 2010. “The role of stromal factors in breast tumorigenicity.” 
The American Journal of Pathology 176(3):1072-4. 
Trojanowska, M, E C LeRoy, B Eckes, and T Krieg. 1998. “Pathogenesis of fibrosis : type 
1 collagen and the skin.” Journal of Molecular Medicine 76:266-274. 
Tyan, S-W, W-H Kuo, C-K Huang, C-C Pan, J-Y Shew, K-J Chang, E Y-H P Lee, and W-
H Lee. 2011. “Breast cancer cells induce cancer-associated fibroblasts to secrete 
hepatocyte growth factor to enhance breast tumorigenesis.” PloS One 6(1):e15313. 
Uchio, K, M Graham, N M Dean, J Rosenbaum, and A Desmouliere. 2004. “Down-
regulation of connective tissue growth factor and type I collagen mRNA expression 
by connective tissue growth factor antisense oligonucleotide during experimental liver 
fibrosis.” Wound Repair and Regeneration 12:60-66. 
Uddin, S, B Majchrzak, J Woodson, P Arunkumar, Y Alsayed, R Pine, P R Young, E N 
Fish, and L C Platanias. 1999. “Activation of the p38 mitogen-activated protein 












Ulloa, L, J Doody, and J Massague. 1999. “Inhibition of transforming growth factor-β / 
SMAD signalling by the interferon-g / STAT pathway.” Nature 397:710-713. 
van Beek, J P, L Kennedy, J S Rockel, S M Bernier, and A Leask. 2006. “The induction of 
CCN2 by TGFβ1 involves Ets-1.” Arthritis Research and Therapy 8: R36 
van Boxel-Dezaire, A H H, M R S Rani, and G R Stark. 2006. “Complex modulation of 
cell type-specific signaling in response to type I interferons.” Immunity 25(3):361-72.  
van de Vijver, M J, Y D He, L J van't Veer, H Dai, A A M Hart, D W Voskuil, G J 
Schreiber, J L Peterse, C Roberts, M J Marton, M Parrish, D Atsma, A Witteveen, A 
Glas, L Delahaye, T van der Velde, H Bartelink, S Rodenhuis, E T Rutgers, S H 
Friend, and R Bernards. 2002. “A gene-expression signature as a predictor of survival 
in breast cancer.” The New England Journal of Medicine 347(25):1999-2009.  
van’t Veer, L J, H Dai, M J van de Vijver, Y D He, A A M Hart, M Mao, H L Peterse, K 
van der Kooy, M J Marton, A T Witteveen, G J Schreiber, R M Kerkhoven, C 
Roberts, P S Linsley, R Bernards, and S H Friend. 2002. “Gene expression profiling 
predicts clinical outcome of breast cancer.” Nature 415:530-536. 
van Kempen, L C L, G N P van Muijen, and D J Ruiter. 2005. “Stromal responses in 
human primary melanoma of the skin.” Frontiers in Bioscience 10:2922-2931. 
Varga, J, and S A Jimenez. 1995. “Modulation of collagen gene expression: its relation to 
fibrosis in systemic sclerosis and other disorders.” Annals of Internal Medicine 
122(1):60-2. 
Vargo-Gogola, T, and J M Rosen. 2007. “Modelling breast cancer: one size does not fit 
all.” Nature Reviews Cancer 7:659-672. 
Verrecchia, F, M-L Chu, and A Mauviel. 2001. “Identification of Novel TGF-β/Smad 
Gene Targets in Dermal Fibroblasts using a Combined cDNA Microarray/ Promoter 
Transactivation Approach.” The Journal of Biological Chemistry 276(20):17058 -
17062. 
Verrecchia, F, M Pessah, A Atfi, and A Mauviel. 2000. “Tumor Necrosis Factor-α inhibits 
TGF-β/Smad Signaling in Human Dermal Fibroblasts via AP-1 Activation.” The 
Journal of Biological Chemistry 275(39):226-231. 
Verrecchia, F, J Rossert, and A Mauviel. 2001. “Blocking Sp1 Transcription Factor 
Broadly Inhibits Extracellular Matrix Gene Expression In Vitro and In Vivo: 













Verrecchia, F, C Tacheau, M Schorpp-Kistner, P Angel, and A Mauviel. 2001. “Induction 
of the AP-1 members c-Jun and JunB by TGF-β/Smad suppresses early Smad-driven 
gene activation.” Oncogene 20(18):2205-11. 
Verrecchia, F, C Tacheau, E F Wagner, and A Mauviel. 2003. “A Central Role for the JNK 
Pathway in Mediating the Antagonistic Activity of Pro-inflammatory Cytokines 
against Transforming Growth Factor-β-driven SMAD3/4-specific Gene Expression.” 
Journal of Biological Chemistry 278(3):1585-1593. 
Verrecchia, F, and A Mauviel. 2004. “TGFβ and TNFα: antagonistic cytokines controlling 
type I collagen gene expression.” Cellular Signalling 16:873-880. 
Verrecchia, F, and A Mauviel. 2002. “Transforming Growth Factor-β Signaling Through 
the Smad Pathway : Role in Extracellular Matrix Gene Expression and Regulation.” 
Journal of Investigative Dermatology 118:211-215. 
Wahab, N A, H Brinkman, and R M Mason. 2001. “Uptake and intracellular transport of 
the connective tissue growth factor: a potential mode of action.” Journal of 
Biochemistry 359:89-97. 
Weigelt, B, H M Horlings, B Kreike, M M Hayes, M Hauptmann, L F A Wessels, D de 
Jong, M J van De Vijver, L J van't Veer, and J L Peterse. 2008. “Refinement of breast 
cancer classification by molecular characterization of histological special types.” 
Journal of Pathology, The 216:141-150. 
Weigelt, B, and M J Bissell. 2008. “Unraveling the microenvironmental influences on the 
normal mammary gland and breast cancer.” Seminars in Cancer Biology 18:311-321. 
Weng, H, P R Mertens, A M Gressner, and Steven Dooley. 2007. “IFN-γ abrogates 
profibrogenic TGF-β signaling in liver by targeting expression of inhibitory and 
receptor Smads.” Journal of Hepatology 46(2):295-303. 
Wenger, C, V Ellenrieder, B Alber, U Lacher, A Menke, H Hameister, M Wilda, T 
Iwamura, H G Beger, G Adler, and T M Gress. 1999. “Expression and differential 
regulation of connective tissue growth factor in pancreatic cancer cells.” Oncogene 
18(4):1073-80. 
Wienke, D, G C Davies, D A Johnson, J Sturge, M B K Lambros, K Savage, S E Elsheikh, 
A R Green, I O Ellis, D Robertson, J S Reis-Filho, and C M Isacke. 2007. “The 
Collagen Receptor Endo180 (CD280) Is Expressed on Basal-like Breast Tumor Cells 
and Promotes Tumor Growth In vivo.” Cancer Research 67(21):10230-10240. 
Willis, B C, J M Liebler, K Luby-Phelps, A G Nicholson, E D Crandall, R M du Bois, and 
Z Borok. 2005. “Induction of epithelial-mesenchymal transition in alveolar epithelial 
cells by transforming growth factor-beta1: potential role in idiopathic pulmonary 












Wolf, K, Y I Wu, Y Liu, J Geiger, E Tam, C Overall, M S Stack, and P Friedl. 2007. 
“Multi-step pericellular proteolysis controls the transition from individual to 
collective cancer cell invasion.” Nature Cell Biology 9(8):893-904.  
Wozniak, M A, and P J Keely. 2005. “Use of three-dimensional collagen gels to study 
mechanotransduction in T47D breast epithelial cells.” Biological Procedures Online 
7(1):144-61.  
Xiao, G, Y E Liu, R Gentz, Q A Sang, J Ni, I D Goldberg, and Y E Shi. 1999. 
“Suppression of breast cancer growth and metastasis by a serpin myoepithelium-
derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.” 
Proc Natl Acad Sci USA 96(7):3700-5.  
Xie, D, K Nakachi, H Wang, R Elashoff, and H P Koeffler. 2001. “Elevated Levels of 
Connective Tissue Growth Factor , WISP-1 , and CYR61 in Primary Breast Cancers 
Associated with More Advanced Features Elevated Levels of Connective Tissue 
Growth Factor , WISP-1 , and CYR61 in Primary Breast Cancers Associated with 
More.” Reactions 8917-8923. 
Xu, Y, P K Sengupta, E Seto, and B D Smith. 2006. “Regulatory factor for X-box family 
proteins differentially interact with histone deacetylases to repress collagen α2(I) gene 
(COL1A2) expression.” The Journal of Biological Chemistry 281:9260-9270. 
Xu, Y, L Wang, G Buttice, P K Sengupta, and B D Smith. 2003. “Interferon γ repression 
of collagen (COL1A2) transcription is mediated by the RFX5 complex.” The Journal 
of Biological Chemistry 278:49134-49144. 
Xu, Y, L Wang, G Buttice, P K Sengupta, and B D Smith. 2004. “Major 
Histocompatibility Class II Transactivator (CIITA) Mediates Repression of Collagen 
(COL1A2) Transcription by.” The Journal of Biological Chemistry 279(40):41319-
41332. 
Yamaguchi, K, K Shirakabe, H Shibuya, K Irie, I Oishi, N Ueno, T Taniguchi, E N And, 
and K Matsumoto. 1995. “Identification of a Member of the MAPKKK Family as a 
Potential Mediator of TGF-β Signal Transduction.” Science 270(5244):1899. 
Yu, X, S Miyamoto, and E Mekada. 2000. “Integrin α2β1-dependent EGF receptor 
activation at cell-cell contact sites.” Journal of Cell Science 2147:2139-2147. 
Yuan, W, T Yufit, L Li, Y Mori, S J Chen, and J Varga. 1999. “Negative modulation of 
α1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition 
by interferon-gamma.” Journal of Cellular Physiology 179:97-108. 
Zeisberg, M, and R Kalluri. 2004. “The role of epithelial-to-mesenchymal transition in 












Zhang, J, B Shen, and A Lin. 2007a. “Novel strategies for inhibition of the p38 MAPK 
pathway.” Trends in Pharmacological Sciences 28(6):286-95. 
Zhang, S, T Fei, L Zhang, R Zhang, F Chen, Y Ning, Y Han, X-H Feng, A Meng, and Y-G 
Chen. 2007b. “Smad7 antagonizes transforming growth factor β signaling in the 
nucleus by interfering with functional Smad-DNA complex formation.” Molecular 
and Cellular Biology 27(12):4488-99.  
Zhang, W, J Ou, Y Inagaki, P Greenwel, and F Ramirez. 2000. “Synergistic cooperation 
between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 
stimulation of alpha 2(I)-collagen (COL1A2) transcription.” The Journal of 
Biological Chemistry 275(50):39237-45.  
Zhou, Z, O J Hamming, N Ank, S R Paludan, A L Nielsen, and R Hartmann. 2007. “Type 
III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells 
through signaling pathways involving both the Jak-STAT pathway and the mitogen-
activated protein kinases.” Journal of Virology 81(14):7749-58.  
 
 
 
 
 
 
